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1
Introduction
1.1 Epigenetics
1.1.1 The Code of Life
Life, as we know it, depends critically on the multiplication of self-replicating or-
ganic entities. With the exception of protists, eukaryotes are multicellular organ-
isms in which individual cells take on specialised roles to the beneﬁt of the organism
as a whole. Each somatic cell is a small semi-autonomous unit which, although
highly specialised in its functionality, shares the same strands of deoxyribonucleic
acid (DNA) at its core. Individual organisms carry small variations in the DNA code
of their species, but by and large they are readily distinguishable as members of
their species. The morphological and structural differences between the different cell
types within an organism are far more complex. Throughout the development of an
organism all cell types differentiate from a single zygote with one unique genome.
The timed activation and deactivation of genes at different stages of development is
crucial to the cellular differentiation process [1].
1-2 INTRODUCTION
1.1.1.1 Genes
The abstract information encoded in the genome is usually discretised in terms of
genes. The deﬁnition of a gene is a subject of continuous debate as there are many
instances of positional and/or functional overlap between genes. Two commonly
cited deﬁnitions are ”A locatable region of genomic sequence, corresponding to a
unit of inheritance, which is associated with regulatory regions, transcribed regions
and/or other functional sequence regions.” [2] or ”A union of genomic sequences
encoding a coherent set of potentially overlapping functional products” [3]. Genes
encoded in DNA are a relatively stable, heritable form of genetic information.
1.1.1.2 Central Dogma of Molecular Biology
DNA, and thus genes, consists of a long string of nucleotides which are linked by
a sugar and phosphate backbone. These nucleotides are adenine (A), cytosine (C),
guanine (G) and thymine (T). DNA in the cell core is present in a condensed form
called chromatin. This molecule is particularly stable because two strands are present
which are complementary to each other. Adenosine forms non-covalent bonds with
thymine and cytosine with guanine.
The central dogma of molecular biology represents the information ﬂow in a
cell [4]. In order for genes to exert an effect in the cell they need to be translated to
ribonucleic acid (RNA). To generate RNA the chromatin needs to be decompressed
so that the translation complex can access it. The messenger RNA (mRNA) is sub-
sequently translated to proteins in the ribosomes and the proteins fulﬁl their function
inside or outside the cell. It is now generally understood that the central dogma is not
entirely accurate as genes may manifest themselves in other forms than proteins (see
Section 1.1.4).
1.1.1.3 Epigenetics
As debated as the deﬁnition of a gene is, the precise deﬁnition of epigenetics is possi-
bly even more contested. Despite a substantial increase in publications on the subject
(see Figure 1.1), multiple deﬁnitions are used to date. Much of the debate stems from
the hereditary nature of certain traits [5].
CHAPTER 1 1-3
(a) (b)
Figure 1.1: Publication frequencies per year for the PubMed query ”epigenom* OR
epigenetic*” in absolute numbers (a) and in proportion to the total number of PubMed
publications (b).
For the purpose of this dissertation the working deﬁnition of the NIH Epigenetics
Roadmap project is adopted: ”[E]pigenetics refers to both heritable changes in gene
activity and expression (in the progeny of cells or of individuals) and also stable,
long-term alterations in the transcriptional potential of a cell that are not necessar-
ily heritable. While epigenetics refers to the study of single genes or sets of genes,
epigenomics refers to more global analyses of epigenetic changes across the entire
genome.” [6]
The following sections will highlight different biological mechanisms of regula-
tion that are considered epigenetic traits.
1.1.2 Histone Modiﬁcations
To achieve the compacted state which allows DNA to be stored within the nucleus,
double stranded DNA (dsDNA) is wrapped twice around an octamer of histone pro-
teins. This structure, called a nucleosome, stores approximately 147 bp of DNA. The
individual nucleosomes are interspersed with ”linker DNA”. The histone proteins
contain extensions (histone tails), which are the target of post-translational modiﬁca-
tions. These modiﬁcations inﬂuence the degree of compaction of the DNA into lower
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and higher order structures and therefore inﬂuence transcription through accessibil-
ity and the recruitment of transcription factors. The concept of a ”histone code” was
introduced which states that a speciﬁc combination of modiﬁcations is required to
obtain a particular effect on gene expression [7, 8]. Transcriptionally active loci for
instance, are featured by histone lysine acetylation [9].
Next to histone modiﬁcations, nucleosome positioning (or phasing) is also in-
volved in the epigenetic regulation of gene expression by chromatin remodeling. Po-
sitioning of the nucleosomes depends on several components and their interactions.
As a result, the core enhancer, promoter, and terminator regions of genes are typically
depleted of nucleosomes, whereas most of the genomic DNA is occupied [10].
1.1.3 DNA Methylation
Cytosine bases can be covalently modiﬁed by the addition of a methyl group to the
C5 carbon residue (5mC) by DNA methyltransferases [11]. In adult human beings
the majority of methylated cytosines occur in a CpG dinucleotide context (note that
this context is symmetrical with regard to the opposite strand) [12]. DNAmethylation
in the promoter region of a gene is typically associated with transcriptional silencing.
The function of gene body methylation is less straightforward but important biolog-
ical functions, such as regulation of splicing and silencing of transposable elements,
have been assigned to methylation in these loci [13, 14].
Cytosine may also be modiﬁed with a hydroxymethyl group. Hydroxymethyl-
cytosine (5hmC) has recently garnered attention as a novel epigenetic marker. It is
hypothesised that 5hmC is an intermediary in active or passive 5mC demethylation.
However, hydroxymethylation is most likely more than an intermediary state. One
potential role lies in brain development where it speciﬁcally localises to gene bodies
of genes involved in neuronal differentiation [15]. Recent ﬁndings also suggest that
hydroxymethylation is critical for the regulation of a range of previously unidentiﬁed
erythroid transcription factors, which likely have an afﬁnity for 5hmC speciﬁcally.
Hydroxymethylation thus plays a critical role in lineage commitment of hematopo-
etic pluripotent cells [16].
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1.1.4 Non-coding RNA
In the central dogma of molecular biology RNA was considered an intermediary car-
rier of information between DNA and proteins. Although it was recognised that in-
formation encoded in RNA may be transferred to the DNA under speciﬁc conditions,
it has since been discovered that RNA exerts effects on the cells function through
a host of mechanisms other than strictly coding for proteins [17]. Although a full
review of different RNA species is beyond the scope of this introduction, a short
selection relevant to the interpretation of the experimental results will be highlighted.
1.1.4.1 microRNA
microRNAs (miRNAs) are short RNA fragments about 22 bp in length, which are
complementary to speciﬁc mRNAs and can thus interfere with normal transcription
of said mRNA. In animals most miRNAs are imprecisely complementary to their
mRNA targets and they inhibit protein synthesis through mRNA degradation or pre-
venting mRNA from being translated. miR16 for example, contains a sequence com-
plementary to the AU-rich element found in the 3’ untranslated region of many unsta-
ble mRNAs, such as TNF-α or GM-CSF [18]. In case of complete complementarity
between the miRNA and the target mRNA sequence, AGO2 can cleave the mRNA
and lead to direct mRNA degradation. If complementarity is imperfect, the silencing
is achieved by preventing translation [19].
Most miRNA genes seem to be solitary, and are expressed under the control of
their own promoters and regulatory sequences. Other miRNA genes are arranged
in clusters, and may be co-regulated with other members of the cluster. Vertebrate
genomes contain about 250 miRNA genes, as shown by complementary DNA cloning
and computational predictions [20].
1.1.4.2 Long Non-coding RNA
Long non-coding RNAs (lncRNAs) are somewhat arbitrarily deﬁned as non-protein
coding transcripts longer than 200 nucleotides [21]. This class of RNAs is estimated
to have tens of thousands of members based on current research [22]. Although the
1-6 INTRODUCTION
majority of these has no known function, those that are well annotated show very
diverse mechanisms of action.
For example, the inactivation of one X-chromosome in female mammals is di-
rected by Xist, one of the earliest and best characterised examples of long ncRNAs.
XIST expression is followed by irreversible layers of chromatin modiﬁcations. The
expression of XIST from one X-chromosome leads to the inactivation of said X-
chromosome. This process occurs in early embryonic stem cell differentiation [23].
In Drosophila lncRNAs induce the expression of the gene UBX by recruiting and
directing the chromatin modifying functions of the trithorax protein ASH1 to HOX
regulatory elements [24]. As a last example consider ZEB2, this gene’s mRNA has a
long 5’ untranslated region (UTR) and requires the retention of a 5’UTR intron that
contains an internal ribosome entry site for efﬁcient translation. However, retention
of the intron is dependent on the expression of an antisense transcript (lncRNA) that
complements the intronic 5’ splice site [25].
1.1.5 Telomeres
1.1.5.1 Telomeres as an Epigenetic Feature
Figure 1.2: Illustration of the end-replication
problem [26].
When cells divide through a process
known as mitosis, the DNA in the
cell’s core is duplicated and passes
on to the new cell. This process is
semi-conservative in the sense that each
daughter cell receives dsDNA which
is made up of an ”old” strand and
a complementary strand newly synthe-
sised before the cell division. In the-
ory both sets of dsDNA are identical and
several proof-reading mechanisms exist
to ensure a faithful copy. However, due to a phenomenon known as the end-
replication problem, by which the very end of each chromosome can not be copied,
both daughter cells have slightly shorter chromosomes (see Figure 1.2). To prevent
loss of genes after multiple divisions, the chromosomes are capped with a repetitive
buffer sequence which may shorten throughout an organisms lifespan without loosing
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vital genetic information. These buffers present on both ends of each chromosome
are known as the telomeres. In humans and other vertebrates the telomeric repeat
sequence is TTAGGG. For additional protection the telomere ends are wrapped up in
a protein complex known as shelterin [27].
Although telomere biology developed as a ﬁeld unto its own, it can be considered
as an epigenetic trait as deﬁned in section 1.1.1.3. Telomeres after all do not display
changes in the DNA code but do alter cell functions depending on the repeat length.
Further it has been demonstrated that telomere length (TL) changes in response to
external and internal stimuli and depends on parental age (and therefore TL) at birth.
In human subjects TL is often measured in whole blood samples where esti-
mates typically vary between 4 and 11 kbp [28]. Due to the repetitive nature of the
telomeric sequence, it is difﬁcult to estimate the exact length with currently available
techniques. Additionally, the estimates of these techniques do not always closely
agree [29].
1.1.5.2 Terminal Restriction Fragments
The oldest method for measuring TL was ﬁrst described in 1990 [30]. This method
is quite robust and reproducible. To date, it is still considered the gold standard to
which all alternatives should be compared.
In brief, the genomic DNA is treated with two endonucleases with a short recog-
nition site (for instance rsa1 and hinf1). Most of the DNA will be broken up into
relatively short pieces except for the telomeres which do not match either recogni-
tion site. In the next step, the terminal restriction fragments (TRF) are loaded on an
agarose gel to separate them by length through electrophoresis. When migration is
complete, the gel is transferred to a membrane by Southern blotting. Subsequently
the DNA is allowed to hybridise with radioactively labelled telomere speciﬁc probes.
The radiation allows the TRF length distribution to be visualised (see Figure 1.3 for
experimental conﬁguration and resulting blot). With the help of length markers the
average telomere length can be determined as follows:
∑
ODi
∑ ODi
Li
(1.1)
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(a) (b)
Figure 1.3: TL determination by TRF [32, chapter 2]. (a) Experimental conﬁguration to
transfer length separated DNA to a nylon membrane by southern blot. (b) Phosphor
imaging of the nylon membrane shows distribution of TL relative to low and high molecular
weight markers.
In formula 1.1 Li represents the length of DNA and ODi the measured optical
density at position i. This formula is applied to a certain range of i, for instance from
3 to 17 kbp.
Below 3 kbp the quantiﬁcation is not reliable. Other limitations of the technique
are the relatively large amounts of DNA required (≥ 2 μg), the specialised equip-
ment needed for handling radioactive materials and the fact that it cannot distinguish
telomeres from subtelomeric regions (regions with a similar sequence to telomeres
that do not possess sufﬁcient restriction sites) [31].
1.1.5.3 qPCR
The quantitative polymerase chain reaction (qPCR), sometimes referred to as real
time PCR, is a modiﬁed version of the original PCR which allows quantiﬁcation by
measuring ﬂuorescent light emission as a proxy for the levels of synthesised dsDNA
between reaction cycles [33]. In theory the amount of dsDNA doubles in every reac-
tion cycle. In practice however the emitted light signal displays a logistic curve with
an initial lag phase where the increase in light intensity is imperceptible and a plateau
phase due to the exhaustion of reagents and/or the saturation of the light intensity.
To quantify the amount of DNA, a ﬂuorescence threshold is selected and the cycle
in which a given sample crosses this threshold is called the quantification cycle (Cq)
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[34]. Cq values are linearly related to the logarithm of the dsDNA concentration. By
comparing Cq values with those of a dilution series or some other known reference,
the amount of DNA can be determined in absolute or relative terms.
PCR primers that are perfectly complementary to the telomere sequence are also
perfectly self-complementary and would therefore be unsuited for (q)PCR. Further,
the primers can bind along the entire telomere which precludes accurate length es-
timations by gel electrophoresis. However, the amount of dsDNA synthesised is
still representative of the initial amount of telomeric sequences. Using 3’ degenerate
primers for the telomeres and a second set of primers for a known single copy gene,
the amount of telomeric DNA can be estimated by normalising the telomere Cq to
the single copy Cq, this is the T/S ratio [31, 35].
The T/S ratio does not provide absolute TL measurements but does allow sam-
ples to be ranked by relative telomere length and many samples can be processed in
parallel using relatively small quantities of DNA. Reasonably good correlations with
TRF measurements have been obtained [29].
1.1.5.4 Other TL Measurement Techniques
Other techniques to measure TL have been used each with their own advantages
and limitations. Fluorescent in situ hybridisation (FISH) can be performed both on
immobilised cells [36] and liquid suspended cells (through ﬂow cytometry) [37]. In
both cases the amount of ﬂuorescent signal from telomere speciﬁc probes is used as
a proxy for TL.
It is also possible to measure the TL of individual chromosomes by a technique
known as single telomere length analysis (STELA). This technique relies on amplify-
ing full length telomeres with primers designed for the subtelomeric regions speciﬁc
to the respective chromosomes [38].
Lastly, it has been proposed that fairly accurate TL estimates can be obtained as
an unforeseen by-product of genomic sequencing data [39]. Although this technique
is still biased by the PCR steps involved in second generation sequencing (see Section
1.3.2), further reﬁnement in sequencing techniques could make this a highly accurate
and cost-efﬁcient technique.
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Figure 1.4: Simpliﬁed diagram of the human circulatory system in anterior view.
Reproduced from WikiMedia under the public domain licence.
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1.2 Cardiovascular Health
1.2.1 Basic Anatomy
The circulatory system, also known as the cardiovascular system, pervades all other
organs of the human body. It is responsible for the circulation of nutrients, metabo-
lites, signalling molecules, oxygen and many other components throughout the body.
It consist of the heart which pumps blood into the arteries, the arterial system which
distributes blood throughout the body and the venous system which guides blood
back to the heart (see Figure 1.4 for a schematic representation). Blood cells, among
which leukocytes, are replenished by the bone marrow.
A normally developed human heart consists of four chambers: the left atrium,
left ventricle, right atrium and right ventricle. The left atrium collects blood from
the superior vena cava and inferior vena cava. From the right atrium blood passes
to the right ventricle from where it is pumped into the pulmonary artery to continue
on to the lungs to exchange CO2 for O2. Oxygen rich blood then returns to the left
atrium through the pulmonary veins. Finally blood is passed to the left ventricle
which pumps blood into the aorta to be circulated in the rest of the body [40].
The chambers of the heart are separated from each other and the arterial system by
a series of valves which impose unidirectional blood ﬂow (see Figure 1.5). The valves
between the atria and ventricles are called atrioventricular valves. The semilunar
valves sit at the openings that lead to the pulmonary trunk and aorta. These latter
valves are termed the pulmonary and aortic valve respectively. The valve located
between the right atrium and the right ventricle is the right atrioventricular valve,
or tricuspid valve. In the opening between the left atrium and left ventricle sits the
mitral valve, also called the bicuspid valve or the left atrioventricular valve.
1.2.2 Filling Patterns
The human heart beats in a two phase cycle, these phases are called systole and dias-
tole. Systole is the phase of contraction and diastole the phase of relaxation. These
phase can be deﬁned both from the ventricular or atrial perspective. At the start of
ventricular systole both ventricles are ﬁlled with blood. Through a powerful contrac-
tion of smooth muscle cells in the ventricle walls, blood is pumped into the aorta
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Figure 1.5: Simpliﬁed diagram of the human heart in anterior view. Adapted from [40].
and the pulmonary trunk. By the end of this contraction roughly 60% of the blood
volume is forced out of the heart, this proportion is known as the ejection fraction
(EF), a measure of systolic function [41]. After the contraction the ventricle walls
start relaxing but without a change in ventricle volume, this period is the isovolumic
relaxation time (IVRT).
The start of the IVRT also marks the end of ventricular systole and the start of
ventricular diastole. During ventricular systole and IVRT the atria have been ﬁlled
with blood from the veins, during ventricular diastole blood ﬂows from the atria to
the ventricles. At ﬁrst the ventricles spontaneously draw in blood from the atria by
returning to their fully relaxed state, this is early ﬁlling. Shortly thereafter the atria
actively pump blood into the ventricles to complete loading, this is late ﬁlling [40].
The ratio of early over late ﬁlling is an indicator of diastolic function. A healthy
heart draws mostly on early, spontaneous ﬁlling whereas an aged heart is less compli-
ant and requires more active ﬁlling. Multiple measures are used to quantify diastolic
function. One of the best known is E/A or the ratio of peak blood ﬂow velocity during
early (E) and late (A) ﬁlling as measured by Doppler echography. Another measure
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is e which represents the movement speed of the cusp of the mitral valve during early
(e) ﬁlling as measured by speckle tracking echography [42].
1.2.3 Atherosclerosis
A healthy vascular system is characterised by smooth arteries, elastic or muscular
depending on the location in the body. Arteries consist of a trilaminar structure:
tunica intima, tunica media and tunica externa. The endothelial cells in contact with
the blood in the arterial lumen, rest upon a basement membrane [40].
Atherogenesis is a slow process that starts as early as birth. Insults to the ar-
terial walls occur primarily at sites of non-laminar or turbulent blood ﬂow (e.g. at
branching sites [43]) due to classic risk factors (such as blood lipids, hypertension,
diabetes, smoking, reactive oxygen species ... [44]), eventually leading to vulnerable
sites. These vulnerable sites accumulate lipids and attract inﬂammatory cells. This
leads to the formation of a lipid-rich core, causing the artery to enlarge outward (i.e.
blood ﬂow continues mostly unimpeded). This ﬁrst stage is called fatty streak and
many streaks recede or remain stable throughout an individual’s lifespan. Some fatty
streaks however, are marked by elevated cytokine signalling which causes an inﬂux
of monocytes. Monocytes differentiate into macrophages which attempt to ingest the
lipids but often fail to process them and become bloated foam cells, signalling for
even more leukocytes to migrate to the lipid core. Unless blood lipid levels (particu-
larly LDL cholesterol) and/or inﬂammatory signalling are remediated, this triggers a
vicious cycle transforming the fatty streak into an atheroma [45].
In the center of an atheroma, foam cells and extracellular lipid droplets form
a core region, which is surrounded by a ﬁbrous cap of smooth-muscle cells and
a collagen-rich matrix. In a growing lipid core proteinases secreted by the acti-
vated leukocytes can degrade the extracellular matrix while pro-inﬂammatory cy-
tokines such as interferon−γ (IFN−γ) can limit the synthesis of new collagen. These
changes can thin the ﬁbrous cap and render it friable and susceptible to rupture.
When the plaque ruptures, blood that comes in contact with the tissue factor in
the plaque coagulates, instigating thrombus formation. A thrombus can settle locally
or in a remote artery causing restricted or blocked blood ﬂow to the downstream
organ. If the thrombus occludes the arteries which feed blood to the heart muscle or
brain this can pose an acute threat to the individual’s life known as acute myocardial
infarction or stroke respectively.
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Figure 1.6: Gradual development of endothelial dysfunction into a ruptured atheroma.
Source: WikiMedia Commons.
A non-occlusive thrombus may eventually resorb as a result of endogenous or
therapeutic thrombolysis. However, a wound healing response triggered by thrombin
generated during blood coagulation can stimulate smooth muscle proliferation in the
ruptured atheroma. Platelet-derived growth factor (PDGF) released from activated
platelets stimulates smooth muscle cell migration. Transforming growth factor−β
(TFG−β), also released from activated platelets, stimulates interstitial collagen pro-
duction. This increased migration, proliferation and extracellular matrix synthesis
by smooth muscle cells, thickens the ﬁbrous cap and causes further expansion of the
intima, often now in an inward direction, yielding constriction of the arterial lumen.
Stenotic lesions produced by the lumenal encroachment of the ﬁbrous plaque in ar-
teries may restrict ﬂow. Particularly under situations of increased cardiac demand
this may lead to ischaemia, commonly provoking symptoms such as angina pectoris
if the coronary arteries are affected. Advanced stenotic plaques, being more ﬁbrous,
may prove less susceptible to rupture and renewed thrombosis [46].
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1.2.4 Epigenetics of Cardiovascular Function, Ageing and Disease
Epigenetic signalling has been ﬁrmly implicated in several diseases [47]. In colon
cancer for instance, several studies have reported that transcriptional silencing of
the gene MGMT is associated with hypermethylation of the promotor region [48,
49]. Yet the function of epigenetic signatures in cardiovascular disease is still largely
unexplored. The study of epigenetic markers is gaining importance as it may aid
in a deeper understanding of molecular mechanisms underlying the modulation of
gene expression in the pathways linked to atherosclerosis, angiogenesis, ischemia-
reperfusion damage, and the cardiovascular response to hypoxia and shear stress,
among many others [50, 51].
1.2.4.1 Telomere Length
One of the ﬁrst in vivo demonstrations of the association between systemic TL and
CVD was a study showing shorter telomeres in periferal blood leukocytes of subjects
with severe coronary artery disease [52]. Later, similar associations were found in
subjects with myocardial infarction [53, 54], chronic heart failure [55], stroke [53]
and degenerative aortic valve stenosis [56].
There is also evidence that replicative senescence (and hence TL) of vascular
endothelial cells is an integral part of atherosclerosis development and progression
[57, 58]. In the tunica intima, an age dependent telomere attrition was observed,
which was higher in arterial regions characterised by higher haemodynamic stress
and increased cell turnover (the same regions that are prone to atherosclerotic lesion
formation) [59, 60]. Systemic telomere length, as measured in the peripheral blood
leukocytes, is also associated with cardiovascular health parameters such as pulse
pressure [61], oxidised low density lipoprotein (ox-LDL) [62] and ﬁlling patterns
[63].
1.2.4.2 DNA Methylation
Hiltunen et al. ﬁrst reported that atherosclerotic lesions are characterised by global
hypomethylation of DNA [64]. Using LINE-1 repeat element methylation as a proxy
for global methylation, revealed lower methylation levels in patients affected by
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CVD. At follow up, individuals with lower LINE-1 methylation had an increased
risk of ischemic heart disease and stroke [65]. Despite advances such as these it has
not been proven conclusively whether global hypomethylation is a consequence or
cause of the proliferation of vascular cells in atherogenesis.
Besides global methylation levels, there are also numerous methylation differ-
ences in speciﬁc genomic locations which have been linked to CVD. There are nu-
merous reviews providing a good overview of loci associated with atherosclero-
sis [66], coronary artery disease, hypertension, ... [50]. Additionally, a very recent
study explored the methylation proﬁle of vascular lesions in a semi-genome-wide
manner [67].
Similar to TL involvement in CVD, it appears that DNA methylation is not only
associated with strong outcomes such as the ones listed above. Changes of DNA
methylation induced by nothing more than the patterns of blood ﬂow have been
shown both in vitro and in vivo [68].
1.2.4.3 Other Epigenetic Traits
Other epigenetic traits linked to cardiovascular function include, among others, his-
tone modiﬁcations in cardiac growth [69], ncRNAs in atherosclerosis [70], miRNAs
controlling cardiovascular differentiation [71] and miRNAs implicated in hyperten-
sion [72].
1.3 High-throughput Analysis
The research presented in this thesis relies heavily on the acquisition and processing
of large quantities of data. This data tracks changes in speciﬁc parameters chosen to
be monitored. These parameters however are only a representation of an underlying
biological phenomenon. In order to drawmeaningful conclusions from large amounts
of data it is crucial to a) use appropriate statistics, b) utilise efﬁcient algorithms and
c) have a good understanding of how the data is related to the biological entity of
interest. Each of these aspects will be addressed in this section.
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1.3.1 Statistical Considerations
Statistics has long been applied to biology and medicine. In turn, speciﬁc require-
ments for biological research have driven further development of new statistical meth-
ods. This link was personiﬁed by Sir Ronald Fisher (1890−1962), both an accom-
plished statistician and geneticist he is perhaps best known as a proponent of the
frequentist school of statistics. The statistical considerations highlighted in the fol-
lowing sections are exempliﬁed by inter group difference but they are just as relevant
to other types of associations such as regression analysis.
1.3.1.1 Traditional Framework
The traditional framework for analysing biological research centres around experi-
ments with a limited number of parameters to be measured and ample replicates to
estimate the contribution of the respective parameters on an outcome of interest. This
type of data can be formalised as a matrix of dimensions mxn where m ≤ n and m,
the number of rows, represents the number of variables measured and n, the number
of columns, describes the sample size.
In the most simple of cases m = 2, i.e. one factor splitting n into two groups and
one variable of interest. In this case well known statistical tests for group comparisons
such as the Student’s or Welch’s t-test may be applied if their speciﬁc conditions are
met. For m ≥ 3 methods such as MANOVA and multivariable linear models may be
applied. Due to measurement errors the observed effect is likely different from the
true effect. Increased n will increase conﬁdence in the estimates of coefﬁcients by
reducing the uncertainty of our observations.
1.3.1.2 Framework for High-throughput Analysis
Similar to the traditional framework, high throughput analyses can be described as a
mxn matrix. However, due to technological advances we are now able to measure
many different parameters in parallel leading to the situation where m >> n.
In the traditional framework, one test is performed at a given signiﬁcance level α
(usually 5% is chosen). In this case there is only a 5% chance of rejecting the null-
hypothesis if the null-hypothesis is true. Multiple testing arises when an experimenter
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sets out to compare two groups with respect to more than one outcome measure.
Consider for instance a list of 100 gene expression values. If in reality all null-
hypotheses are true (expression is identical in all of the 100 genes), the expected
number of incorrect rejections is 5. If the tests are independent, the probability of at
least one incorrect rejection is 99.4% (= 1− (1− 0.05)100). These errors are called
false positives or Type I errors.
Several methods have been developed to keep the number of false positives in
check for high-throughput analyses. One way of achieving this is to control the
family-wise error rate (FWER). The FWER may be formulated as the probability of
making at least one Type I error, or the probability of making at least one false posi-
tive decision. One example is the Bonferroni correction which simply sets a new sig-
niﬁcance threshold by dividing the cut-off α by the number of tests performed [73].
This is however a very conservative correction and in practice it is more useful to
retain a few false positives rather than missing results due to false negatives.
One technique addressing this concern is frequently used throughout this thesis:
the Benjamini-Hochberg false discovery rate (FDR) [74]. The concept behind FDR
is to control the number of false positives within those variables which are declared
statistically signiﬁcant. Similar to the 5% threshold for Type I errors used in the
traditional frequentist approach, we wish to limit the number of false positives to a
threshold value α. This procedure is formalised as follows:
Pk ≤ k
m
α (1.2)
Assume an experiment where m null-hypotheses were tested and a list of m P-
values (P) in ascending order was obtained. For each k fromm to 1 we check whether
the inequality in 1.2 holds true. All k null-hypotheses starting from the ﬁrst one
where this is the case, are rejected and the difference is considered signiﬁcant. The
Benjamini-Hochberg procedure assumes independence of all m hypotheses but also
works in several cases of dependence [75]. More importantly it is scalable with m
(even for millions of hypotheses) and does not depend on the true number of null-
hypotheses that should be rejected. For example, assume 1000 features are compared
between two groups and 20 (100) measures are returned signiﬁcant by our statistical
test. If the FDR is set at 5%, we expect on average 1 (5) false positive(s) in a list of
20(100) signiﬁcant features. Note that in practice the extent to which truly differential
features are recovered, depends on the magnitude of the difference, experimental
noise and sample size.
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1.3.2 Bioinformatics for Sequencing Data
Even the most simple tasks involved in analysing biological data require signiﬁcant
amounts of time if performed manually (the reader is invited to align a 25 bp se-
quence to a random 1000 bp reference or calculate the FDRs for 100 paired t-test in a
two group comparison). In practice the human genome is approximately 3∗109 bp in
length, the number of sequences to be aligned are often expressed in millions, a gene
expression comparison covers thousand of actively transcribed genes and large pop-
ulation studies typically involve hundreds if not thousands of subjects. These kinds
of problems are not tractable by hand or even with basic computational techniques.
Like most scientiﬁc disciplines there is no comprehensive deﬁnition of what con-
stitutes bioinformatics. In broad terms bioinformatics is a discipline that uses com-
puter science, mathematical, statistical and engineering principles to investigate bio-
logical systems. Many sub-ﬁelds of bioinformatics exist but it is beyond the scope of
this introduction to list all of them [76]. Most relevant to the subsequent chapters is
the rise of sequence data analysis as a major discipline within bioinformatics.
1.3.3 Sequencing Data
The ability to sequence DNA fragments constituted a major breakthrough for bio-
logical research, the importance of which was acknowledged with the Nobel prize in
Chemistry in 1980. The Sanger method of sequencing more speciﬁcally, would dom-
inate sequencing efforts throughout the 1980’s, 1990’s and early 2000’s. Although
the Sanger method and its subsequent improvements revolutionised sequencing, it
is always limited in scope. Every reaction can determine only a single puriﬁed se-
quence.
For applications like expression proﬁling and metagenomics a complex mix of
different (c)DNA species must be examined. Although hybridisation probe arrays
offer one possible solution to this problem, they do not offer the same combination
of ﬂexibility and granular detail.
The ﬁrst next generation sequencers, the Roche 454 and Illumina Genome Anal-
yser, enabled the parallel sequencing of an arbitrarily complex mix of (c)DNA al-
beit with their own speciﬁc trade-offs. 454-sequencing offered ∼ 500000 reads per
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run with a maximum length of approximately 500 bp [77]. The ﬁrst generation of
Genome Analysers sacriﬁced read length (20 to 55 bases initially) for greatly in-
creased throughput (2 to 10 million fragments per lane with 8 lanes on a plate) [78].
Both platforms have known multiple iterations since their introduction improving
both on hardware and software allowing for faster sequencing with more accuracy
and throughput. The research presented in this thesis only uses data from Illumina
type sequencing.
Figure 1.7: Overview of the Illumina sequencing
process. Adapted from [79].
Illumina sequencing (see
Figure 1.7) relies on photo-
sensitive terminators that al-
low each base to be read by a
photo detector upon incorpora-
tion, one known base at a time.
To produce a sufﬁciently strong
light signal, each fragment to
be sequenced is hybridised to a
”spot” on the plate using uni-
versal adapters that were lig-
ated to the fragment of inter-
est. These adapters allow for
the ampliﬁcation of the target
fragment by bridge ampliﬁca-
tion. In this process each frag-
ment is ampliﬁed locally by
PCR but they remain contained
to the respective spots because
the primers are attached to the
plate. Once the bridge ampli-
ﬁcation is complete, all com-
plementary strands are washed
away and each spot carries
multiple single stranded DNA
copies of the original fragment.
In theory all copies incorporate
the same nucleotide in each se-
quencing cycle and their com-
bined light signal is strong enough to detect.
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The light signals are then converted to a base call which determines the identity
of a base in a given position on a given fragment. The call is made with a certain
certitude of correctness which is reported along with the base’s identity in a ﬂat text
ﬁle format known as ”fastq” (see Figure 1.8). A single read from an Illumina machine
consists of four lines: 1) a unique identiﬁer line which usually contains the machine
id and the position on the plate, 2) a line with each individual base call, 3) a line
beginning with a ”+” character optionally followed with more information and 4) a
line of single characters which encode the base call conﬁdence of each base and is
therefore of equal length as the base call line [80]. In paired-end mode, two fastq ﬁles
are generated, the ﬁrst containing reads from one end of each fragment and the second
from the other end. The reads in both ﬁles appear in the same order, a requirement
for many applications.
Figure 1.8: An example of 6 reads in the typical 4-line fastq format.
There are many ways to process fastq ﬁles depending on the application. In
human experiments typical steps include: quality control, trimming adaptors at the
5’ end and low quality bases at the 3’ end, mapping reads to a reference genome or
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transcriptome and ﬁnally summarising the results. For each of these steps several
tools are available depending on the application [81–83], whether they be published
open-source software, licensed software or self-scripted solutions.
In this thesis three main types of sequencing experiments were performed: 1)
RNA sequencing, 2) genome wide methylation enrichment sequencing and 3) tar-
geted bisulphite sequencing. The general workﬂow and speciﬁc data properties of
each will be highlighted below.
1.3.4 RNA Sequencing
The general purpose of RNA sequencing is to obtain a snapshot of the transcription
and splicing activity of cells. Several techniques have been devised to extract RNA
from cells and enrich the fragments of interest.
1.3.4.1 RNA Preparation
The ﬁrst hurdle is the overwhelming abundance of ribosomal RNA (rRNA). rRNA
is an integral component of the ribosomes that constitute the translation machinery.
Estimates vary between cell types but the proportion of rRNA is usually in excess
of 80% [84]. Although there are good applications for rRNA proﬁling, usually in
the realms of evolutionary [85] and microbial community research [86], for many
other applications this represents a situation where less than 20% of the sequences is
actually relevant to the research question.
Several techniques exist to enrich the non-ribosomal fraction of RNA: capturing
based on the polyadenylated tail of mRNA [87], rRNA removal by probes which rely
on conservation of the ribosomal sequences [88] or removal of the most abundant
cDNA species (obtained from RNA) by duplex-speciﬁc nuclease [89]. Platform spe-
ciﬁc RNA sequencing protocols are usually available and the sequencing is relatively
straightforward as the RNA is converted to cDNA before sequencing. These pro-
tocols vary by input material (RNA input amount, fresh frozen, formalin-ﬁxed and
parafﬁn-embedded, ...) and output (paired vs single end, directional, coverage, ...).
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1.3.4.2 Normalisation
Once sequencing is complete and data pre-processing has been handled, the se-
quences need to be mapped with a splicing-aware alignment algorithm like Bowtie2
[90] or STAR [91]. The mapping results are then summarised by genomic features.
These features are usually genes, transcripts or exons. After converting mapped
sequences to feature coverage, the ﬁrst step of analysis is typically normalisation.
Normalisation is an essential step in sequence data analysis. If we are looking for
expression differences between two samples but the number of total fragments se-
quenced for sample 2 is twice the number for the ﬁrst sample, it would appear that
all genes have roughly double the expression of the ﬁrst sample even if the samples
are identical.
Several methods have been used for normalisation. The simplest is the introduc-
tion of uniform correction factors per sample to adjust for the mean coverage [92].
More intricate correction procedures include accounting for feature length and total
coverage (Fragments Per Kilobase of exon per Million fragments mapped: FPKM)
[87], log transformation of the data after correcting for feature length and application
of micro-array analysis techniques [93] or adjusting for the coverage distribution of
each sample when calculating scaling factors [94].
An example of this last class of methods is known as trimmed mean of M-values
(TMM) normalisation. The underlying assumption is that even if a sample is charac-
terised by extreme expression values in a few genes, the majority of genes will have
”moderate” expression values. Because sequencing experiments have a limited num-
ber of ”slots” (i.e. reads) available, a highly expressed gene will not only produce a
lot of reads, it will also suppress other genes ability to be picked up in reads. TMM
normalisation counteracts this by ﬁrst calculating log transformed ratio’s of expres-
sion (a.k.a. fold change). Subsequently it discards an arbitrarily chosen percentage
of genes with the highest expression or highest absolute fold changes (30% by de-
fault) and calculates scaling factors based on two assumptions. The ﬁrst being that
the majority of genes most likely have little or no change in expression and secondly
that more highly expressed genes are more stable and should be attributed additional
weight in normalisation.
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1.3.4.3 Comparing Expression Data
After normalisation the sequence data can be compared between groups. Summed
sequence reads as a proxy for gene expression values are prone to substantial vari-
ation whether it be due to technical or biological variation. This behaviour can be
modelled quite well by a negative binomial (NB) distribution [95]. But the facts that
many genes are tested at once and that the number of replicates is usually limited by
the experimental cost, makes test moderation, i.e. avoiding unrealistic small variance
estimates, crucial in order to avoid spurious results [96]. One way of achieving this
was implemented in the R package ”edgeR” [97]. In this approach, three sources of
information regarding the dispersion of reads are combined: an estimate of disper-
sion across all genes in a sample, an estimate of variance in function of the expression
level and lastly an estimate of dispersion per gene (across samples). Each of these
dispersions needs to be estimated. Robinson et al. initially proposed a relatively sim-
ple quantile adjusted conditional maximum likelihood method [95] but have since
expanded the estimation methods to better describe the nature of RNA-seq data and
allow more complex experimental designs. Regardless, the end result is a disper-
sion parameter ϕ which can be plugged into a NB distribution describing the reads.
Finally, in the case of a two-group comparison, an exact P-value can be calculated
analogues to the Fisher exact test but replacing the hypergeometric distirbution by a
NB distribution for P-value calculation. For more complex designs generalised linear
models are used with slight modiﬁcations to estimate the coefﬁcients [98].
A substantial range of other tools is available, each with their own approach to
handling variance estimation, signiﬁcance testing, multiple testing correction and re-
porting [99–101]. These analysis steps are also required for sequencing data obtained
from other sources than RNA but one should keep in mind that some applications,
such as methylation enrichment sequencing, have very different read distribution
properties.
1.3.5 Methylation Enrichment Sequencing
To query the methylation status of cytosine residues over the entire length of the
genome a relatively simple and cost effective technique was developed. Instead of in-
specting the entire genome, the relevant sections can be isolated by afﬁnity capturing
of 5mCpG [102]. When the enrichment step is followed by sequencing this method is
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known by several names: MethylCap-seq [103], MBD-seq [104], and MBD-isolated
genomic sequencing (MIGS) [105]. For clarity the term MethylCap-seq will be used
throughout this thesis.
The conceptual basis for MethylCap-seq is depicted in Figure 1.9. In the ﬁrst
step, genomic DNA is fragmented usually by sonication but alternatives such as
nebulisation [106] are also suitable. In the second step, sonicated DNA fragments
are captured by naturally occurring or speciﬁcally modiﬁed Methyl Binding Domain
(MBD) containing proteins such as MBD2 or MCEP2 which are afﬁxed to beads
or elution columns. Under low salt concentrations these proteins will preferentially
bind methylated CpGs in a non-covalent way. The last step is to elute the bound DNA
with increasing salt concentrations. Low salt concentrations will release fragments
that are slightly methylated while high concentrations will also elute fragments with
multiple methylated CpGs.
Figure 1.9: Schematic outline of the MethylCap procedure. Genomic DNA is ﬁrst
fragmented. Glutathione S-Transferase−MBD fusion protein coupled to magnetic beads is
then used in an (automated) capture process. Methylated DNA fragments from the genomic
DNA pool is bound to the immobilised GST−MBD under low salt conditions. A salt
gradient is subsequently used to wash and elute DNA fragments from the immobilised
GST−MBD. FT: Flow Through [103].
The eluted DNA can then be sequenced and the resulting fragments mapped to
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the reference genome. This results in coverage maps that reﬂect the methylation
status in the sample. It should be noted that MethylCap-seq actually yields no in-
formation about the methylation degree of any speciﬁc CpG dinucleotide and the
resolution is limited to the fragment sizes. Most studies use paired-end sequencing.
But even though contemporary Illumina type sequencers easily obtain reads 100 bp
long, which means a 200 bp fragment is fully covered in a paired-end run, the se-
quencer cannot distinguish between unmethylated CpG and 5mCpG (or 5hmCpG for
that matter).
To analyse this type of data it is assumed that the methylation degree in a given
region is proportionate to the sequencing coverage. It has been demonstrated that
CpG density and CG-content are sources of bias which can make certain parts of the
genome unnameable to analysis by MethylCap-seq [107, 108]. In practice sequence
coverage is not necessarily comparable between regions in the same sample but fairly
similar to the same region in other samples. Lastly, coverage of a region can be
expressed in terms of the number or reads within a region but can also be quantiﬁed
as the maximum coverage in a region. For the analyses in this thesis we rely on
maximum coverage as this measure is independent of the length of the region.
As far as data analysis is concerned, methods developed for differential expres-
sion detection in RNA-seq are compatible with MethylCap-seq data as long as one
accounts for the fact that the coverage distribution and number of variables are quite
different. Exploratory analyses have shown that TMM for instance, often does not
offer any improvements over simple library size scaling (data not shown).
1.3.6 Bisulﬁte Conversion Based Methods
Although MethylCap-Seq offers a good trade-off between coverage and cost, it only
provides a very rough estimate of the methylation degree in each region. The de facto
standard for DNA methylation is bisulphite sequencing.
Bisulﬁte sequencing measures methylation by using a chemical conversion which
it is named for. By treating DNA with (sodium) bisulphite, cytosine bases are con-
verted to uracil (see Figure 1.10). Uracil has the same base pairing behaviour as
thymine. If the converted DNA is ampliﬁed by polymerases the C-G base pair will
be converted to T-A. However, when a cytosine is methylated it is protected from
conversion and will remain a C-T base pair [109].
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Figure 1.10: Bisulﬁte-mediated conversion of cytosin to uracil. Adapted from [110]
The bisulphite treated DNA can be analysed in several ways but whole genome
sequencing offers unparalleled coverage and detail. This strategy is very costly as
high coverage is needed to obtain a reliable methylation throughout most of the
genome [111]. Additionally, CpG dinucleotides are considerably under-represented
in the human genome [112] and thus much of the sequencing capacity is wasted. To
increase coverage in the relevant sections of the genome one possible solution is re-
duced representation bisulphite sequencing (RRBS) [113]. This technique relies on
restriction enzymes which are indifferent to methylation such as Msp1 which has a 3’
-CCGG-5’ restriction site. By amplifying only the regions surrounding these break-
points (typically 500 bp) only ∼ 1% of the genome is sequenced. Other options exist
but will not be discussed here [114].
A different way to use bisulphite treated DNA is to perform (q)PCR with two
primer pairs, one for the case of unconverted, originally methylated, cytosine and
another for the converted thymine (unmethylated cytosine) [115, 116]. These tech-
niques, collectively referred to as methylation speciﬁc PCR (MSP), offer consider-
able cost reduction when dealing with large sample sizes but even though tools are
available for primer design (such as MethPrimer [117]), in practice it can be difﬁcult
if not impossible to design good primers for a speciﬁc region.
An intermediate in this range of techniques is targeted bisulphite sequencing. In
this approach primers are designed which target a predeﬁned region of interest. These
primers typically contain no or few CpG dinucleotides and are thus able to amplify
the target regardless of methylation status. One or several regions per sample may
be ampliﬁed and the amplicons are then sequenced, typically at very high coverage
resulting in very precise methylation estimates [118]. Despite these advantages, the
accuracy of these estimates is still not optimal because sequence differences as a
result of the bisulphite conversion tend to affect the efﬁciency of the PCR ampliﬁca-
tion [119,120].
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The analysis of sequencing reads from bisulphite treated DNA is fairly straight-
forward. For each cytosine (or group of neighbouring cytosines) a methylation per-
centage is obtained. These percentages can simply be summarised or compared be-
tween treatment groups. One analysis package implements both logistic regression
by modelling log odds of the treatment groups (i.e. logarithm of the percentage
methylated divided by the percentage unmethylated) while accounting for the cov-
erage depth and, a Fisher’s exact test in case no replicates are present [121].
All of these methods share a set of caveats that should always be considered
when interpreting results [111]. Getting the reaction circumstances for bisulphite
conversion right is a difﬁcult process. If the exposure time is too long or the bisulphite
concentration too high, a substantial amount of DNA will be destroyed by the caustic
nature of the reaction. If the time is too short or insufﬁcient bisulphite is used, the
conversion of cytosine may be incomplete and yield false positive methylation results.
Lastly, bisulphite converted DNA typically shows strand breaks which reduce the
average fragment length considerably. Therefore primers should always be designed
to amplify a relatively short amplicon (typically less than 500 bp). Lastly, some
regions may no longer be mappable to the genome as the conversion of cytosine to
thymine can greatly reduce the sequence complexity.
1.3.7 Limitations of Sequencing Data Analysis
As mentioned above, sequencing data is best modelled by a NB distribution char-
acterised by a mean and a dispersion parameter. Although the above mentioned
”edgeR” package (and therefore also the ”methylKit” package which uses ”edgeR”
code for the actual differential methylation analysis) was developed and optimised
with NB distributions in mind, there are still unresolved questions about the be-
haviour of such data in more complex experimental design.
In chapters 3 and 4, we will introduce an experimental design which includes
repeated measurements of the same subjects for both within and between subject
comparisons. For within subject comparisons, power can be gained by using what
are in effect repeated measurements. This can be taken into account by introducing
subject identity as a random effect using mixed models or by incorporating it using
ﬁxed effects. The former has the advantage that both within and between subject
effects can be assessed, but, imposes additional assumptions.
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Random effects are assumed to be normally distributed and orthogonal on the
ﬁxed effects. The use of subject speciﬁc ﬁxed effects on the other hand, requires
fewer assumptions but these models are less suited for estimating effects of variables
that do not change over time. For NB data, the use of subject speciﬁc effects is not
well studied yet, and they might lead to liberal P-values [122]. These limitations will
be discussed in more detail in sections 3.4 and 4.4.
1.3.8 Pathway Analyses
Sequencing experiments are often used to generated a ranked list of genes. This is
not a true endpoint for biological research. More formally a ranked gene list can be
seen as a basis on which to generate new research hypotheses. To derive biologi-
cally meaningful results, pathway analysis seeks to place observed gene expression
or methylation differences in a functional context. For instance, if 10% of the sig-
niﬁcantly differentially expressed genes are kinases, as opposed to 1% of the genes
in the human genome which are kinases, this is a strong indication that kinases in
general are relevant to the research questions (without putting too much emphasis
on any particular kinase coding gene). Pathway analysis methods fall in three broad
categories: 1) singular enrichment analysis (SEA), 2) gene set enrichment analysis
(GSEA) and 3) modular enrichment analysis (MEA) [123].
1.3.8.1 Pathway Repositories
Regardless which pathway analysis method one chooses, a reference database of
known pathways and their constituent genes is required. Several repositories are
available each varying in focus, content curation or accessibility such as KEGG, Re-
actome, WikiPathways ... [124].
1.3.8.2 Singular Enrichment Analysis
The most traditional strategy for enrichment analysis is to take the users preselected
genes of interest (e.g. differentially expressed genes between experimental versus
control samples) and then iteratively test the enrichment of each annotation term
one-by-one in a linear mode. Thereafter, the individual, enriched annotation terms
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passing the enrichment P-value threshold are reported in a tabular format ordered by
the enrichment probability (enrichment P-value). The enrichment P-value calcula-
tion, i.e. number of genes in the list that hit a given biology class as compared to pure
random chance.
A common weakness of tools in this class is that the linear output of terms can
be overwhelming (from hundreds to thousands). Therefore, the interrelatedness of
relevant terms can be diluted. For example, relevant GO terms like apoptosis, pro-
grammed cell death, induction of apoptosis etc. may be spread out across this long
list. In addition, the quality of pre-selected gene lists could largely impact the enrich-
ment analysis, which makes singular enrichment analysis (SEA) analyses unstable to
a certain degree when using different statistical methods or cut-off thresholds.
1.3.8.3 Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) uses the core principles of SEA, but with a
distinct algorithm to calculate enrichment P-values as compared to SEA [125]. The
core concept of GSEA is the elimination of the need for a cut-off. Besides reducing
the need for arbitrary factors in the gene selection step that could impact SEA analy-
ses, this strategy offers the added advantage of deriving information from all genes to
a varying extent by using a weighing factor. The maximum enrichment score (MES)
is calculated from the rank order of all gene members in the annotation category.
Thereafter, enrichment P-values can be calculated by comparing the MES to a MES
distribution obtained by randomly shufﬂing the samples (i.e. permutation).
However, tools in the GSEA class are also characterised by certain limitations.
First, the GSEAmethod requires a summarised biological value (e.g. fold change) for
each of the genes as input. Sometimes, it is a difﬁcult task to summarise many bio-
logical aspects of a gene into one meaningful value when, for instance, one considers
different splice forms of a gene. Additionally, the underlying assumption is made
that genes with large differences in expression (e.g. fold changes), which drive the
enrichment P-values, are contributing more to the biology. In practice, small changes
in signal transduction genes can result in larger downstream biological consequences.
Depending on the questions that the researcher is asking, the mildly changed signal
transduction genes may be more relevant than genes with large expression changes.
One last concern is that GSEA is underpowered in cases where the number of repli-
cates is low because this limits the number of potential permutations.
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1.3.8.4 Modular Enrichment Analysis
Modular enrichment analysis (MEA) inherits the basic enrichment calculation found
in SEA and incorporates extra network discovery algorithms by considering term-
term relationships. MEA tools organise and condense a wide range of heterogeneous
annotation content, such as GO terms, protein domains, pathways and so on, into
term or gene classes. These methods take into account the redundant and networked
nature of biological annotation content in order to concentrate on building the larger
biological picture rather than focusing on an individual term or gene. Such data-
mining logic seems closer to the nature of biology in that a biological process works
in a network manner.
However, the limitation of MEA is that ”orphan” terms or genes (without strong
relationships to neighbouring terms/genes) could be left out from the analysis. Thus,
it is important to examine those terms or genes that are left out during MEA analyses
[126]. In addition, the quality of the pre-selected gene list impacts the analytic results,
just as it does in SEA analysis.
1.3.8.5 Other Considerations
The classiﬁcations listed so far offer a useful insight into the general nature of path-
way analysis tools. However, there are other ways in which tools within a category
may vary and certain properties may be shared between categories [127].
The ﬁrst property is the deﬁnition of the null hypothesis. In pathway analysis
there are two ways in which the null hypothesis is deﬁned. The ﬁrst states that the
genes in the gene set (pathway) of interest are no more enriched in the signiﬁcantly
differentially expressed genes than they are in the rest of the gene list. The second
states that no single gene in the gene set is differentially expressed. Pathway analysis
tools based on these hypotheses are called competitive or self-contained respectively.
The interpretation of the results differ for both and they have different properties as
self-contained tests are typically more easily rejected.
A second property relates to the calculation of P-values. Most current methods
use gene permutation to determine whether genes are enriched in the signiﬁcant set
i.e. how likely is it to obtain a comparable enrichment when all gene rankings are
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shufﬂed at random and the same number of genes at the top of the list are considered
signiﬁcant. This approach operates under the assumptions that there is no correlation
between genes in the ranking. In practice, this is often not the case which can lead
to a substantial overestimation of the number of signiﬁcant pathways. An alternative
method is to shufﬂe the samples several times and determine the ranking for each
permutation in order to estimate the probability of a certain enrichment. This latter
method preserves any correlation that may be present in the gene expression levels
and thus arrives at much more conservative estimates.
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1.4 Study Rationale
1.4.1 The Asklepios Study on Successful Cardiovascular Ageing
The Asklepios Study is a longitudinal population study focusing on the interplay be-
tween ageing, cardiovascular haemodynamics and inﬂammation in (preclinical) car-
diovascular diseases [128]. The 2524 participants (1301 women) are a representative
cohort of 35-55-year-old individuals, free from overt cardiovascular disease at study
initiation, randomly sampled from the twinned Belgian communities of Erpe-Mere
and Nieuwerkerken.
Baseline examinations conducted in 2002-2004 include: questionnaires, conven-
tional risk factors and biochemistry. Additional phenotypes under study include a)
vascular structure and function and b) cardiac structure and function. A novel aspect
of the study is ”integrated” non-invasive biomechanical assessment of cardiac, arte-
rial and ventriculovascular function. This integrated haemodynamic phenotype is be-
ing tested in detection, prediction and prevention of clinical cardiovascular pathology
(atherosclerosis progression, atherothrombosis, development of heart failure etc.). A
second aspect is the systematic evaluation of peripheral blood leukocyte TL as a
marker for biological ageing.
Previous studies of the Asklepios population have revealed, among other ﬁndings,
several aspects of telomere dynamics in cardiovascular ageing. In this population
women had longer telomeres than men, inﬂammation and oxidative stress markers
were correlated with TL but classical CVD risk factors were not [129]. In addition
preclinical atherosclerosis was also not correlated with TL [130]. Lastly, paternal age
at birth was an independent predictor of adult TL [131].
Concurrently, the Asklepios study has also resulted in approximately 80 non
telomere related publications ranging from dietary studies [132], over biometric nor-
malisation strategies [133] to a novel risk stratiﬁcation strategy [134].
Currently the ﬁrst follow-up round (2012-present) is being conducted after an
average follow-up of 10 years. Baseline examinations are repeated and the incidence
of (cardiovascular) events is recorded. This follow-up round also introduced the col-
lection of whole blood RNA and the investigators intend to include a small cohort of
new participants to study intergenerational differences.
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1.4.2 Asklepios and Epigenetics
Drawing on various elements introduced in this chapter, the remainder of this thesis
seeks to expand our current understanding of cardiovascular ageing. More speciﬁ-
cally high-throughput data analysis will be applied to link epigenetic signals to other
parameters of cardiovascular health.
Chapter 2 introduces the Asklepios study population which provided the patient
data and samples at the core of this thesis. After a summary of the current under-
standing of how telomere length and cardiovascular health parameters are related,
this chapter focusses on the associations between telomere length on one hand and a
series of functional parameters such as left ventricular ﬁlling and vascular stiffness
on the other.
The study of DNA methylation changes is highlighted in Chapter 3. A small pilot
group of subjects was selected, half of which remained in good cardiovascular health,
the other half showed a marked increase in atherosclerosis. Initial ﬁndings were
validated in a second group of subjects and novel potential markers of atherosclerosis
were identiﬁed.
In Chapter 4 the methylation data are revisited but this time with a particular
focus on the epigenetic changes that occur in the course of ageing. Through the addi-
tional power conferred by a paired study design, this study found distinct differences
between ageing as a linear function of age (cross-sectional analysis) and ageing at
the individual level (longitudinal analysis).
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Altered ﬁlling patterns in ageing
2.1 Introduction
The progression of acquired cardiovascular diseases (CVD) throughout the human
life can typically be tracked by a series of gradual changes in physical, chemical
and biological parameters. Levels of systolic blood pressure (SBP), cholesterol, C-
reactive protein (CRP), smoking status and sex have all been linked with an increased
likelihood of adverse cardiovascular events [1–3]. Telomere length (TL), although
not used in clinical practice, is one such parameter that has repeatedly been linked
with cardiovascular health and disease development [4].
Telomeres are the nucleotide-protein complexes that shield the chromosomal
ends from erosion caused by the end-replication problem during cell division and
distinguishes them from double-stranded breaks to prevent chromosomal fusion [5].
Throughout the replicative lifespan of cells, their TL will decrease until a critical
threshold is reached. Critically short telomeres will typically lead to a cell crisis re-
sulting in senescence, apoptosis or immortalisation [6]. TL is of particular interest
because it potentially provides a cumulative measurement of stresses throughout life
representing ”biological age” [4].
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Although there is still uncertainty about the mechanism(s) by which telomere
biology and CVD pathogenesis affect each other, results from both molecular biology
and epidemiology have repeatedly shown signiﬁcant associations [7–11]. The same
is true for cardiovascular risk factors such as insulin resistance, hypertension [12],
smoking status [13], oxidative stress and inﬂammation [14].
Systemic TL has also been linked to left ventricular (LV) structure and function
but mostly in smaller, patient-speciﬁc settings and not in a general population [15–
22]. Shorter TL can be found in heart failure (HF) patients [23, 24] and patients
suffering from chronic HF have an increased morbidity if their telomeres are shorter
[25]. However, reports on the association between TL and indicators of diastolic
dysfunction show conﬂicting results [18, 19]. Similarly, a positive correlation has
been described between LVM and PBL TL [20–22], but other studies did not detect
a signiﬁcant association between TL and LVM index or LV hypertrophy [18, 26, 27].
The population-based Asklepios Study offers the advantages of a large sample
size and the measurement of numerous potential confounders of TL and CVD. We
therefore investigated the relations between systemic TL and proven prognostic pa-
rameters [28–32] of vascular stiffness, cardiac stiffness, systolic function, diastolic
function and ventricular mass, to shed light on the baseline state of these correla-
tions.
2.2 Methods
2.2.1 Study Population
All data presented in this paper were collected during the ﬁrst round of the Askle-
pios study on successful (cardiovascular) ageing. The study comprises 2524 subjects
approximately 35 to 55 years of age, free from overt cardiovascular disease or other
signiﬁcant pathologies at baseline. The full description of the study design, inclusion
criteria, detailed methodology and population baseline characteristics have been pub-
lished previously [33]. The study was conducted in concordance with the principles
of the Declaration of Helsinki. All subjects gave written informed consent and the
study was approved by the Ghent University Ethical Committee. For the analyses re-
ported here, we used the subset of 2509 subjects for which reliable TL and all major
TL confounder measurements (age, sex, paternal age at birth) were available (cf. De
Meyer et al. [34]).
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2.2.2 Biochemical Analyses
All subjects were fasting, had refrained from smoking for at least 6 hours and were
screened for active infection/inﬂammation before blood sampling. Conventional serum
parameters were measured using commercial reagents according to the manufac-
turer’s recommendations on a Modular P automated system (Roche Diagnostics,
Mannheim, Germany), in an ISO 9002 certiﬁed reference laboratory [33]. Coefﬁ-
cient of variation of all tests was < 3.0%. These parameters included Interleukin-6
(IL-6), C-reactive protein (CRP), oxidised low-density lipoprotein (ox-LDL), serum
uric acid concentrations and brain natriuretic peptide precursor [33].
2.2.3 Telomere Length
For TL-analyses, whole blood was collected in EDTA tubes cooled to 4◦C. DNA
isolation was performed within 3 days of collection using the Puregene Genomic Pu-
riﬁcation Kit (Gentra Systems, Minnesota, USA). The DNA was long-term stored at
-80◦C before TL measurement in duplicate. 5 μg was digested with 5U RsaI and 10U
HinfI followed by gel electrophoresis, Southern blotting, radioactive hybridisation of
the telomeric fragments and weight markers, phospho-imaging and quantiﬁcation
(expressed as kbp: kilo base pairs) [14].
2.2.4 Echocardiographic and Vascular Examination
Blood pressure was recorded using bilateral triplicate measurements (1 minute inter-
vals) on a rested, sitting subject using a validated oscillometric Omron HEM device
(Omron Healthcare Co. Ltd., Kyoto, Japan). Blood pressure values of these six
readings were averaged and the mean value of systolic blood pressure (SBP) is used
throughout this study. The subjects underwent a resting echocardiographic exami-
nation and a scan of the left and right carotid and femoral arteries (VIVID 7, GE
Vingmed Ultrasound, Horten, Norway). Left ventricular (LV) internal dimensions
were measured at end-diastole (LVEDD) with the area-length method. Sphericity
was deﬁned as LV width divided by LV length and is expressed as a percentage.
Standard 2-D volumetric methods were used to calculate ejection fraction (EF) from
end-diastolic and end-systolic LV volumes and to calculate LV mass (LVM). The
LVM was scaled allometrically following the recommendations of Chirinos et al. [35]
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as LVM/(Height)1.7 to account for the effects of both obesity and blood pressure
on LVM. We also scaled LVM to the body surface area (g/m2) [36].
Other cardiac and arterial measurements included the following: systolic (s’),
and early (e’) and late (a’) diastolic septal mitral annulus pulsed wave tissue Doppler
(TDI) velocities, pulsed wave Doppler early (E) and late (A) diastolic transmitral
ﬂow velocities, E-wave propagation velocity (Vpe) and carotid-femoral pulse wave
velocity (PWV). PWV was calculated as follows:
PWV =
ΔLS−F −ΔLS−C
ΔTQ−F −ΔTQ−C (2.1)
In formula 2.1 ΔLS−F and ΔLS−C are the distances measured from sternal
notch to femoral and carotid measuring sites respectively, ΔTQ−F and ΔTQ−C are
the time delays between the start of the QRS complex and the onset of systolic ﬂow
in the femoral and carotid artery measured by pulse wave Doppler imaging (full
methodology described in the online supplements of Rietzschel et al. [33]). CW
Doppler recordings were used to measure isovolumic relaxation time (IVRT) as the
interval from the closure spike of the aortic valve to onset of mitral ﬂow.
2.2.5 Data Analysis
Statistical analyses were performed in R 2.15.2. Continuous variables are reported
as the mean value with standard deviation. Means of groups were compared with
Student (homoscedasticity) or Welch t-test (heteroscedasticity) as appropriate. To
evaluate the contribution of the different confounders to the response variables under
study we applied general linear models as implemented in the glm’ function. We
report both P-values and the estimated unstandardised effect sizes (b) for TL in these
models.
2.3 Results
Baseline characteristics of the population are presented in Table 2.1.
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Table 2.1: Baseline characteristics of the Asklepios study population.
Variable Women (n = 1291) Men (n = 1218) P-valuea Population (n = 2509)
Age (years) 45.9 ± 6.0 46.1 ± 5.9 0.316 46.0 ± 6.0
Weight (kg) 66.7 ± 12.7 82.0 ± 12.4 <2.2E-16 74.1 ± 14.7
Height (cm) 163 ± 6 176 ± 7 <2.2E-16b 169 ± 9
Body Mass Index (kg/m2) 25.1 ± 4.6 26.5 ± 3.7 <2.2E-16b 25.8 ± 4.3
Systolic Blood Pressure (mmHg) 123 ± 14 131 ± 13 <2.2E-16b 127 ± 14
Pulse Pressure (mmHg) 45.5 ± 9.1 48.3 ± 7.4 <2.2E-16b 46.9 ± 8.4
Pulse Wave Velocity (m/s) 6.60 ± 1.45 6.65 ± 1.46 0.397 6.62 ± 1.45
Heart Rate (min−1) 67.2 ± 9.5 64.0 ± 10.7 6.01E-15b 65.6 ± 10.2
Used Antihypertensive Drugs 145 (11.2%) 118 (9.69%) 0.284c 263 (10.5%)
PBL TL (kbp) 7.96 ± 0.73 7.78 ± 0.71 3.26E-9 7.87 ± 0.73
E (cm/s) 78.9 ± 14.2 70.6 ± 13.0 <2.2E-16b 74.9 ± 14.2
A (cm/s) 63.5 ± 11.9 59.6 ± 10.9 <2.2E-16b 61.6 ± 11.6
e’ (cm/s) 9.41 ± 2.13 8.63 ± 1.83 <2.2E-16b 9.03 ± 2.03
a’ (cm/s) 8.67 ± 1.55 9.23 ± 1.46 <2.2E-16 8.94 ± 1.53
E/A 1.29 ± 0.32 1.22 ± 0.29 2.65E-7b 1.25 ± 0.31
e’/a’ 1.13 ± 0.36 0.970 ± 0.29 <2.2E-16b 1.05 ± 0.34
E/e’ 8.68 ± 1.99 8.41 ± 1.78 3.36E-4b 8.55 ± 1.90
s’ (cm/s) 7.91 ± 1.13 7.93 ± 1.20 0.756 7.92 ± 1.16
Vpe (m/s) 79.4 ± 22.1 71.9 ± 19.5 <2.2E-16d 75.7 ± 21.2
DT (ms) 167 ± 29 170 ± 30 9.29E-4 168 ± 30
Isovolumic Relaxation Time (ms) 81.8 ± 13.8 90.2 ± 12.9 <2.2E-16 85.9 ± 14.0
LV Ejection Fraction (%) 64.8 ± 6.7 62.5 ± 6.4 <2.2E-16 63.7 ± 6.7
LVEDD (mm) 44.9 ± 3.9 49.4 ± 4.4 <2.2E-16b 47.1 ± 4.7
Sphericity (%) 56.9 ± 6.4 57.2 ± 6.5 0.246 57.0 ± 6.4
Left Ventricular Mass (g) 124 ± 31 179 ± 40 <2.2E-16b 151 ± 45
LVM index (g/m1.7) 54.2 ± 13 69.0 ± 15.0 <2.2E-16b 61.3 ± 15.9
NTproBNP (pg/ml) 81.3 ± 64.1 36.4 ± 39.2 <2.2E-16bd 59.5 ± 58.0
a: P-value for comparison between sexes using independent t-test (b:unequal variance) or chi-square test (c).
d: Data was log transformed before statistical testing
LVM: allometrically scaled Left Ventricular Mass index, PBL TL: Periferal Blood Leukocyte Telomere Length,
E & A: peak transmitral ﬂow velocities during early (E) and late (A) diastolic ﬁlling, e’ & a’: peak movement
speed of mitral annulus during early (e’) and late (a’) diastolic ﬁlling, DT: transmitral Deceleration Time,
NTproBNP: N-terminal prohormone of brain natriuretic peptide, LVEDD: Left Ventricular End-Diastolic Di-
ameter, s’: peak systolic mitral annulus movement speed, Vpe: pulse propagation velocity in early diastole
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2.3.1 Main Correlates of Telomere Length
Previous studies of the Asklepios population showed that TL length correlates with
age and gender. Mean TRF was shown to be inversely correlated with age (P <1E-
25). The yearly telomere attrition calculated from these cross-sectional baseline data
was estimated at 26 base pairs (bp). Mean TRF was found to be dependent on gender
(P < 1E-8) with men having on average 172 bp shorter telomeres than women. After
age adjustment, this difference was 166 bp (P < 1E-8). The cross-sectional data
showed that telomere attrition proceeded faster in men (30.0 bp per year, R2= 0.062)
compared to women (20.3 bp per year, R2= 0.028) [14]. Further, paternal age showed
a substantial positive linear correlation with TL (R2= 0.127, P < 1E-29) [34].
It has been proposed that socio-economic status (SES) captures a large fraction
of TL variability [37]. Using higher education (college or university) as a proxy for
SES, we indeed discovered a correlation with TL (b= 0.06827, P = 0.024) but it did
not remain upon addition of the two main confounders age and gender (b = 0.0462,
P = 0.119).
2.3.2 Diastolic Function
Unadjusted models yielded positive linear associations between TL and E/A, e’/a’
(Figure 2.1) and E/e’ (Table 2.2, Model 1). In successive (general linear) models,
known major confounders of diastolic function were added, i.e. age and sex in Model
2, additionally heart rate (HR), systolic blood pressure (SBP) including use of anti-
hypertensive drugs and body mass index (BMI) in Model 3. We did not remove
non-signiﬁcant independent variables from the proposed models in Table 2.2 for the
individual response variables as removal of the non-signiﬁcant terms did not alter the
signiﬁcance of the TL component. Addition of further potential confounders: LV
sphericity, oxidative stress (oxidised-LDL cholesterol, serum uric acid) or inﬂamma-
tory markers (high-sensitive CRP, IL-6), did not signiﬁcantly alter the TL - diastolic
dysfunction relationships when added to Model 3 as an independent variable (data
not shown).
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Figure 2.1: TL ∼ E/A. Scatterplot showing the unadjusted correlation between telomere
length (TL) and the ratio of early (E) over late (A) mitral annulus movement speed for
women (red) and men (blue) with the regression line for both combined (black)
In all models the positive association between E/A and TL remained signiﬁcant
(see Table 2.2, P ≤ 0.002) with Model 3 accounting for approximately 43.2% of E/A
variability (2.64% of the total variability could be attributed to TL). Examining the
data separately by sex, we found that, upon adjustment for confounders (Model 3),
the association between E/A and TL was signiﬁcant in both women (b = 0.030, P =
0.001) and men (b = 0.023, P = 0.014). A similar approach was adopted for the
e’/a’ ratio. Results of the linear models were included in Table 2.2 and demonstrated
signiﬁcance of the adjusted associations for e’/a’ (Model 3: b = 0.018, P = 0.012).
Looking at both sexes separately, TL was a signiﬁcant independent variable in women
(b = 0.022, P = 0.032), but only borderline in men (b = 0.016, P = 0.098). Both
for E/A and e’/a’ b is larger in women and the P-value smaller. To formally test for
this difference we added an interaction term for gender and TL length to Model 3.
The interaction term proved not to be signiﬁcant (P = 0.293 for E/A, P = 0.136 for
e’/a’).
We further examined the components of these ratios (E/A and e’/a’) separately
to determine whether the associations were attributable to one of both components
or whether the ratios contained additional information beyond the terms they consist
of. Surprisingly, the results indicated that neither E (b = 0.226, P = 0.535) nor e’
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(b = 0.043, P = 0.341) were correlated with TL (Model 3). There was however a
correlation of TL with A (b = −0.905, P < 0.001) and a’ (b = −0.079, P = 0.040).
Accordingly, E/e’ was not correlated upon adequate adjustment (Model 3: b =
0.014, P = 0.775), neither were other indices of diastolic function: ﬂow propagation
velocity of the E-wave (Vpe; b = 0.212, P = 0.718), mitral inﬂow deceleration
time (b = −0.302, P = 0.712) or duration of the atrial contraction (b = −0.028,
P = 0.938). Only IVRT was inversely correlated with PBL TL (Figure 2.2, Model 3:
b = −0.900, P = 0.011). IVRT was also inversely correlated with PBL TL after age,
sex and paternal-age adjustment (PBL TL as dependent variable; b = −2.92E − 3,
P = 0.010). Additionally, we found no signiﬁcant association with brain natriuretic
peptide (log(NT-proBNP): b = −0.005, P = 0.617) upon adjustment.
2.3.3 Systolic Function and LV Structure
We could not document signiﬁcant associations between TL and systolic function
after adequate adjustment (Model 3, EF: b = 0.016, P = 0.933 and s’: b = −0.038,
P = 0.238). Similarly no associations were found with LV structure assessed by
LV end-diastolic diameter (LVEDD: b = −0.124, P = 0.261) and LV mass (b =
−0.214, P = 0.801), body surface area adjusted LV mass (b = 0.010, P = 0.981)
or allometrically height-adjusted LV mass (b = 0.023, P = 0.943).
2.3.4 Arterial Stiffness
No signiﬁcant partial correlation was found between PWV and age-adjusted TL (cf.
supra), a result that remained unchanged after additional adjustments (Model 3, b =
−0.001, P = 0.971). The same is true for pulse pressure (PP) in the Asklepios
population (Model 3, b = 255E − 6, P = 0.999).
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Table 2.2: The association of TL (kbp) with different parameters of cardiovascular function
using general linear models.
Response variable (RV) Model 1 Model 2 Model 3
E/A b 0.0696 0.0249 0.0264
P 2.83E-16 1.25E-03 8.09E-05
e’/a’ b 0.0764 0.0178 0.0182
P <2.2E-16 0.0281 0.0120
E (cm/s) b 1.91 0.195 0.226
P 1.09E-06 0.600 0.535
A (cm/s) b -1.60 -0.860 -0.905
P 5.37E-07 4.62E-03 4.51E-04
e’ (cm/s) b 0.397 0.050 0.043
P 8.93E-13 0.304 0.341
a’ (cm/s) b -0.211 -0.068 -0.079
P 5.77E-07 0.100 0.0403
E/e’ b -0.158 -0.0214 -0.0124
P 2.62E-3 0.677 0.794
DT (ms) b -1.86 -0.123 -0.302
P 2.24E-02 0.881 0.712
IVRT (s) b -2.70 -0.941 -0.900
P 2.32E-12 9.25E-03 0.0115
log(NTproBNP (pg/ml))
b 0.017 -0.004 -0.005
P 0.119 0.657 0.617
LVM index (g/m1.7) b -2.37 -0.194 0.0228
P 5.41E-08 0.616 0.943
LVEDD (mm) b -0.497 -0.164 -0.124
P 1.11E-04 0.158 0.261
EF (%) b 0.0216 -0,0183 0.0156
P 0.906 0.922 0.933
s’ (cm/s) b 0.018 -0.033 -0.038
P 0.579 0.315 0.238
Model 1: RV ∼ TL
Model 2: RV ∼ TL + Age + Sex
Model 3: Model 2 + Systolic BP + Heart Rate + BMI + Used Antihypertensive Drugs
E & A: peak transmitral ﬂow velocities during early (E) and late (A) diastolic ﬁlling, e’ & a’: peak move-
ment speed of mitral annulus during early (e’) and late (a’) diastolic ﬁlling, DT: transmitral Deceleration
Time, IVRT: Isovolumic Relaxation Time, NTproBNP: N-terminal prohormone of brain natriuretic peptide,
LVM: allometrically scaled Left Ventricular Mass index, LVEDD: Left Ventricular End-Diastolic Diameter,
EF: Ejected Fraction of end-diastolic volume, s’: peak systolic mitral annulus movement speed
b: effect size (unstandardised), P: P-value of TL component
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2.4 Discussion
Our main ﬁnding is that we can extend a number of previously described associa-
tions between PBL TL and cardiovascular structure and function - usually detected
in smaller, diseased cohorts - towards a middle-aged, apparently healthy population.
After adjustment for confounders, we could not document an association with sys-
tolic function, cardiac structure or vascular stiffness. We do however document an
intriguing association with certain parameters of LV ﬁlling.
2.4.1 LV Filling and Diastolic Function
As mentioned in the introduction, previous reports on the association between TL and
indicators of diastolic dysfunction have led to apparently conﬂicting results. Quar-
tiles of telomere length were shown to correlate with diastolic dysfunction in CAD
patients (evaluated by E/A and pulmonary vein ﬂow) [18]. In contrast both E/A-ratio
and diastolic dysfunction were not correlated with PBL TL in a study of elderly sub-
jects (> 85 years) [19]. This can potentially be explained by the very different nature
of the populations under study. Our data showed a signiﬁcant association between
PBL TL and both the E/A-ratio and the e’/a’-ratio and with IVRT [38], but not with
the E/e’-ratio (see Table 2.2 for details). E/e’ is mainly used as an indicator of ele-
vated ﬁlling pressures, reﬂecting more advanced diastolic dysfunction not likely to
be present in healthy subjects [39]. Concurrently, NT-proBNP, a biochemical marker
reﬂecting elevated ﬁlling pressure and diastolic dysfunction [40], was not associated
with PBL TL after correction for confounders (Model 3).
Analysis of the terms constituting the E/A and e’/a’ ratios in this population sug-
gests that TL was associated with atrial contraction (A and a’), rather than with pa-
rameters that could reﬂect myocardial relaxation or ﬁlling pressure, such as E and e’,
or reﬂect myocardial stiffness, such as shortened mitral deceleration time [41]. As
previous publications only described correlations with E/A but not with the individual
components, we cannot tell whether this was the case in other study populations.
Relaxation and stiffness induce opposite effects on mitral E and A and hence
on E/A [41]. The present data do not provide sufﬁcient evidence for an indepen-
dent association between PBL TL and LV relaxation or LV stiffness in the general
middle-aged population. Although there is an association with longer IVRT after
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correction for heart rate and blood pressure, it is difﬁcult to attribute this to myocar-
dial relaxation without a persisting association with the best validated determinants
e’ and Vpe [42]. The persisting associations with atrial contraction ﬂow velocity (A)
and with the simultaneously occurring annular velocity (a’) then most likely affects
compound measures such as E/A and e’/a’. One could speculate that increased IVRT
and enhanced atrial contraction represent an early and subtle delay of myocardial
relaxation, which is not yet apparent in other measurements. We therefore would de-
scribe the ﬁndings as correlation between PBL TL and altered ﬁlling pattern without
sufﬁcient evidence for diastolic dysfunction.
2.4.2 LV Systolic Function, Structure and Vascular Stiffness
In this population without overt cardiac disease, we report that PBL TL was not as-
sociated with minor changes in systolic parameters such as EF and tissue Doppler
movement speed of the septal mitral annulus (s’). Increased LV mass correlates with
increased all-cause and cardiovascular mortality [43] and a positive correlation has
been described between LVM and PBL TL [20–22]. However, our ﬁndings do not
support an association between PBL TL and LVM, body surface area scaled LVM or
height-scaled LVM in the context of a relatively young population. Two other studies
also failed to detect an association between TL and LVM index or LV hypertrophy
in two older populations (∼ 65 years) [18, 26]. These ﬁndings and the fact that the
former studies do not agree on whether normotensive or hypertensive patients show
a TL - LVM correlation, lead us to the conclusion that there is likely an as of yet
unidentiﬁed confounder at work. A third study found no cross-sectional or longi-
tudinal associations between PBL LTL and cardiac measurements including LVM
(adjusted for body surface area) [27].
With respect to vascular stiffness, no signiﬁcant associations between PWV (or
PP) and TL were found in either sex. Previous studies have reported this association
to be signiﬁcant in men [15, 44]. The discordance may be attributable to age and
health characteristics of the respective populations. Indeed these populations were
featured by a higher mean age (∼ 10 years) and a higher mean PWV (60% higher)
compared to the Asklepios study albeit with a different measurement protocol for
PWV.
2-12 ALTERED FILLING PATTERNS IN AGEING
2.4.3 Socio-economic Status
Socio-economic status (SES) has been correlated with TL and SES itself is signiﬁ-
cantly correlated with variables that reﬂect poorer health status [37]. Limited access
to health services, poor dietary options, increased stress etc. can affect TL. Having
a higher education (college or university) as a proxy for SES was correlated with TL
in the Asklepios population but not so after correction for the confounders of age and
gender. Addition of higher education to our model did not affect the correlations with
E/A or e’/a’ (data not shown).
2.4.4 Limitations
The Asklepios data set does not yet include any longitudinal information thus limiting
it to all the drawbacks associated with cross-sectional study designs. Particularly
claims of causality can not be made with cross-sectional data alone. Despite the
extensive characterisation of the Asklepios study, there are some descriptors of CV
function which were not measured (e.g. pulmonary venous ﬂow). We cannot exclude
the involvement of these factors.
2.4.5 Mechanistic Insights
There are two general models in which TL is tied to cardiovascular health. The ﬁrst
states that telomere shortening is a primary driver of (cardiovascular) ageing. In
support of this model our ﬁndings indicate that the associations between some pa-
rameters of LV ﬁlling and telomere length, are not limited to (chronic) HF patients,
but may already be present in a young to middle-aged, apparently healthy population
and are more pronounced in women. It is tempting to speculate that telomere biology
could be mechanistically involved in the early pathogenesis of diastolic dysfunction
and possibly HF by extension. As a matter of fact, in mice, knock-out of the telom-
ere elongating enzyme telomerase, resulted in shortened telomere length over several
generations which was associated with the development of overt chronic HF [45].
However, telomere biology in mice cannot be easily transposed to humans and addi-
tional experiments would be absolutely necessary to pinpoint the exact mechanisms.
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Figure 2.2: TL ∼ IVRT. Scatterplot showing
the unadjusted correlation between telomere
length (TL) and isovolumic relaxation time
(IVRT) (red) and the regression line (black)
In our data, TL was clearly cor-
related with E/A, e’/a’ and IVRT but
not with other indices of diastolic func-
tion. We further explored the relation-
ship between PBL TL and other car-
diac and hemodynamic parameters such
as sphericity of the ventricle, Vpe, du-
ration of the A-wave and deceleration
time (data not shown). No signiﬁcant
associations were found that could help
provide clues as to the mechanism by
which PBL TL and diastolic function
might be linked.
The second model states that TL is
merely an epiphenomenon, an indicator
inﬂuenced by conditions in the ageing
body. Accelerated telomere attrition in
subjects with mildly impaired diastolic function could also be caused by oxidative
stress and inﬂammation, two factors that are known to affect diastolic function as
well as telomere length [14, 23, 46–48]. In this case it might be expected that the
addition of oxidative stress and inﬂammation would cause reduced signiﬁcance for
TL. However, additional markers (CRP, oxidised LDL, IL-6 and serum uric acid) did
not substantially alter the signiﬁcance of the PBL TL component relative to Model
3 in Table 2.2 (data not shown). It should be noted though that these markers only
reﬂect point measurements of oxidative stress and inﬂammation, which are variable
by nature, whereas telomere length has been hypothesised to reﬂect their cumulated
effects (reviewed in De Meyer et al. [4]).
Our data, at present, are insufﬁcient to determine the more likely model. Some
of the non-replicated associations might still become apparent with ageing, assum-
ing that a certain threshold of telomere attrition needs to be reached before it has a
measurable effect on cardiovascular stiffness or visa versa.
2.5 Conclusion
Our results show that several parameters of cardiovascular structure and function
which have been associated with TL, fail to replicate in a well-phenotyped middle-
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aged population sample. However, PBL TL is associated with subtle changes in
certain parameters of LV ﬁlling in this population. Further investigation of the un-
derlying biological mechanisms is warranted to provide insights into the relationship
between PBL TL, diastolic function and cardiovascular health.
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3
Peripheral Blood Leukocyte DNA
Methylome Reﬂects Atherosclerosis
Progression
3.1 Introduction
The dynamics of atherosclerosis, the gradual thickening of vascular endothe-
lial walls by accumulation of saturated fatty cells, are inﬂuenced by a host of
factors [1]. Some are considered intrinsic, others are deemed environmental
inﬂuences and interactions between them are abundant [2]. Several genomic
loci are associated with an increased risk or severity of atherosclerotic plaque
formation [3]. Since an individual’s genetic code is set at conception, it is con-
sidered a non-modiﬁable risk factor. However, genetic factors explain only a
limited portion of atherosclerotic risk [4]. Some of this missing variability
might be attributable to epigenetics.
Epigenetics is commonly deﬁned as the continuum of heritable alterations
that affect gene expression without being reﬂected in the genetic code itself
[5]. Epigenetic effectors include histone modiﬁcations, DNA modiﬁcations,
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non-coding RNAs and telomeres. Epigenetic changes are induced by both
internal and environmental cues and are generally reversible [6].
Recent advances in technologies for measuring epigenetic changes have
led to a steady increase in research assessing the role of epigenetics in the
pathogenesis of atherosclerosis [7]. One marker particularly, 5-methylcytosine
in genomic DNA, has garnered much attention. The majority of studies have
established DNA methylation proﬁles in vasculature affected by atheroscle-
rosis [8, 9]. Additionally, it was demonstrated in APOE-null mice that the
appearance of vascular lesions was preceded by DNA methylation alterations
in aortic tissue but also in peripheral blood mononuclear cells [10].
Indeed, atherosclerosis is considered an inﬂammatory disease [11] and our
current understanding of atherosclerosis hinges on the notion that macrophages
are recruited from the bloodstream to sites of increased endothelial stress [12].
Yet few studies address atherosclerosis related epigenetic changes in circulat-
ing leukocytes. Despite the fact that blood contains a complex and changing
mix of cell types [13], the accessibility of peripheral blood makes it an inter-
esting research subject as it may lead to straightforward clinical applications.
In cancer for instance, blood DNA methylation markers are being evaluated
for this purpose [14]. Previous research targeting blood elucidated athero-
sclerosis related changes in miRNA expression [15], methyl metabolism [16],
CpG methylation levels in repeat elements [17,18] and gene speciﬁc changes
in CpG methylation [19–23]. This study aims to identify novel genomic loca-
tions in leukocytes, that exhibit DNA methylation changes during atheroscle-
rosis progression through genome-wide screening.
To this end, we selected a subset of female participants from the Asklepios
longitudinal study on successful ageing. Using data from both study rounds,
the subjects were classiﬁed in two groups: progressors and non-progressors.
At study initiation (ﬁrst round) only volunteers without overt cardiovascular
disease were included. We deﬁned progressors as those subjects who devel-
oped more pronounced − but still subclinical − atherosclerosis in the decade
between both study rounds. Non-progressors were those who remained sta-
ble in terms of the extent of atherosclerosis. Only females were evaluated
to avoid sex-related epigenomic variation and signiﬁcantly fewer members of
the male subpopulation were available in the non-progressor arm, thus it was
more difﬁcult to match according to the stricter inclusion criteria imposed for
this research.
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3.2 Methods
3.2.1 Study Population Selection
All data presented in this paper, were collected from participants of the Askle-
pios study on successful (cardiovascular) ageing. This study comprises 2524
subjects approximately 35 to 55 years of age, free from overt cardiovascu-
lar disease or other signiﬁcant pathologies at enrolment in 2002-2004. The
participants returned for follow up examination in 2013-2015. The full de-
scription of the study design, inclusion criteria, detailed methodology and
population baseline characteristics were published previously [24]. All sub-
jects gave written informed consent, the study complies with the declaration
of Helsinki and was approved by the Ghent University Ethical Committee.
For the analyses reported here, we used two non-overlapping subsets of 20
and 46 subjects.
3.2.2 Biochemical Analyses
All subjects were fasting and were screened for active infection/inﬂammation
before blood sampling. Conventional serum parameters were measured using
commercial reagents according to the manufacturer’s recommendations on
a Modular P automated system (Roche Diagnostics, Mannheim, Germany),
in an ISO 9002 certiﬁed reference laboratory. Coefﬁcient of variation of all
tests was< 3.0%. These parameters included Interleukin-6 (IL-6), C-reactive
protein (CRP), oxidised low-density lipoprotein (ox-LDL), total cholesterol,
high-density lipoprotein (HDL) and low-density lipoprotein (LDL) concen-
trations among others.
3.2.3 Echocardiographic and Vascular Examination
Blood pressure was recorded using bilateral triplicate measurements (1 minute
intervals) on a rested, sitting subject using a validated oscillometric Omron
HEM device (Omron Healthcare Co. Ltd., Kyoto, Japan). Blood pressure
values of these six readings were averaged and the mean value of systolic
blood pressure (SBP) is used throughout this study. The subjects underwent a
resting echocardiographic examination and a scan of the left and right carotid
and femoral arteries (VIVID 7, GE Vingmed Ultrasound, Horten, Norway).
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3.2.4 Experimental Design
Asklepios Study participants were classiﬁed in two categories. The ﬁrst group
consisted of those who showed good cardiovascular health in the second round,
i.e. they did not develop signiﬁcant atherosclerosis since their initial enrol-
ment during the ﬁrst round as evaluated by echography (from here on called
”non-progressors”). The second group consisted of those that where healthy
in the ﬁrst round but developed substantial atherosclerosis since (from here on
called ”progressors”). The extent of atherosclerosis was assessed as the aug-
mentation of plaque size and thickness near vascular branching sites. Other
parameters of atherosclerosis progressions such as intima media thickness or
oxLDL concentration were not considered.
To minimise the effect of confounding variables that might alter the epi-
genetic proﬁle and to exclude participants with obvious indications of poor
cardiovascular health, we retained only subjects that met these criteria. More
speciﬁcally, we required that the subject was female, had a systolic blood
pressure below 140 mmHg and less than 90 mmHg diastolic blood pressure
in both study rounds, had a BMI smaller than 31 in both study rounds, did
not use any statins prior to or during the study and was a self-reported non-
smoker. We further balanced both groups as best as possible with respect
to the following criteria: age, BMI, BMI change between study rounds and
blood pressure.
3.2.5 Methylated CpG Enrichment Sequencing
3.2.5.1 Experimental Procedures
We used stored DNA samples collected for the Asklepios study obtained from
whole blood samples. We selected 10 Progressors and 10 Non-Progressors
and analysed their DNA from both the ﬁrst and second round. To assess repro-
ducibility we included a technical replicate in each round, parallel processing
from sampling of stock DNA onward, for a total of 42 samples.
MethylCap-Seq was performed using theMethylCap kit (Diagenode, Lie`ge,
Belgium) according to the manufacturer’s instructions. We opted for high salt
concentration elution. The enriched fragments were prepared as a paired-end
library with the NEBNext Ultra DNA Library Prep (New England Biolabs,
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Massachusetts, USA). Library quality was assesed by High Sensitivity DNA
chip on a 2100 Bioanalyzer (Agilent Technologies, California, USA). The li-
braries were sequenced 2x50bp on a HiSeq 2000 (Illumina, California, USA).
With the exception of two samples, we pooled 4 samples equimolarly per lane
based on qPCR measured concentration (Kapa Biosystems, Massachusetts,
USA) while ensuring that the technical replicate samples were placed in 4
different lanes. With exception of the technical replicates each lane (sample
pool) contained both the ﬁrst and second round samples of one progressor
and one non-progressor. Sequencing was performed in 2 separate runs with
sample pools randomly distributed between runs. Sequencing results for all
samples are listed in Supplementary Table C.3.
The sequenced reads were mapped to the human genome using bowtie
(v0.12.7) [25]. The bowtie parameters were set to 0 mismatches in the seed
(ﬁrst 28 nucleotides). Only unique paired reads were retained and both frag-
ments were required to locate within 400bp of each other on the human re-
ference genome (GRCh37/hg19). For each sample duplicate paired reads
with the exact same location were discarded, as these are most likely am-
pliﬁed from the same DNA fragment. Quality control was performed with
FastQC (v0.10.1). All samples were of high quality (Phred Score, dupli-
cation levels, elevated CpG content) and did not require resequencing ac-
cording to these quality metrics or the CpG-enrichment plots (Supplemen-
tary Figure B.1) [26]. The mapped reads were summarised to the ’Map of
the Human Methylome’ Build 3 (http://www.biobix.be/map-of-
the-human-methylome/) . This map contains 3618706 unique genomic
locations that are susceptible to DNA CpG methylation called ’methylation
cores’ (MCs). For each MC, the maximum coverage within the MC was de-
termined per sample.
The resulting count table was used for differential methylation analyses
in R (v3.0.1). First we performed additional QC by estimating the correla-
tion coefﬁcients between the technical replicates after normalising the counts
by simple library size scaling based on the number of unique mapped pairs,
adding 1 to each count and log transforming the data (Supplementary Fig-
ure B.2). Although the replicates show reasonably good correlation (round 1
R = 0.862, P < 2.2E-16, round 2 R = 0.971, P < 2.2E-16), the correlation
is better for the second round suggesting modest deterioration of reproducibil-
ity due to storage at -80◦C over time. When we performed unsupervised clus-
tering on the 2000 MCs with the highest overall variance, the cluster dendro-
gram (Supplementary Figure B.3) shows a clean pairing of ﬁrst and second
round samples with the exception of one subject (AS1.07 and AS2.28). We
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additionally looked for the presence of homozygous or heterozygous SNPs
in all known SNPs with a coverage higher than 10. Pairing of samples by
an independent, blinded investigator recovered the correct sample pairings
(triplets for technical replicates). We therefore concluded that no samples
were swapped and that MethylCap-Seq was successful.
Prior to analyses, we selected the technical replicates with the highest cov-
erage (AS1.20 and AS2.47) reducing the number of samples to 40. The MCs
were annotated based on their location relative to Ensembl features (release
72).
3.2.5.2 Analysis Strategy
In this chapter there were three research questions of interest. First, what
MCs are differentially methylated between subjects with atherosclerosis pro-
gression and without in the second study round? Second, what MCs differ-
entiated between progressors and non-progressors in the ﬁrst study round and
might therefore be predictive. Third, were there MCs that consistently dif-
fered between progressors and non-progressors irrespective of age (i.e. in
both study rounds). We used the edgeR package (v3.4.2) to detect differential
methylation [27].
In this study design, there was a potential interaction between progressor
status and study round. We modelled the main effects and the interaction in
a ﬁxed effects model by eliminating the intercept term and a ﬁxed effect with
four levels: ”NonProgressor-Round1”, ”Progressor-Round1”, ”NonProgressor-
Round2” and ”Progressor-Round2”. The contrasts corresponding to the three
research questions are listed in Table 3.1.
Table 3.1: Contrasts for differences between progressors and non-progressors with study
round and implicit interaction term encoded as a ﬁxed effect with four levels.
Round 1 Round 2 Average
NonProg-Round1 -1 0 -0.5
Prog-Round1 1 0 0.5
NonProg-Round2 0 -1 -0.5
Prog-Round2 0 1 0.5
Note that this model does not include a variable for the individual subjects.
For the comparison in each round separately, this model is appropriate as there
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are no repeated measurements of the individual and the addition of a ﬁxed
effect for subject identity would mask the atherosclerosis related effects. For
the global comparison however, not taking the paired nature of the samples
into account would ignore correlations between the repeated measurements
of the same study subjects in both rounds.
For NB data, the use of ﬁxed effect models that account for subject speciﬁc
effects is not well studied yet. Fixed effect model can be expected to give un-
biased point estimates for within subject comparisons in NB distributed data,
but there might be issues with the estimation of the standard errors that are
provided by standard software [28]. We opted not to include a subject spe-
ciﬁc effect. This means that our differential methylation analysis comparing
all progressor samples to all non-progressor samples, could be overconﬁdent
because the correlation between ﬁrst and second round samples of the same
subject was not taken into account. The following strategy was implemented
to evaluate the P-value estimates of the edgeR package.
We performed a single permutation in which the samples progressor sta-
tus for half of the progressors and non-progressors were switched (in both
rounds identically). This represented a divergent permutation that eliminated
potential atherosclerosis progression effects while preserving the within sub-
ject correlation. An enrichment of low P-values in the permuted dataset would
indicate that the P-values were too liberal and the inference on the real data
has to be interpreted with care.
3.2.6 Targeted Bisulﬁte Deep Sequencing
Based on the results obtained in the MethylCap experiment we selected 16
locations to validate the epigenetic differences observed. We used an inde-
pendent set of 23 non-progressors and 23 progressors selected according to
the criteria described above. Sufﬁcient round 1 DNA was available for all
subjects. In round 2, DNA was unavailable for 6 subjects. For 1 subject no
blood could be drawn. For the remaining 5 subjects, yield of the extraction
was insufﬁcient. We also included a methylated and unmethylated control in
the form of in vitro methylated DNA (S7821, Millipore, Massachusetts, USA)
and DNA from a methyltransferase double knock-out cell line (HCT116) for
a total of 88 samples and one no-DNA blank (negative for all primers, not
included in sequencing).
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Bisulﬁte conversion was performed with the EZDNAMethylation− Light-
ning kit (Zymo Research, California, USA) according to the manufacturer’s
instructions. After bisulphite treatment we ampliﬁed the regions of interest
with the primers listed in Supplementary Table C.4. Primers were designed
taking into account that primers may only contain few if any CpG as this
might cause the PCR reaction to fail. For the design we used an in-house tool
based on Primer3 [29]. If this approach failed to ﬁnd primers with accept-
able thermal parameters we used MethPrimer [30]. For each subject - primer
pair combination, digital electrophoresis (LabChip Gx, Perkin Elmer, Mas-
sachusetts, USA) was performed to conﬁrm the presence of the desired prod-
uct. Short DNA fragments, most likely primer dimers, were removed by High
Pure PCR Puriﬁcation Kit (Roche, Basel, Switzerland). The concentration
of the remaining product was determined by PicoGreen measurement (Life
Technologies, California, USA). The samples were prepared for sequencing
with the Truseq DNA PCR-free Kit (Illumina) with the following alterations
to the protocol. We had less than 1 μg of total amplicon DNA available per
sample. To avoid an additional PCR step, the adapters were diluted ten-fold
to reduce library preparation input requirements. The quality of the resulting
library was assessed by High Sensitivity DNA chip on a 2100 Bioanalyzer
(Agilent Technologies). Sequencing was performed on a single MiSeq lane
(Illumina) with all samples loaded as an equimolar mix according to qPCR
(Kapa Biosystems, performed on a Roche Lightcycler). All fragments were
sequenced for 250 bases in a paired-end fashion. As some target regions were
shorter than this length, they were in effect fully covered in duplicate but se-
quencing does not extend beyond the primer boundaries.
Data preprocessing, including base calling, demultiplexing, trimming and
fastq generation was automatically performed in Illumina BaseSpace with
standard settings as provided by the manufacturer (Illumina). Additionally we
inspected the quality of the reads with FastQC. This inspection showed con-
sistent read quality in both the forward and reverse read. The sequencing data
was analysed using the Bismark package (v 0.10.0, available from http://
www.bioinformatics.babraham.ac.uk/projects/bismark/)
[31]. Default parameters were used for Bismark with the following excep-
tions: ”-q” to indicate the input was in fastq format, ”–bowtie2” to use Bowtie
2 as the underlying mapping software, ”–no-mixed” and ”–no-discordant”
were speciﬁed to allow only fragments that map as proper pairs with both
reads on the opposing strands and ﬁnally, the maximum allowed fragment
size was raised to 550 bp with ”–maxins 550” to allow mapping of the longest
amplicon.
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Differential methylation in the BS-seq data was evaluated with the methyl-
Kit package [32]. First we ﬁlter out any CpG methylation calls from non-
targeted regions and CpGs with low coverage (<100). Next, we used the
package’s ”calculateDiffMeth” function to calculate differential methylation
with the options ”weighted.mean = FALSE” and ”slim = FALSE”. These
options respectively specify that we have equal conﬁdence in methylation
percentages above our selected cut-off of 100x coverage and that Benjamini-
Hochberg correction should be used for multiple testing correction [33]. Be-
sides analysing the individual CpG locations, we also used the ”regionCounts”
function to aggregate results for each of the amplicons. Differential methyla-
tion analysis was performed as described above.
However, BS-seq results provide methylation percentages and per base
coverages. These are modelled with logistic regression models by the methyl-
Kit package. Again, one could consider adding a subject speciﬁc effect for
the global comparison. However, inclusion of subject speciﬁc ﬁxed effects
is known to result in biased point estimates for multinomial data [34, Chap-
ter 13.3]. Hence, more sophisticated methods are needed to address subject
speciﬁc effects for multinomial data.
Moreover, the user interface of methylKit limited the analyses to simple
two group comparisons. Non-progressors and progressors differential methy-
lation was compared for the ﬁrst round, second round and all samples. The
latter comparison did not take potential correlation between ﬁrst and second
round measurements into account in any way. The results should therefore be
interpreted with care.
The R-code employed in this chapter may be consulted in Appendix A.2.
3.2.7 Pathway Analyses
Analyses were performed with the Entrez identiﬁers obtained in the differ-
ent gene rankings. These identiﬁers where then used to perform singular
enrichment analysis with the online tool WebGestalt [35]. As background
we used the ”hsapiens genome” and speciﬁed the following non-default op-
tions: ”Benjamini Hochberg” multiple testing correction and an FDR cut-off
of 0.001. WebGestalt offers a choice of reference databases. In this chapter
we limit ourselves to the KEGG database.
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WebGestalt is a pathway analysis tool of the SEA class with competitive
hypothesis testing and a gene permutation strategy for P-value estimation.
This implies that the Type I error control is not optimal as the underlying hy-
pergeometric test assumes that methylation levels in the different genes are
independent. For gene expression this is usually not the case. For MCs the
problem of correlation is harder to quantify as each gene contains several
MCs. Although neighbouring MCs are often correlated, wider spaced MCs in
the same gene often are not. A ranking of the pathways is useful for interpre-
tation of the data, but the FDR estimates should be interpreted with care.
3.3 Results
3.3.1 Differential Methylation Proﬁles
We opted to sequence both round 1 and round 2 DNA of 10 progressors and
10 non-progressors after enrichment for CpGmethylation (MethylCap-seq) as
a cost-effective means to perform genome wide screening. To minimise the
effect of potential confounders we carefully matched subjects in both groups
(see section 3.2.4) and opted for stringent inclusion criteria: non-smoking, no
arterial hypertension, no use of statins, BMI< 31kg/m2 and all subjects were
female. See Supplementary Table C.1 for characteristics of both groups.
Summary statistics for the MethylCap-seq results are listed in Supplemen-
tary Table C.3. We obtained a median of 38,340,030 ([30,638,088; 53,897,975]
IQR) paired-end 50 bp reads per sample. As quality control we veriﬁed tech-
nical replicates, CpG enrichment and sample identity. Enrichment of CpG
containing regions was successful and in line with previously published re-
sults for the kit used (see Supplementary Figure B.1) [26]. By using both
the methylation proﬁles (vide infra) for unsupervised clustering and SNP in-
formation, we concluded mistaken sample identity was unlikely (see section
3.2.5).
To summarise the MethylCap-seq data we used a predeﬁned set of ge-
nomic locations based on aggregated MethylCap-seq samples. We will refer
to these locations as methylation cores (MCs, see section 3.2.5). We modelled
methylation by coding the progressor status and study round in one variable
with four levels: round 1 non-progressor, round 1 progressor, round 2 non-
progressor and round 2 progressor.
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This design does not include a variable for the individual subjects (see sec-
tion 4.2.3.2). This means that our differential methylation analysis comparing
all progressor samples to all non-progressor samples, could be overconﬁdent
because the correlation between ﬁrst and second round samples of the same
subject was not taken into account (see section 3.4). For the comparisons of
ﬁrst and second round samples separately, this should not be a problem.
We inspected the density plots of the P-values for the contrasts of interest
to those obtained from a permuted dataset. For both rounds combined and the
second round, it was clear that low P-values were more enriched in the actual
results. This indicated that many MCs for these two comparisons were likely
truly differentially methylated. However, the slight enrichment of lower P-
values in the permutation for the two rounds combined, indicated that the FDR
might not be properly controlled at its nominal value. For round 1 results,
there was clear enrichment of low P-values, comparable to the actual results
set. It is therefore expected that many false positives were returned for this
comparison. A relatively low number of MCs was called signiﬁcant in this
round and these results should be interpreted with care(see Supplementary
Figure B.4).
In differential methylation results obtained for all samples (from both
study rounds), 675 MCs were signiﬁcantly differentially methylated between
progressors and non-progressors (FDR<0.05, see digital Supplementary Ta-
ble DS1). Of these MCs, 364 were intergenic and 311 were located in 322
Ensembl annotated features. This represents an enrichment of intergenic lo-
cations compared to the full set of MCs (Chi-square p=0.007) but the propor-
tions of genic locations were representative (promoter: 30, exon: 32, intron:
296; Chi-square p=0.292). Overall there were 524 hypomethylated MCs and
151 hypermethylated MCs in progressors.
Table 3.2: Differentially methylated loci between atherosclerosis progressors and
non-progressors in the ﬁrst study round.
Methylation Core Ensembl Gene Id HUGO chr beg end logFC P-value FDR
41185718 ENSG00000134317 GRHL1 2 10138660 10138991 2,79 8,08E-09 0,017
41845833 4 127021827 127022269 2,35 9,70E-09 0,017
41314995 2 117595094 117595469 4,06 2,94E-08 0,028
42229427 6 83420498 83420499 -4,32 3,88E-08 0,028
42948695 X 73097124 73098374 2,06 3,92E-08 0,028
39655520 11 34048277 34048520 4,68 9,89E-08 0,043
41689643 ENSG00000213139 CRYGS 3 186263000 186263117 -3,21 1,08E-07 0,043
41872398 ENSG00000164142 FAM160A1 4 152444053 152444054 -3,21 1,09E-07 0,043
42315903 6 158699137 158699180 -3,21 1,10E-07 0,043
40170716 ENSG00000215407 AC126603.1 15 20480571 20481091 -1,53 1,20E-07 0,043
41247066 2 57560789 57560947 1,54 1,50E-07 0,045
42425056 ENSG00000196313 POM121 7 72402073 72402605 1,09 1,51E-07 0,045
40946333 1 222034296 222034672 2,09 1,62E-07 0,045
3-12 CHAPTER 3
Examining only ﬁrst round samples, i.e. to identify loci that independently
predict atherosclerosis progression, we found 13 MCs that were differentially
methylated (FDR<0.05, Table 3.2). For the second round samples, thereby
assessing the relation between atherosclerosis and the leukocyte methylome,
there were 26 signiﬁcant MCs (Table 3.3). There was no overlap between the
ﬁrst and second round signiﬁcant MCs. This could be due to the large number
of MCs that make multiple testing correction very strict or the fact that a
number of false positives are expected in the ﬁrst round results as indicated
by the permutation study.
Table 3.3: Differentially methylated loci between atherosclerosis progressors and
non-progressors in the second study round.
Methylation Core Ensembl Gene Id HUGO chr beg end logFC P-value FDR
40171412 15 21910675 21911919 -1,59 2,22E-09 0,007
39665408 11 43095972 43096078 -3,27 4,16E-09 0,007
42569384 ENSG00000120907 ADRA1A 8 26669621 26669865 -4,32 9,44E-09 0,011
39673314 11 48626544 48626566 -4,38 1,32E-08 0,011
42299298 ENSG00000235652 AL356599.1 6 146146305 146146577 -1,95 1,46E-08 0,011
41365752 ENSG00000054219 LY75 2 160704508 160704633 -4,35 1,94E-08 0,012
41365752 ENSG00000054219 LY75 2 160704508 160704633 -4,35 1,94E-08 0,012
42559165 ENSG00000147408 CSGALNACT1 8 19509417 19509583 -3,69 2,41E-08 0,012
40868885 ENSG00000073754 CD5L 1 157813530 157813753 -2,09 3,62E-08 0,013
40014313 13 77985653 77985843 -2,85 3,93E-08 0,013
40065111 14 24323159 24323213 -4,20 3,93E-08 0,013
39494593 ENSG00000244402 RN7SL314P 10 37586441 37586542 -3,08 4,12E-08 0,013
39494593 ENSG00000240800 RP11-20F24.1 10 37586441 37586542 -3,08 4,12E-08 0,013
41804500 ENSG00000109339 MAPK10 4 87251813 87252057 -3,25 7,18E-08 0,020
40637956 19 19471488 19471714 -3,25 7,22E-08 0,020
42615824 ENSG00000147573 TRIM55 8 67061832 67062047 -2,11 1,16E-07 0,029
41142613 ENSG00000133424 LARGE 22 34215915 34216098 -1,58 1,24E-07 0,029
40423783 ENSG00000242606 AC025627.14 17 19501992 19502229 -1,66 1,27E-07 0,029
40423783 ENSG00000240945 AC025627.18 17 19501992 19502229 -1,66 1,27E-07 0,029
41850672 4 131618463 131618492 -2,95 1,46E-07 0,031
42821225 9 116586067 116586194 -2,11 1,59E-07 0,031
40170897 ENSG00000180229 AC026495.2 15 20612474 20612823 -1,55 1,65E-07 0,031
40170897 ENSG00000240746 AC026495.1 15 20612474 20612823 -1,55 1,65E-07 0,031
42670163 8 115437947 115438508 -1,49 1,80E-07 0,032
40805330 1 79828783 79829112 -1,60 2,32E-07 0,039
40045939 13 106216692 106216993 -1,78 2,41E-07 0,039
41734238 4 19832603 19832612 -2,81 2,68E-07 0,042
41297977 2 103487240 103487323 -2,12 2,93E-07 0,044
42146928 6 11482433 11482601 -2,51 3,33E-07 0,048
40211855 15 54075544 54075620 -3,47 3,55E-07 0,049
Comparing the overlap between the signiﬁcant hits in one round and the
list of MCs meeting the nominal signiﬁcance cut-off of P < 0.05 in the other
round we ﬁnd that 2 of 13 round 1 loci were present in the second round
list and 3 of 26 round 2 loci were present in the ﬁrst round list. When we
evaluated the overlap by associated gene names at the P = 0.05 level, 4 out
of 5 round 1 genes and 11 out of 15 round 2 genes were signiﬁcant in the other
round as well (note that genes may cover multiple MCs and that several MCs
are not located in annotated genes). Moreover, the predominant direction of
differential methylation was identical for all genes.
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3.3.2 Validation
We validated a subset of our ﬁndings by targeted bisulphite deep sequencing.
An independent set of 23 progressors and 23 non-progressors was selected
with the same criteria and matching procedure (see Supplementary Table C.2
for summary statistics). We opted for a non-overlapping set of volunteers as
we already validated the utility of MethylCap-seq as an exploratory tool [36]
and given limited resources this choice should result in the most biologically
reproducible results. The validation loci were manually chosen from the sig-
niﬁcant MethylCap-seq results. The ampliﬁcation primers are listed in Sup-
plementary Table C.4. It should be noted that insufﬁcient DNA was available
for 4 progressors and 2 non-progressors in the second round. Additionally,
some subject - primer pair combinations yielded no PCR ampliﬁcation after
bisulphite treatment (see digital Supplementary Table DS3 for coverage in
each).
A similar deﬁnition of the design matrix was not possible because the in-
terface of the methylKit package, used for analysis of the validation data, only
allows the user to pass a single factor with two levels (in this case ”progres-
sor” or ”non-progressor”). This did not pose a problem for the progressor
versus non-progressor comparisons of the ﬁrst or second round data, which
we performed separately, as only one factor (progression status) needs to be
compared. However, for the comparison of all progressor versus all non-
progressor samples, this most likely led to anti-conservative results as the
assumption of independent samples was clearly not met.
We successfully converted, ampliﬁed and sequenced 15 out of 17 selected
loci which showed evidence of differential methylation between progressors
and non-progressors in at least one of three hypotheses, i.e. ﬁrst round dif-
ferential methylation, second round differential methylation and differential
methylation irrespective of time point. Out of these 15 regions, 10 were sig-
niﬁcantly differentially methylated over the entire region in at least one of the
3 hypotheses and 13 showed differential methylation in at least one hypoth-
esis at the individual CpG level (see Table 3.4 for an overview). Yet at the
regional level the direction of differential methylation corresponded with the
results obtained from MethylCap-seq data in only 7 loci for one of the hy-
potheses. At the level of the individual signiﬁcant CpGs we found that the
same 7 regions and ADRA1A contained at least one CpG with corresponding
direction in at least one of the hypotheses.
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Figure 3.1: Boxplot of methylation degree in 3 CpG locations that were signiﬁcantly
correlated with atherosclerosis progression.
This rate of conﬁrmation was lower than the FDR set in the screening stage
but this was not unexpected considering the fact that FDR calculations are
very assumption dependent and typically vary between used statistical meth-
ods. Additionally, the actual methylation differences were relatively small
(typically between 0.5% and 3%, see Figure 3.1 for a few examples). Diffe-
rential methylation analysis results of the amplicons and individual CpGs are
listed in digital Supplementary Tables DS4 and DS5 respectively.
3.3.3 Pathway Analyses
Potentially affected pathways were identiﬁed using the online toolWebGestalt
[35]. This is a tool of the SEA class and uses gene permutation for P-value
estimation (see section 1.3.8). This means that correlation between features
(MCs in this case), is not taken into account which may lead to liberal rejec-
tion of the null hypothesis. The results should therefore be interpreted with
care.
While a low FDR is crucial for interpretation of the gene-level results,
pathway analysis beneﬁts from a larger set of putatively differential loci (i.e.
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increased power), even if this means including slightly more false positives.
Therefore, we relaxed the gene-wise signiﬁcance threshold for pathway anal-
yses to 10% FDR but made the requirements for pathway signiﬁcance stricter
(FDR<0.001).
For the ﬁrst round this yielded no signiﬁcant results (data not shown).
In the second round, only 1 pathway was signiﬁcant at FDR<0.001 (Table
3.5). The number of differentially methylated MCs for round 1 and round 2
samples combined was much larger. Consequently, no less than 35 pathways
were potentially affected (FDR<0.001, digital Supplementary Table DS2).
3.3.4 Potential Genomic Deletion
Based on the MethylCap-seq data we concluded that a genomic deletion in
the lncRNA RP11-10O22.1 (ENSG00000241168) of progressors was a plau-
sible explanation for the observed proﬁles (see Figure 3.2, Fisher exact test
P = 0.005). At the time of writing nothing is known about this transcript
but both losses and gains of this region were reported in individuals from var-
ious ethnicities (see Database of Genomic Variants [37]). As expected we
saw higher failure rates for this locus in the BS-seq data but, unlike the pilot
group, the distribution of these failures alone was not signiﬁcant in the vali-
dation group (P = 0.5559, Fisher exact test). However, the methylation per-
centages that we did obtain in the validation study were signiﬁcantly different
between progressors and non-progressors both for individual CpGs (≥ 0.27%,
q-value≤ 0.0002) and the amplicon as a whole (0.27%, q-value=9.886E-11)
which implies the possibility of similar or combined modulation of gene ex-
pression by methylation or deletion.
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3.4 Discussion
In this study we demonstrated for the ﬁrst time in a human population that
atherosclerosis progression is reﬂected in consistent but subtle modiﬁcations
in the peripheral blood leukocyte DNA methylation proﬁle, independent of
other known major risk factors. Importantly, several loci were independently
associated with atherosclerosis progression in apparently healthy subjects,
thereby providing atherosclerosis susceptibility biomarkers. However, differ-
ences were typically subtle (< 5% difference in methylation degree), which
may be related to the study design but also the validation methodology.
Through limitations arising from the need to perform genome-wide exper-
iments in a cost-efﬁcient manner, the challenges involved in interpreting DNA
methylation proﬁles from whole blood are considerable. Firstly, under ideal
circumstances separate analyses of DNA obtained from the various leukocyte
subtypes would have yielded more detailed information than whole blood. It
has been demonstrated that the complex mix of cell types that make up the cir-
culating leukocytes, can confound epigenetic proﬁles obtained in the context
of ageing as was demonstrated using Illumina’s Inﬁnium HumanMethylation
450k bead array technology. These effects are fairly consistent though, which
allowed for the development of algorithms that estimate the proportions of the
major cell types [38, 39]. Of the 49950 MCs that matched cell type associ-
ated probes, only 2 were found to be differentially methylated in the present
study, suggesting that most of our results do not solely reﬂect changes in cell
type composition of the subjects’ blood. Even if the latter would be the case,
our data provide a comprehensive basis to elucidate associations of leukocyte
fractions with atherosclerosis progression in the future.
The second drawback to this mix of cell types is that highly signiﬁcant
changes in one type might be diluted by a steady or opposite methylation lev-
els in the other types. Whereas in a single cell type the theoretical methyla-
tion values should approach 0, 50 or 100%, our validation experiment found
a range of intermediary methylation values (mostly larger than 50%). Fur-
ther, the absolute differences were smaller than one might expect based on
the MethylCap-seq data, although this can at least partially be attributed to
the fact that the MethylCap-seq assay requires a threshold degree of methy-
lation (i.e. multiple neighbouring methylated CpGs) before a locus can be
picked up consistently [26].
Third, there are still considerable limitations to the methods available for
the analysis of both the MethylCap-seq and BS-data. Even edgeR, despite
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being one of the most ﬂexible tools to date, has limitations. The NB na-
ture of sequencing data complicates the analysis of a complex design such
as ours. More speciﬁcally the presence of paired samples can be seen as re-
peated measurements of the same subject for the comparison of progressors
and non-progressors at both time points combined (between subject compari-
son). This might have led to some overoptimism in rejecting null hypotheses
for this comparison as measurements are likely correlated between rounds.
An analysis of a permuted version of the data indicated this methodological
limitation may have had some impact on the comparison of all samples and
a signiﬁcant inﬂuence in the ﬁrst round samples. Further, the analysis tool
edgeR does not allow the addition of random effects to model subject iden-
tity. If we had added subject identity as a ﬁxed effect this would absorb any
variation between progressors and non-progressors. More research into the
consequences of adding subject speciﬁc ﬁxed effects to models of NB data is
needed [28].
Lastly, the methylKit package used for the validation data uses edgeR for
the underlying differential methylation calculations. However it is far more
limited as it only allows the user to pass a single treatment factor with two
levels. Again, this did not pose a problem for comparisons in the separate
rounds, but likely led to some overoptimism in calling genes differentially
methylated when we compared all progressors to all non-progressors because
the correlation between ﬁrst round and second round measurements of the
same subject, were not taken into account. A rewriting of the code was beyond
the scope of this thesis but would be essential to use the full potential of our
experimental design.
Given these limitations the reproducibility of the loci we identiﬁed could
be questioned. However, the fact that many results were still consistent upon
validation, in two independent population samples and with two different
techniques even in such a complex background, suggests that future research
focussing on the identiﬁcation of the cell types driving the observed methyla-
tion differences may lead to biomarkers with clinical utility.
3.4.1 Gene Methylation and Atherosclerosis Progression
Several identiﬁed genes fulﬁl roles that can be linked with atherosclerosis. To
underscore the relevance of our results we will highlight a few. For example,
GRHL1, the most signiﬁcant result for round 1, is one of the genes activated
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by PPARα, which is an important regulator of lipid metabolism in atheroscle-
rosis [40]. We also found several genes directly related to atherosclerosis and
inﬂammatory processes such as LY75 (also known as CD205), a modulator of
oxLDL metabolism of dendritic cells [41] and the apoptosis inhibitor CD5L
(a.k.a. AIM or API6) [42]. A potential role for other genes is less straight-
forward, but the link to atherosclerosis is plausible. CHGN2 expression for
instance, was increased by a pro-atherosclerotic diet in mice [43]. Another
gene, MAPK10 (a.k.a. JNK3), is a member of the janus kinases which are
mostly associated with atherosclerosis in vascular cells [44]. Yet MAPK10
was proposed as a key gene with regard to focal adhesion in coronary artery
disease [45]. The differentially methylated gene adenylate cyclase 8 (ADCY8
a.k.a. AC8 or ADCY3), encodes a membrane bound protein which is involved
in the vascular and muscular contraction, Ca2+ signalling and several secre-
tory pathways. Adenylate cyclases in general are involved in transendothelial
migration of leukocytes [46]. Lastly, mutations in ACTA2, one of the round 2
candidate genes, were associated with a range of vascular diseases [47].
A potential deletion in lncRNA RP11-10O22.1 was strongly associated
with atherosclerosis progression in our genome wide screening but not in the
validation population. This result is not entirely unexpected as a deletion
would constitute a heritable, non-modiﬁable change and would most likely
have been detected in previous research. None the less, this locus showed
differential methylation in our validation population which might obscure or
mimic the effects of a deletion. Further research into the association between
this locus and atherosclerosis is warranted.
3.4.2 Relation to Biological Processes
Among the pathway level results we found several biological processes that
might be related to atherosclerosis progression. Pathways such as ”Calcium
signaling pathway”, ”Regulation of actin cytoskeleton” and ”Leukocyte trans-
endothelial migration” might reﬂect macrophage mobilisation to sites of athe-
rosclerotic plaque development. A less expected result was the ”Neuroactive
ligand-receptor interaction” pathway. Closer inspection of the latter path-
way revealed differential methylation in several receptor encoding genes that
are associated with atherosclerosis or related CVD before such as glucagon-
like peptide receptors [48], growth hormone receptor [49] and leptine recep-
tor [50].
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Pathway analyses are inherently limited to those pathways which have
already been described. But besides the possibility of yet unidentiﬁed path-
ways, nearly half of the differentially methylated MCs we identiﬁed, stem
from unannotated loci (not within 2000 bp upstream or the 3’ end of an En-
sembl feature) and were validated at a comparable rate as the annotated loci.
At this point it is too early to speculate how these loci might be involved but
several mechanisms of action are possible (unidentiﬁed lncRNA [51], regula-
tion of nearby genes [52], structural conformation of DNA [53] . . . ).
3.4.3 Relation to Prior Research
Previous research [9] identiﬁed 1858 Illumina 450k probes with differential
methylation between paired atherosclerotic lesions and non-atherosclerotic
tissue in veins from the same subjects. Although we examined leukocytes
and the commonalities of our results should be limited, we did attempt a
comparison. Indeed none of the 16 of our differentially methylated MCs
that overlap an Illumina 450k probe (progressors vs non-progressors both
rounds, FDR<0.05), was differentially methylated in vascular lesions (data
not shown).
3.4.4 Predicting Atherosclerosis Progression
There is a long standing interest in predicting the progression of atherosclero-
sis and subsequent cardiovascular events [54]. Our study population was re-
latively young and selected to be a population representative sample without
clinically overt CVD at baseline and can thus be expected to have good cardio-
vascular health at enrolment. Due to the younger age and the relative health
of the population, it is too early to have signiﬁcant outcome data. Therefore
we currently do not dispose over data indicating a heightened risk of events.
However, we did identify 13 genomic locations which show a strong correla-
tion with atherosclerosis progression in the subsequent decade. Most of the
sites are not located within a known gene and the potentially affected genes
are currently not known in an atherosclerosis context (GRHL1, POM121) or
have no conﬁrmed function at all (FAM160A1). None the less, in our valida-
tion population we conﬁrmed 2 of the 4 selected loci.
The performance of biomarkers is indifferent to the true biological under-
pinnings and this study showed that leukocyte DNA methylation has potential
for early classiﬁcation of patients from a simple blood sample. The next step
in evaluating these markers is to test their performance in a larger cohort.
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Figure 3.2: Methylation proﬁle at a site of differential methylation obtained by
MethylCap-seq. The ﬁrst 10 samples are non-progressors, the last 10 are progressors. This
region encompasses a known copy number variation site.
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3.5 Conclusions
DNA methylation constitutes a measurable, modiﬁable risk factor for athe-
rosclerosis. We found that atherosclerosis progression is reﬂected in an epi-
genetic proﬁle throughout the genome of peripheral blood leukocytes. These
methylation differences are likely driven by a subset of cell types. We fur-
ther demonstrated that healthy subjects prone to atherosclerosis development
in the subsequent decade, were characterised by differential methylation in
a small set of CpG locations. Validation experiments at a larger scale are
required to evaluate their potential as biomarkers.
3.6 Acknowledgements
Besides the acknowledgements from chapter 2, we would also like to thank
Sarah De Keulenaer, Ellen De Meester, Johan Vandersmissen and Jean-Pierre
Renard for their indispensable mastery of the wet-lab side of this study.
3-24 CHAPTER 3
References
[1] D. H. Blankenhorn and H. N. Hodis. Atherosclerosis–reversal with ther-
apy. West J Med, 159(2):172–9, 1993.
[2] S. M. Ho, A. Johnson, P. Tarapore, V. Janakiram, X. Zhang, and Y. K.
Leung. Environmental epigenetics and its implication on disease risk
and health outcomes. ILAR J, 53(3-4):289–305, 2012.
[3] Y. Chen, J. Rollins, B. Paigen, and X. Wang. Genetic and genomic in-
sights into the molecular basis of atherosclerosis. Cell Metab, 6(3):164–
79, 2007.
[4] C. Sabatti, S. K. Service, A. L. Hartikainen, A. Pouta, S. Ripatti, J. Brod-
sky, C. G. Jones, N. A. Zaitlen, T. Varilo, M. Kaakinen, U. Sovio,
A. Ruokonen, J. Laitinen, E. Jakkula, L. Coin, C. Hoggart, A. Collins,
H. Turunen, S. Gabriel, P. Elliot, M. I. McCarthy, M. J. Daly, M. R.
Jarvelin, N. B. Freimer, and L. Peltonen. Genome-wide association
analysis of metabolic traits in a birth cohort from a founder population.
Nat Genet, 41(1):35–46, 2009.
[5] S. L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard. An oper-
ational deﬁnition of epigenetics. Genes Dev, 23(7):781–3, 2009.
[6] D. C. Dolinoy and R. L. Jirtle. Environmental epigenomics in human
health and disease. Environ Mol Mutagen, 49(1):4–8, 2008.
[7] M. P. Turunen, E. Aavik, and S. Yla-Herttuala. Epigenetics and athero-
sclerosis. Biochim Biophys Acta, 1790(9):886–91, 2009.
[8] J. Kim, J. Y. Kim, K. S. Song, Y. H. Lee, J. S. Seo, J. Jelinek, P. J.
Goldschmidt-Clermont, and J. P. Issa. Epigenetic changes in estrogen
receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro
vascular senescence. Biochim Biophys Acta, 1772(1):72–80, 2007.
[9] S. Zaina, H. Heyn, F. J. Carmona, N. Varol, S. Sayols, E. Condom,
J. Ramirez-Ruz, A. Gomez, I. Goncalves, S. Moran, and M. Esteller.
A DNA Methylation Map of Human Atherosclerosis. Circ Cardiovasc
Genet, 2014.
[10] G. Lund, L. Andersson, M. Lauria, M. Lindholm, M. F. Fraga, A. Villar-
Garea, E. Ballestar, M. Esteller, and S. Zaina. DNA methylation poly-
morphisms precede any histological sign of atherosclerosis in mice lack-
ing apolipoprotein E. Journal of Biological Chemistry, 279(28):29147–
29154, 2004.
DNA METHYLOME AND ATHEROSCLEROSIS PROGRESSION 3-25
[11] P. Libby. Inﬂammation in atherosclerosis. Nature, 420(6917):868–74,
2002.
[12] R. Ross. Atherosclerosis–an inﬂammatory disease. N Engl J Med,
340(2):115–26, 1999.
[13] R. P. Richardson, C. D. Rhyne, Y. Fong, D. G. Hesse, K. J. Tracey, M. A.
Marano, S. F. Lowry, A. C. Antonacci, and S. E. Calvano. Peripheral
blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) ad-
ministration to normal human subjects. Inﬂuence of elicited hormones
and cytokines. Ann Surg, 210(2):239–45, 1989.
[14] P. W. Laird. The power and the promise of DNA methylation markers.
Nat Rev Cancer, 3(4):253–66, 2003.
[15] Y. Wei, M. Nazari-Jahantigh, L. Chan, M. Zhu, K. Heyll, J. Corbalan-
Campos, P. Hartmann, A. Thiemann, C. Weber, and A. Schober. The
microRNA-342-5p fosters inﬂammatory macrophage activation through
an Akt1- and microRNA-155-dependent pathway during atherosclerosis.
Circulation, 127(15):1609–19, 2013.
[16] K. H. Loland, O. Bleie, H. Borgeraas, E. Strand, P. M. Ueland,
A. Svardal, J. E. Nordrehaug, and O. Nygard. The association between
progression of atherosclerosis and the methylated amino acids asymmet-
ric dimethylarginine and trimethyllysine. PLoS One, 8(5):e64774, 2013.
[17] M. A. Subramanyam, A. V. Diez-Roux, J. R. Pilsner, E. Villamor, K. M.
Donohue, Y. Liu, and N. S. Jenny. Social factors and leukocyte DNA
methylation of repetitive sequences: the multi-ethnic study of athero-
sclerosis. PLoS One, 8(1):e54018, 2013.
[18] W. Perng, E. Villamor, M. R. Shroff, J. A. Nettleton, J. R. Pilsner, Y. Liu,
and A. V. Diez-Roux. Dietary intake, plasma homocysteine, and repet-
itive element DNA methylation in the Multi-Ethnic Study of Atheroscle-
rosis (MESA). Nutr Metab Cardiovasc Dis, 24(6):614–22, 2014.
[19] G. P. White, P. M. Watt, B. J. Holt, and P. G. Holt. Differential pat-
terns of methylation of the IFN-gamma promoter at CpG and non-CpG
sites underlie differences in IFN-gamma gene expression between hu-
man neonatal and adult CD45RO- T cells. J Immunol, 168(6):2820–7,
2002.
[20] J. M. Seo, J. Y. Lee, G. E. Ji, and J. C. You. Down-regulation of
ATP-binding cassette transporter G1 expression by unmethylated CpG
3-26 CHAPTER 3
oligodeoxynucleotides in RAW 264.7 macrophages. Exp Mol Med,
43(9):510–6, 2011.
[21] R. J. Wierda, H. F. Kuipers, M. C. van Eggermond, A. Benard, J. C.
van Leeuwen, S. Carluccio, S. B. Geutskens, J. W. Jukema, V. E. Mar-
quez, P. H. Quax, and P. J. van den Elsen. Epigenetic control of CCR5
transcript levels in immune cells and modulation by small molecules in-
hibitors. J Cell Mol Med, 16(8):1866–77, 2012.
[22] L. Jia, L. Zhu, J. Z. Wang, X. J. Wang, J. Z. Chen, L. Song, Y. J. Wu,
K. Sun, Z. Y. Yuan, and R. Hui. Methylation of FOXP3 in regulatory T
cells is related to the severity of coronary artery disease. Atherosclero-
sis, 228(2):346–52, 2013.
[23] S. P. Guay, D. Brisson, B. Lamarche, P. Marceau, M. C. Vohl, D. Gaudet,
and L. Bouchard. DNA methylation variations at CETP and LPL gene
promoter loci: new molecular biomarkers associated with blood lipid
proﬁle variability. Atherosclerosis, 228(2):413–20, 2013.
[24] E. R. Rietzschel, M. L. De Buyzere, S. Bekaert, P. Segers, D. De Bac-
quer, L. Cooman, P. Van Damme, P. Cassiman, M. Langlois, P. Van Oost-
veldt, P. Verdonck, G. De Backer, and T. C. Gillebert. Rationale, design,
methods and baseline characteristics of the Asklepios Study. Eur J Car-
diovasc Prev Rehabil, 14(2):179–91, 2007.
[25] B. Langmead, C. Trapnell, M. Pop, and S. L. Salzberg. Ultrafast
and memory-efﬁcient alignment of short DNA sequences to the human
genome. Genome Biol, 10(3):R25, 2009.
[26] Tim De Meyer, Evi Mampaey, Michal Vlemmix, Simon Denil, Geert
Trooskens, Jean-Pierre Renard, Sarah De Keulenaer, Pierre Dehan, Ger-
ben Menschaert, and Wim Van Criekinge. Quality Evaluation of Methyl
Binding Domain Based Kits for Enrichment DNA-Methylation Sequenc-
ing. PloS one, 8(3):e59068, 2013.
[27] M. D. Robinson, D. J. McCarthy, and G. K. Smyth. edgeR: a Biocon-
ductor package for differential expression analysis of digital gene ex-
pression data. Bioinformatics, 26(1):139–140, 2010.
[28] P. D. Allison and R. P. Waterman. Fixed-effects negative binomial re-
gression models. Sociological Methodology 2002, Vol 32, 32:247–265,
2002. Bv13u Times Cited:117 Cited References Count:15 Sociological
Methodology.
DNA METHYLOME AND ATHEROSCLEROSIS PROGRESSION 3-27
[29] A. Untergasser, I. Cutcutache, T. Koressaar, J. Ye, B. C. Faircloth,
M. Remm, and S. G. Rozen. Primer3–new capabilities and interfaces.
Nucleic Acids Res, 40(15):e115, 2012. Untergasser, Andreas Cutcu-
tache, Ioana Koressaar, Triinu Ye, Jian Faircloth, Brant C Remm, Maido
Rozen, Steven G eng Research Support, N.I.H., Intramural Research
Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.
England 2012/06/26 06:00 Nucleic Acids Res. 2012 Aug;40(15):e115.
Epub 2012 Jun 22.
[30] L. C. Li and R. Dahiya. MethPrimer: designing primers for methylation
PCRs. Bioinformatics, 18(11):1427–31, 2002.
[31] F. Krueger and S. R. Andrews. Bismark: a ﬂexible aligner and methyla-
tion caller for Bisulﬁte-Seq applications. Bioinformatics, 27(11):1571–
2, 2011.
[32] A. Akalin, M. Kormaksson, S. Li, F. E. Garrett-Bakelman, M. E.
Figueroa, A. Melnick, and C. E. Mason. methylKit: a comprehensive
R package for the analysis of genome-wide DNA methylation proﬁles.
Genome Biol, 13(10):R87, 2012.
[33] Y. Benjamini and Y. Hochberg. Controlling the False Discovery Rate
- a Practical and Powerful Approach to Multiple Testing. Journal of
the Royal Statistical Society Series B-Methodological, 57(1):289–300,
1995.
[34] G. Molenberghs and G. Verbeke. Models for Discrete Longitudinal
Data. Springer, New York, 1st edition, 2005.
[35] J. Wang, D. Duncan, Z. Shi, and B. Zhang. WEB-based GEne SeT AnaL-
ysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res, 41(Web
Server issue):W77–83, 2013.
[36] Martijn Clausen, Lieuwe J. Melchers, Leonie Bruine de Bruin, Mir-
jam F. Mastik, Lorian Slagter-Menkema, Harry J. Groen, Bert van der
Vegt, Bernard F. Van der Laan, Tim De Meyer, Wim Van Criekinge,
G Bea Wisman, Jan L. Roodenburg, and Ed Schuuring. Abstract 645:
DNA methylation marker discovery for the prediction of nodal metas-
tases in head and neck cancer. Cancer Research, 73(8 Supplement):645,
2013.
[37] J. R. MacDonald, R. Ziman, R. K. Yuen, L. Feuk, and S. W. Scherer.
The Database of Genomic Variants: a curated collection of struc-
3-28 CHAPTER 3
tural variation in the human genome. Nucleic Acids Res, 42(Database
issue):D986–92, 2014.
[38] A. E. Jaffe and R. A. Irizarry. Accounting for cellular heterogene-
ity is critical in epigenome-wide association studies. Genome Biol,
15(2):R31, 2014.
[39] E. A. Houseman, W. P. Accomando, D. C. Koestler, B. C. Christensen,
C. J. Marsit, H. H. Nelson, J. K. Wiencke, and K. T. Kelsey. DNA methy-
lation arrays as surrogate measures of cell mixture distribution. BMC
Bioinformatics, 13:86, 2012.
[40] D. M. Flavell, Y. Jamshidi, E. Hawe, I. Pineda Torra, M. R. Taskinen,
M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, B. Staels,
G. Miller, S. E. Humphries, P. J. Talmud, and M. Syvanne. Peroxisome
proliferator-activated receptor alpha gene variants inﬂuence progres-
sion of coronary atherosclerosis and risk of coronary artery disease.
Circulation, 105(12):1440–5, 2002.
[41] T. Nickel, D. Schmauss, H. Hanssen, Z. Sicic, B. Krebs, S. Jankl,
C. Summo, P. Fraunberger, A. K. Walli, S. Pfeiler, and M. Weis. oxLDL
uptake by dendritic cells induces upregulation of scavenger-receptors,
maturation and differentiation. Atherosclerosis, 205(2):442–50, 2009.
[42] S. Arai, J. M. Shelton, M. Chen, M. N. Bradley, A. Castrillo, A. L.
Bookout, P. A. Mak, P. A. Edwards, D. J. Mangelsdorf, P. Tontonoz,
and T. Miyazaki. A role for the apoptosis inhibitory factor AIM/S-
palpha/Api6 in atherosclerosis development. Cell Metab, 1(3):201–13,
2005.
[43] V. Y. Anggraeni, N. Emoto, K. Yagi, D. S. Mayasari, K. Nakayama,
T. Izumikawa, H. Kitagawa, and K. Hirata. Correlation of C4ST-1 and
ChGn-2 expression with chondroitin sulfate chain elongation in athero-
sclerosis. Biochem Biophys Res Commun, 406(1):36–41, 2011.
[44] G. Sumara, M. Belwal, and R. Ricci. ”Jnking” atherosclerosis. Cell
Mol Life Sci, 62(21):2487–94, 2005.
[45] S. W. Duan, X. H. Luo, and C. Z. Dong. Identiﬁcation of susceptibility
modules for coronary artery disease using a genome wide integrated
network analysis. Gene, 531(2):347–354, 2013.
[46] F. Sanchez-Madrid and M. A. del Pozo. Leukocyte polarization in cell
migration and immune interactions. EMBO J, 18(3):501–11, 1999.
DNA METHYLOME AND ATHEROSCLEROSIS PROGRESSION 3-29
[47] D. C. Guo, C. L. Papke, V. Tran-Fadulu, E. S. Regalado, N. Avidan, R. J.
Johnson, D. H. Kim, H. Pannu, M. C. Willing, E. Sparks, R. E. Pyeritz,
M. N. Singh, R. L. Dalman, J. C. Grotta, A. J. Marian, E. A. Boer-
winkle, L. Q. Frazier, S. A. LeMaire, J. S. Coselli, A. L. Estrera, H. J.
Saﬁ, S. Veeraraghavan, D. M. Muzny, D. A. Wheeler, J. T. Willerson,
R. K. Yu, S. S. Shete, S. E. Scherer, C. S. Raman, L. M. Buja, and D. M.
Milewicz. Mutations in smooth muscle alpha-actin (ACTA2) cause coro-
nary artery disease, stroke, and Moyamoya disease, along with thoracic
aortic disease. Am J Hum Genet, 84(5):617–27, 2009.
[48] N. Panjwani, E. E. Mulvihill, C. Longuet, B. Yusta, J. E. Campbell,
T. J. Brown, C. Streutker, D. Holland, X. M. Cao, L. L. Baggio, and
D. J. Drucker. GLP-1 Receptor Activation Indirectly Reduces Hepatic
Lipid Accumulation But Does Not Attenuate Development of Atheroscle-
rosis in Diabetic Male ApoE(-/-) Mice. Endocrinology, 154(1):127–139,
2013.
[49] A. Maitra, J. Shanker, D. Dash, P. R. Sannappa, S. John, P. Siwach,
V. S. Rao, H. Sridhara, and V. V. Kakkar. Polymorphisms in the pitu-
itary growth hormone gene and its receptor associated with coronary
artery disease in a predisposed cohort from India. J Genet, 89(4):437–
47, 2010.
[50] M. Aijala, M. Santaniemi, R. Bloigu, Y. A. Kesaniemi, and O. Ukkola.
Leptin receptor Arg109 homozygotes display decreased total mortality
as well as lower incidence of cardiovascular disease and related death.
Gene, 534(1):88–92, 2014.
[51] M. J. Hangauer, I. W. Vaughn, and M. T. McManus. Pervasive transcrip-
tion of the human genome produces thousands of previously unidentiﬁed
long intergenic noncoding RNAs. PLoS Genet, 9(6):e1003569, 2013.
[52] C. E. Nelson, B. M. Hersh, and S. B. Carroll. The regulatory content of
intergenic DNA shapes genome architecture. Genome Biol, 5(4):R25,
2004.
[53] I. Jimenez-Useche and C. Yuan. The effect of DNA CpG methylation on
the dynamic conformation of a nucleosome. Biophys J, 103(12):2502–
12, 2012.
[54] D. G. Hackam and S. S. Anand. Emerging risk factors for atherosclerotic
vascular disease: a critical review of the evidence. JAMA, 290(7):932–
40, 2003.

4
A Longitudinal Assessment of Ageing
Related Leukocyte DNA Methylation
Alterations in the Middle-aged Asklepios
Study Population
4.1 Introduction
Ageing is widely recognised as a complex phenomenon that is inﬂuenced by
several genes [1], disease, environmental factors and random chance [2].
Currently several studies have found DNAmethylation markers of chrono-
logical age, particularly in whole blood leukocytes but also in saliva [3, 4].
However, it is difﬁcult to isolate epigenetic effects related to ageing from the
host of other factors that inﬂuence an individual’s epigenetic proﬁle such as
the proportions of leukocyte subtypes and generational effects.
Several studies partially remediate these problems by careful analysis ad-
justing for cellular heterogeneity using a computational approach [5] or the
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use of twins in an attempt to reduce background noise [6–8]. A very re-
cent cross-sectional study analysed age-related DNA methylation changes in
leukocyte sub-populations (monocytes and T-cells). This study demonstrated
that T-cell speciﬁc epigenetic alterations are also found in monocytes. How-
ever, when limiting these results to loci that are also functionally relevant to
the expression level of corresponding gene, the overlap is absent. Upon fur-
ther evaluation of the latter loci, hypomethylation is predominantly found in
older age, located in predicted enhancers and often linked to antigen process-
ing and presentation genes [9]. This study somewhat contrasts a previous
investigation of a leukocyte DNA methylation based ageing model that also
appears to be functional for different tissues and is reﬂected in the transcrip-
tome, though here no formal discrimination was made between expression
and non-expression linked ageing associated DNA methylation changes [4].
Based on these and other studies, e.g. [10], it is clear that a fraction of
whole blood leukocyte ageing results will reﬂect cellular heterogeneity, but
also that a large fraction − at least for DNA methylation − is shared be-
tween leukocyte subsets, making whole blood leukocytes an interesting topic
of research. Generational effects may arise with respect to telomere length,
another potential problem ignored in said studies [11, 12]. For example, air
pollution is linked with leukocyte DNA methylation alterations [13], has an
age dependent impact [14] and is also subject to evolution over time [15]. In
other words, putative age dependent alterations may as well reﬂect changing
external factors. To the best of our knowledge no studies yet have used the
most straightforward method to account for such effects: to follow up epige-
netic changes in individuals over the course of several years and to use the
baseline measurements to control for inter-individual and inter-generational
methylation differences.
We used methylation enrichment sequencing which offers a broader scope
than most studies mentioned so far, which rely primarily on methylation probe
arrays. One previous study used this methodology for a large sample of
subjects with a broad age-span [16]. In this chapter we present the ﬁrst
methylome-wide methylation data obtained from whole blood in the same
subjects at two distinct time-points.
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4.2 Methods
4.2.1 Study Population Selection
For the analyses reported here, we used the same two non-overlapping sub-
sets of 20 and 46 Asklepios study volunteers as described in Chapter 3. The
methodology is very similar and only the differences will be highlighted here.
4.2.2 Experimental Design
For the purpose of this ageing study we used atherosclerosis progressor sta-
tus as a potential confounding factor. A general population sample would
most likely contain a signiﬁcant number of (subclinical) atherosclerosis cases
and ageing differences between progressors and non-progressors are of sec-
ondary interest. However, we accounted for a potential interaction between
progressor status and ageing in order to use an appropriate model for each
methylation core (see section 4.2.3.2). Although study design was the same,
the primary difference regarding the analyses was that accounting for the cor-
relations between the paired samples could boost the power to detect ageing
related methylation differences.
4.2.3 Methylated CpG Enrichment Sequencing
4.2.3.1 Pre-processing
Data generation and pre-processing for this experiment was described in sec-
tion 3.2.5. Brieﬂy, we generated MethylCap-seq reads, mapped them, gen-
erated coverage proﬁles for the methylation cores (MCs) in the Map of the
Human Methylome and analysed differential methylation in R (v3.0.1). The
MCs were annotated based on their location relative to Ensembl features (re-
lease 72). Prior to analyses, the technical replicates with the highest coverage
(AS1.20 and AS2.47) were selected, reducing the number of samples to 40.
Library size scaling normalisation was applied.
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4.2.3.2 Analysis Strategy
In this chapter three main research questions are of interest. First, what
MCs changed in methylation degree between study rounds? Second, were
there age-associated patterns in non-progressors? And third, were there age-
associated differences in the progressors? The paired nature of the samples
offers an additional advantage in the sense that baseline measurements can be
adjusted for individually in each subject. Conversely, not taking the paired
nature of the samples into account, ignores correlations between the measure-
ments in both rounds and leads to a loss in power since we assessed within-
subject effect in this chapter.
One way to pose these questions would be to deﬁne a model with three
factors: study round, progressor status and subject identity. A classical ap-
proach for data analysis consists of a mixed effects model with two ﬁxed
effects for round and progressor status, and a random effect for subject iden-
tity. However to the best of our knowledge, there were no analysis packages
to date that were able to model random effects while borrowing strength from
the large number of features in a sequencing experiment while offering the
same usability as edgeR.
Another approach is to incorporate subject identity as a ﬁxed effect in the
model. This has the advantage of fewer assumptions being imposed than in a
traditional mixed model (i.e. normality of the random effects and orthogonal-
ity of random and ﬁxed effects). This model can be implemented in standard
software for analysing sequencing experiments. The inclusion of subject spe-
ciﬁc ﬁxed effects leads to proper inference for within subject effects in many
distributional families. However, it only allows for conditional inference.
For NB data, the use of ﬁxed effect models that account for subject speciﬁc
effects are not well studied yet. The ﬁxed effect model can be expected to give
unbiased point estimates for the within subject effects for the NB distribution
but there might be issues with the estimation of the standard errors that are
provided by standard software [17].
We adopted a subject speciﬁc ﬁxed effect model in edgeR. However, in-
corporating a ﬁxed effect for subject identity, study round, progressor status
and their interaction would lead to an overspeciﬁed model, i.e. the difference
between progressors and non-progressors at base-line would be aliased with
the subject speciﬁc effects. Therefore an alternative parametrization was pro-
posed with a subject speciﬁc ﬁxed effect and a factor RoundProg with three
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levels (Round1, NonProgRound2 and ProgRound2). Note, the Round1 level
was encoded as the reference class and allowed to immediately estimate diffe-
rential methylation between both rounds in non-progressors and progressors
by the parameters for NonProgRound2 and ProgRound2 respectively. The
global differential methylation between round 1 and round 2 could then be
estimated as the average over the NonProgRound2 and ProgRound2 effects.
The corresponding contrasts are listed in Table 4.1.
Table 4.1: Contrasts for differences between round 1 and round 2 with progressor status and
subject speciﬁc ﬁxed effects, i ranges from 1 to 20.
Non-progressors Progressors Average
Subjecti 0 0 0
Round 2 NonProg 1 0 0.5
Round 2 Prog 0 1 0.5
Since the use of models with subject speciﬁc ﬁxed effects is not well stud-
ied, we evaluated the P-values using a single permutation in which the sam-
ples’ study round was switched for half of the non-progressor subjects and
half of the progressor subjects. This represented a divergent permutation that
eliminated potential round effects while preserving the within subject corre-
lation. An enrichment of low P-values in the permuted dataset would indicate
that the P-values were too liberal and inference on the real data has to inter-
preted with care.
4.2.4 Bisulphite Sequencing
Based on the results obtained in the MethylCap experiment we selected 6
locations to validate the epigenetic differences observed. As there was insuf-
ﬁcient DNA available for 6 subjects, the corresponding ﬁrst round samples
were excluded for the purpose of paired analyses but not for the group-wise
comparison. We also included a methylated and unmethylated control in the
form of in vitro methylated DNA (S7821, Millipore, Massachusetts, USA)
and DNA from a methyltransferase double knock-out cell line (HCT116) for
a total of 88 samples and one no-DNA blank (negative for all primers, not
included in sequencing).
After bisulphite treatment we ampliﬁed the regions of interest with the
primers listed in Supplementary Table C.5. All fragments were sequenced for
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250 bases in a paired-end fashion. As some target regions were shorter than
this length, they were in effect fully covered in duplicate (i.e. once from each
side) but sequencing does not extend beyond the primer boundaries.
Data preprocessing, including base calling, demultiplexing, trimming and
fastq generation was automatically performed in Illumina BaseSpace with
standard settings as provided by the manufacturer (Illumina). The sequencing
data was analysed using the Bismark package (v 0.10.0) [18]
Differential methylation in the BS-seq data was evaluated with the methyl-
Kit package [19]. Besides analysing the individual CpG locations, we also
used the ”regionCounts” function to aggregate results for each of the ampli-
cons.
Ideally the design matrix introduced in section 4.2.3.2 should be used for
the validation experiment. However, BS-seq results provide methylation per-
centages and per base coverages. These are modelled with logistic regres-
sion models by the methylKit package. Inclusion of subject speciﬁc ﬁxed
effects, however, is known to result in biased point estimates for multinomial
data [20, Chapter 13.3]. Hence, more sophisticated methods are needed to
address subject speciﬁc effects for multinomial data.
Moreover, the user interface of methylKit limited the analyses to simple
two group comparisons. First and second round methylation were compared
for non-progressors, progressor and all samples. This means that the latter
comparison does not take progressor status into account in any way and the
results should therefore be interpreted with care.
The R-code employed in this chapter may be consulted in Appendix A.2.
4.2.5 Pathway Analyses
Analyses were performed with the Entrez identiﬁers obtained in the MC rank-
ing. These identiﬁers where then used to perform singular enrichment analy-
sis with the online tool WebGestalt [21]. As background we used the ”hsapi-
ens genome” and speciﬁed the following non-default options: ”Benjamini
Hochberg” multiple testing correction and an FDR cut-off of 0.001. We-
bGestalt offers a choice of references, in this chapter we limit ourselves to
the KEGG database.
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WebGestalt is a pathway analysis tool of the SEA class with competitive
hypothesis testing and a gene permutation strategy for P-value estimation.
This implies that the Type I error control is not optimal as the underlying hy-
pergeometric test assumes that methylation levels in the different genes are
independent. For gene expression this is usually not the case. For MCs the
problem of correlation is harder to quantify as each gene contains several
MCs. Although neighbouring MCs are often correlated, wider spaced MCs in
the same gene often are not. A ranking of the pathways is useful for interpre-
tation of the data, but the FDR estimates should be interpreted with care.
4.3 Results
As outlined in the previous chapter we studied two subsets of middle-aged
individuals who are part of the Asklepios longitudinal study on cardiovascu-
lar ageing. We disposed over whole blood DNA from both the ﬁrst study
round (2002-2004) and the follow-up round which is ongoing at the time of
writing. Subjects were called back according to their availability but the ave-
rage timespan between both rounds for this subset was 9.1±0.58 years. In the
ﬁrst round the age-range of participants was 46±6 years (mean ± standard
deviation).
To identify time-associated differences we performed a genome-wide screen-
ing experiment. First we analysed the methylation differences between both
rounds in a longitudinal manner for the complete dataset but also for the non-
progressors and progressors separately in section 4.3.1. We validated a subset
of these ﬁndings with BS-seq in section 4.3.3. And ﬁnally we performed path-
way analysis based on the results obtained in the genome-wide screening in
section 4.3.4.
4.3.1 Differential Methylation Proﬁles
To study these questions, we modelled methylation counts using a subject spe-
ciﬁc ﬁxed effect and ProgRound a factor with three levels (coding for round 1,
round 2 non-progressor and round 2 progressor). Overall differential methy-
lation between round 1 and round 2 was assessed in all samples as well as
within non-progressors and progressors separately.
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As mentioned in section 4.2.3.2 there are limitations to the analysis of
paired samples in most analysis tools including edgeR which was used here.
More speciﬁcally there are concerns about the underestimation of P-values
[17]. To evaluate the extent of overoptimism we examined the P-value distri-
bution of three contrasts in the real data set and a permuted data set. These
contrasts correspond to the inter-round differences for all samples, only the
non-progressors and only the progressors.
Supplementary Figure B.5 shows the density plots of the P-values. For the
progressors the density plot shows no enrichment of low P-values compared
to the permuted data set. For the non-progressors and all subjects there is
substantial enrichment in the lower P-values for the real data but not for the
permuted samples. This indicates that the results for these comparisons are
probably reliable although there seem to be few ageing-related differences in
the progressors.
We identiﬁed 14678 DMRs (FDR<0.05, digital Supplementary Table DS6a)
between the ﬁrst and the second round samples, 7113 of these were not lo-
cated in the promoter region (-2000 to +300 bp) or gene body of an Ensembl
feature. Of the remaining 7565 DMRs, 691 were located in a promoter, 1003
overlapped an exon and 6725 overlapped an intron. This distribution represent
a slight enrichment of exons and intergenic regions (Chi-square P = 0.006).
The overlap with cell type associated probes is modest but signiﬁcant (n=98,
P < 0.001).
We identiﬁed 19829 DMRs (FDR<0.05, digital Supplementary Table DS6b)
between the ﬁrst and the second round non-progressor samples, 9582 of these
were not located in the promoter region (-2000 to +300 bp) or gene body of
an Ensembl feature. Of the remaining 10247 DMRs, 860 were located in a
promoter, 1495 overlapped an exon and 9053 overlapped an intron. This dis-
tribution represent a slight enrichment of promoters and exons (Chi-square
P = 0.001). Again, the overlap with cell type associated probes is modest but
signiﬁcant (n=121, P < 0.001).
We identiﬁed no DMRs (FDR<0.05, digital Supplementary Table DS6c)
between the ﬁrst and the second round progressor samples.
4.3.2 Relation to Prior Research
We looked for overlap between the regions identiﬁed in this study (all sam-
ples comparison) and those performed by Horvath et al. [22] (age range 3 to
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101 years) and McClay et al. [16] (age range 25 to 92 years) based on the
online Supplementary tables available for these publications. We found no
overlap between our results (global comparison) and either of the 3 analy-
sis approaches in these two studies for the exception of 1 methylation probe
from Horvath et al. supplementary table 4, which overlaps a differentially
methylated region from the inter-round analysis.
4.3.3 Validation
Table 4.2: Validation results time differences per amplicon. Amplicon details are listed in
Supplementary Table C.5.
PrimerPair ID NonProg NonProg Prog Prog Meth. Average Average
FDR Meth. Diff. FDR Diff. FDR Meth. Diff.
INTERGEN5 1 0,99 -0,34% 0,00 0,09% 0,00 -0,13%
INTERGEN6 2 0,00 0,68% 0,00 -0,12% 0,00 0,31%
INTERGEN6 1 0,00 -0,65% 0,00 -0,35% 0,00 -0,50%
ADRA1A 1 0,01 -1,41% 0,07 -0,20% 0,53 -0,81%
TLL2 1 0,00 0,18% 0,00 0,30% 0,38 0,23%
PUS7L 1 0,00 -0,41% 0,31 -0,57% 0,00 -0,47%
GPR176 1 0,57 -0,22% 0,02 -0,08% 0,07 -0,16%
From the ageing associated MCs we selected 6 for validation in an inde-
pendent set of subjects. The 7 primer pairs for the targeted amplicons are
listed in Supplementary Table C.5. The validation results of non-progressors
and progressors separately are listed in Table 4.2. As mentioned in section
3.3.2, the methylKit package used for analysis, only allows for simple two-
group comparisons. Because the validation regions were chosen from the
average inter-round differences, the inter-round comparison of all samples
was also made but the results should be interpreted with care as progressor
status could not be taken into account.
Considering the aggregated methylation levels of the amplicons, we were
able to conﬁrm the methylation patterns (both signiﬁcance and consistency)
in 4 out of 6 MCs for the non-progressors and 3 out of 6 for the progressors.
Considering methylation levels of individual CpGs within the amplicons, we
were able to validate 5 out of 6 methylation cores for both non-progressors
and progressors (Supplementary Table C.6). This increased validation rate
is the consequence of some MCs containing neighbouring CpGs which show
opposite methylation changes (Figure 4.1) an aspect which will be examined
in more detail in section 4.4.
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4.3.4 Pathway Analyses
We identiﬁed 49 KEGG pathways (FDR<0.001, digital Supplementary Table
DS7a) associated with ageing differences based on the inter-round differen-
tially methylated regions. The top 3 pathways identiﬁed were ”Metabolic
pathways”, ”Focal adhesion” and ”Pathways in cancer”.
4.4 Discussion
In this study we reported the ﬁrst genome-wide screening of DNAmethylation
in a longitudinal setting. The added power of a paired design allowed us to
identify a multitude of loci which showed differential methylation during the
ageing process of a middle-aged population, apparently healthy during the
ﬁrst round of the study.
As mentioned in chapter 3, the analysis of paired data is not straightfor-
ward both for MethylCap-seq and BS-seq data. More speciﬁcally current
methods for paired analyses of NB data are overconﬁdent in rejecting null hy-
potheses (see section 4.3.1). Although a semi-random permutation approach
indicated that there were real differences between the study rounds, more con-
servative estimates of the signiﬁcance might be appropriate. There were also
indications that non-progressors were driving many of the observed associ-
ations. A deﬁnite analysis of this data requires more in-depth examination
of this discrepancy and potentially the development of new methods for ran-
dom effect modelling in NB data. Further, there were severe limitations with
respect to the statistical methods available to model subject speciﬁc effects
for bisulphite sequencing data. Developing these methods was beyond the
scope of this research but would be absolutely necessary to utilize a complex
experimental design such as this one.
Ageing is a complex phenomenon that affects different parts of the body
in different ways. It is therefore essential to consider which aspects of ageing
are universal and which are tissue speciﬁc [22]. Additionally, tissue compo-
sition can confound epigenome-wide association studies [5]. We looked for
overlap between our results and a set of genomic loci associated with cell type
composition of blood. The overlap was greater than compared to the athero-
sclerosis progression associated loci reported in the previous chapter. This
suggests that our results partially reﬂect changing cell type composition with
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ageing. Although a method for inferring cell type composition is available for
Illumina 450k data, this method can currently not be applied to MethylCap-
seq data.
Since there was only limited overlap between studies, further analysis is
required to explain our results. The McClay et al. [16] study for instance,
used a principle component analysis to ”remove unknown confounders” but
this method could potentially eliminate a number of valid ageing-associated
regions. This might also be due to the fact that the methylation changes were
small (< 1% at the amplicon level) as evident from the validation experi-
ment. Additionally, in this study we considered ageing of peripheral blood
leukocytes in a relatively narrow age range. This age range might be one of
the reasons that our results had almost no overlap with previous publications
which studied correlation between DNA methylation (degree) and calendar
age in a wider age range. Regions that gain or lose methylation at a rate rel-
evant to the lifespan of a human being would go unnoticed in the short time
frame of this study as we were not sufﬁciently powered to pick up such small
differences.
Despite this lack of overlap we successfully replicated 5 out of 6 selected
methylation differences in an independent subset of participants. We also
observed that opposite methylation differences within a MC may occur which
obscure age-associated differential methylation when considering the MC as a
whole. Although we selected the validation loci based on the MethylCap-seq
results, it is unclear at this point how such opposing methylation patterns in
close proximity affect MethylCap-seq results in general. These consideration
will be further evaluated in chapter 5.
We also performed pathway analyses. We chose WebGestalt as it is a
tool that could be easily combined with the MC rankings we obtained. It is
a competitive hypothesis test based on gene permutations and therefore does
not take potential correlation between MCs into account. The pathway re-
sults may be anti-conservative. Further, these analyses assume that differen-
tial methylation affects pathways in a way similar to differential expression.
This is another reason why we chose a simple enrichment based pathway
analysis tool. Although methylation, in most cases, likely doesn’t correlate
linearly with expression, the same is true for gene expression and pathway
functionality. A doubling of the expression of a non-rate limiting enzyme in
a metabolic pathway may not have an appreciable effect on the pathway as
a whole. Further there are genes with pleiotropic effects and pathways such
as ”Pancreatic secretion” are likely not truly active in leukocytes whether the
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Figure 4.1: Methylation degree in 7 CpGs which are signiﬁcantly differentially methylated
between study rounds.
pathway was identiﬁed in expression or methylation data. Therefore the in-
terpretation of pathway level results has similar limitations for expression and
methylation data, they are indicative, not ﬁnal.
We observed a near complete overlap between signiﬁcant age-associated
pathways (gene level paired FDR<0.05, pathway level FDR<0.001, n=67)
and atherosclerosis associated pathways (gene level FDR<0.05, pathway level
FDR<0.001, n=35). This raises an interesting point of discussion: to what ex-
tent is ageing of PBL equivalent to the effect of atherosclerosis progression on
PBL? Inspecting the results at the level of the individual methylation cores,
the overlap between atherosclerosis (FDR<0.05, n=675) and time related dif-
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ferences (FDR<0.05, n=14678) is limited to 4 MCs. Repeating this exercise
at the level of Ensembl gene identiﬁers, there were 158 overlaps (FDR<0.05,
atherosclerosis n=323, time n=4845). We further compared the Entrez iden-
tiﬁers between the overlapping pathways where the overlap of 126 was in
the same order of magnitude (atherosclerosis MCs, FDR<0.05; time MCs,
FDR<0.05). We also examined these overlaps for atherosclerosis progression
FDR<0.1 and although the overlap was greater both for MCs and genes, the
overlap was relatively small (data not shown). For each shared pathway we
calculated the overlap and union of affected genes in either time or atheroscle-
rosis and listed the ratio of the overlap divided by the union (Supplementary
Table C.7). This ratio was 33.3% on average, ranging between 16.8% and
47.1%.
To summarise, there is minimal overlap at the level of the MCs, modest
overlap at the gene level and high overlap at the pathway level. These results
suggest our experimental design was successful at distinguishing atheroscle-
rosis related methylation changes from those associated with ageing. Yet at
the functional level, there is considerable similarity between the changes as-
sociated with ageing and the changes associated with atherosclerosis progres-
sion.
4.5 Conclusions
We studied differential methylation patterns associated with ageing across two
study rounds spanning roughly a decade. We found a multitude of loci with
altered methylation degree between study rounds. Further methodological
improvements with respect to the statistical analysis of sequencing count data
are required to fully utilise the paired study design. These initial analyses sug-
gest that the distinct methylome changes in leukocytes associated with ageing
and atherosclerosis progression, are closely related at the pathway level.
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Conclusions and Perspectives
5.1 Introduction
The completion of the ﬁrst human draft genomes around the year 2000 insti-
gated a never seen attempt to unravel the genetic determinants of most human
phenotypes and diseases. Though not completely unsuccessful, at the turn of
the last decade it became clear that the huge budgets spent in, for example
genome-wide association studies, did not deliver a fraction of the expected
genetic causal variants [1].
Though most likely many variants remain to be identiﬁed, and the impact
of complex effects, e.g. epistasis, is hard to assess with the existing models,
it has become clear that another facet of biology may be an at least equally
important driver of human variation and disease: the gene-environment inter-
action. If the modiﬁcations in gene expression due to a varying environment
can also be inherited meiotically, but most often mitotically, the phenomenon
is typically dubbed ”epigenetics”. Several studies, for example Schuebel et
al. [2], have suggested that the impact of epigenetics is often larger than the
role of genetics. Perhaps this is fortunate as the involvement of epigenetics
also implies that a subject’s future is less predetermined from birth than was
originally anticipated.
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The advances made in genetics technology, e.g. second generation se-
quencing and microarrays, can also be utilised for epigenetics and gene ex-
pression studies alike, which has led to a wave of novel studies. Initially,
mostly cancer epigenetics studies were performed, with DNA methylation
featuring as the most widely analysed epigenetic trait. Though cancer re-
mains the focus of most epigenetics studies, more recent successful efforts
also focused on ageing associated diseases such as Alzheimer’s disease [3],
osteoporosis [4] and cardiovascular disease [5].
In this doctoral thesis, the link between epigenetics and cardiovascular
ageing was further explored, with results regarding both telomere biology and
DNA methylation. This research used samples from and is situated within the
framework of the large-scale Asklepios Study on successful (cardiovascular)
ageing, which tries to build a complete picture of the ageing process and has
always envisaged to include epigenetics analyses, such as telomere length and
DNA methylation studies.
5.2 Telomere Length
In chapter 2 we explored how peripheral blood leukocyte telomere length
relates to a number of diagnostic parameters for vascular stiffness, cardiac
stiffness, systolic function and ventricular mass in the Asklepios population.
Although each of the parameters has been associated with PBL TL before,
this was usually performed separately and in smaller studies of populations
with a speciﬁc phenotype (i.e. old age or CVD). This was the ﬁrst study to
describe how these parameters were related to TL in a healthy middle-aged
population.
Most of the parameters were not signiﬁcantly associated with PBL TL
in this population. This does not preclude the possibility that some of them
will correlate more with PBL TL as the Asklepios study ages. Based on our
current results it seems less likely that shortening telomeres precede several
indicators of cardiovascular ageing and disease such as ejection fraction, pulse
wave velocity and left ventricular mass.
However, we did conﬁrm a correlation with E/A and e’/a’. These ratios
are measures of diastolic function and we discovered an unexpected correla-
tion between PBL TL and isovolumic relaxation time, another parameter of
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diastolic function. We also observed a slight difference in correlation strength
between women and men, but this proved non-signiﬁcant in the current data
set. Future Asklepios Study rounds will follow up on this difference as women
have an increased occurrence of diastolic heart failure [6].
The question whether TL shortening is a cause, consequence or innocent
bystander of CVD and ageing, is an unresolved debate [7]. Altered ﬁlling
patterns are an early sign of diastolic dysfunction and this leaves room for a
causal role for telomeres. But although TL correlates reasonably well between
tissues [8], we currently cannot propose a mechanism by which it might be
linked to diastolic function. Our results encourage a line of thought where
TL is associated early on, passively if not causally, in the pathogenesis of
diastolic dysfunction and possibly heart failure by extension. At the time of
writing the second study round is incomplete but repeating the analyses from
chapter 2 might provide more insight into the evolution of TL and diastolic
function.
5.3 DNA Methylation and Cardiovascular Ageing
In chapters 3 and 4 we used a subset of the Asklepios study for which second
round examinations were completed and stored DNA was available. With the
second round phenotypes available, we were able to design a study that sheds
light on the correlations between DNA methylation, atherosclerosis develop-
ment and ageing.
We ﬁrst performed a genome-wide screening by methylation enrichment
sequencing and selected several loci for validation in an independent subset
of participants by targeted bisulphite deep sequencing. This approach led to
identiﬁcation of a multitude of genomic loci which show differential methy-
lation between study rounds or between atherosclerosis progressors and non-
progressors. These loci were located both in annotated genes and intergenic
regions and were validated at similar rates in both. This underscores the value
of performing genome-wide screening rather than limiting oneself to a prede-
ﬁned set of regions as one does with array based technologies.
Although we chose our subjects and experimental design to eliminate
as much bias as possible, the currently available techniques for differential
count analysis are inadequate to utilise the full extent of the study design.
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More speciﬁcally, the estimation of P-values for the progressors versus non-
progressors comparison from negative binomial count data is likely somewhat
optimistic. The main analysis tool (edgeR) cannot account for the paired na-
ture of the samples in our design with a mixed effects model. For the ageing
related comparisons this was not a major issue. For the comparisons between
progressor and non-progressor, it was because the use of ﬁxed effects models
for NB data is not well studied [9]. This may have caused some overoptimism
in calling certain regions differentially methylated when combining ﬁrst and
second round samples.
In order to estimate the extent of overoptimism in rejecting null hypothe-
ses for the attempted comparisons, we analysed the results of restricted per-
mutations of the samples. These permutations could not determine to what
extent the P-values needed to be adjusted. They did show that, for the ma-
jority of the comparisons, the P-values of the true sample ordering were con-
sistently lower. This suggests that the observed effects were truly related to
the phenotypes of interest. Alongside the ongoing technological advances
in sequencing technology, there is a need to develop appropriate statistical
methods that can cope with negative binomial data in complex experimental
set-ups including several confounding factors and a subject speciﬁc term in
the form of random effects.
For the validation experiments, we analysed the methylation percentages
with a tool (methylKit) that was straightforward in terms of data (pre-)processing
but was limited to simple two-group comparisons. This may have caused
overoptimism in conﬁrming differential methylation between progressors and
non-progressors over both rounds combined. For the inter-round comparison
the use of models with a subject speciﬁc term was not possible as these gen-
erally lead to biased effect size estimates [10]. Here to, more comprehensive
analysis methods and ﬂexible tools are required to model our experimental
design in its entirety.
In the course of analysing the validation data, it became apparent that most
loci showed minimal differences in methylation degree. For some loci the dif-
ference was even signiﬁcant but opposite to the results of the genome-wide
screening (hypomethylation in screening and hypermethylation in validation
or visa versa). There are several factors that might account for these observa-
tions.
First, the different nature of both technologies used to asses methylation
is difcult to account for. Although bisulte sequencing offers an unambiguous
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methylation degree at nucleotide (cytosine) based resolution, the technology
is susceptible to PCR bias introduced by the methylation degree it attempts to
measure [11]. Methylation enrichment sequencing on the other hand, offers a
cost-efcient means of scanning an entire genome but only provides a relative
methylation measure biased by CpG and GC content and copy number vari-
ation [12]. But contrary to the bisulphite sequencing results, these biases are
less relevant when comparing the same locus between (non-tumour) samples,
as is the case in this doctoral thesis.
Second, MethylCap-seq afnity for a region is likely inﬂuenced by the num-
ber of neighbouring methylated CpGs and it is currently unknown howmethy-
lation changes in neighbouring CpGs affect binding afnity. For example, a
change in methylation status of one or two cytosines in a larger series of ad-
jacent CpGs in a single molecule of DNA implies only a modest quantitative
methylation difference (as observed during validation), but may already have
a major impact on the (more qualitative) afﬁnity of the methyl-binding do-
main used. Note that these methyl-binding domains have a biological origin
and that their binding afﬁnity may better reﬂect the biological relevance than
quantitative bisulphite sequencing data. In several cases during validation,
signiﬁcant effects were observed opposite to what was predicted. As these
effects were present in both directions (i.e. both hyper- and hypomethylation)
and were also signiﬁcant when using other statistical methodologies such as
the independent samples t-test (data not shown) and samples were not grouped
by phenotype during experimental protocols, it is unlikely that these effects
were caused by biases introduced during MethylCap-seq and/or bisulphite se-
quencing. Moreover, during validation it occurred that neighbouring CpGs
were both signiﬁcantly associated with the phenotype, yet one in the expected
direction and one in the opposite direction. However, this observation can
be biologically meaningful, as the impact of methylation is very CpG loca-
tion prone, with effects even depending on the methylation status of single
CpGs [13]. As the net-impact of adjacent but opposite methylation events on
MethylCap afﬁnity is a priori unclear, additional research − on the obtained
validation data as well − is absolutely necessary to pinpoint the relevance of
the individual effects observed and to resolve any remaining ambiguity.
Last, although we chose PBL leukocyte DNA for its accessibility, it is im-
portant to remember that it is composed of a complex mix of cell types, each
with its own speciﬁc methylation proﬁle [14]. It is therefore straightforward to
hypothesise that the observed small differences are in fact large differences of
an individual cell types, e.g. of monocytes or basophils which typically con-
stitute less than 8% or 1% of all leukocytes respectively (NIH reference values
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from http://www.nlm.nih.gov/medlineplus/ency/article/
003657.htm)) or even monocyte subsets. If this is indeed the case, signif-
icant differences will be obscured by the methylation status of the other cell
types, thereby introducing extra noise (but not bias) in the measurements.
Next to yielding additional biological insight, the identiﬁcation of the rel-
evant cell type may therefore also lead to more discriminative biomarkers
with potential for clinical application. Current innovation in technology may
even lead to a scenario where such tests are still applicable on whole blood
leukocyte DNA if combined with a computational separation of leukocyte
sub-populations (see section 5.5 Perspectives).
These and other technical challenges not withstanding we were able to
identify subtle but consistently differentially methylated loci and individual
CpGs. In addition to the loci associated with more advanced atherosclerosis,
we also identiﬁed 13 loci which were predictive of atherosclerosis progression
in the subsequent decade. Although we conﬁrmed two of these loci in the
validation arm of this study, the number of samples was too small to perform
a rigorous evaluation of the predictive power of these potential biomarkers.
5.4 Conclusion
Cardiovascular ageing is an intricate phenomenon with both pre-determined
and modiﬁable risk factors. Approaching this subject from an epigenetic per-
spective creates an opportunity to incorporate this complexity. Although we
did not dispose over telomere data from the second round, chapter 2 clearly
showed that epigenetics are likely involved early on in cardiovascular ageing
and that longitudinal studies are required to separate cause and effect.
In the conception of our experimental design we intended to study athe-
rosclerosis progression primarily (chapter 3) and used an orthogonal analysis
of the available data to examine ageing-related methylation changes indepen-
dently (chapter 4). Despite some challenges during validation, we identiﬁed
two non-overlapping sets of loci for which the methylation state was associ-
ated with atherosclerosis or ageing, respectively. However, when we sum-
marised the ﬁndings for atherosclerosis progression and ageing to a more
functional level, i.e. biological pathways, we discovered a near complete
overlap in potentially differentially methylated pathways despite clearly dis-
tinct loci being altered in both processes. Our combined ﬁndings suggest
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that, at least as far as DNA methylation of peripheral blood leukocytes is con-
cerned, there is great functional similarity between ageing and atherosclerosis
progression. This hypothesis is very intuitive as having poor cardiovascular
health is not unlike being physically older despite having the same calendar
age. More research is required to characterise this functional similarity and
to determine whether it is reﬂected in other cellular mechanisms such as gene
expression or protein interactions.
5.5 Perspectives
Epigenetics is almost per deﬁnition featured by versatility, leading to the no-
tion that any assessment of an epigenetic property will only provide a snap-
shot of the more complex underlying processes. Longitudinal studies, such as
the Asklepios study on successful cardiovascular ageing, therefore provide an
ideal setting to study epigenetics. Several current limitations are expected to
be remediated during the coming rounds of the study. Furthermore, technolo-
gical advances will enable us to assess epigenetic features in an increasingly
more comprehensive (genome-wide), cheaper, faster and more accurate man-
ner.
Though telomere length has often been independently associated with car-
diovascular ageing, and causality has been proposed, only a few studies as-
sessed telomere length in a longitudinal fashion and once the second round
is completed, the Asklepios Study will be one of these. Next to the fact that
telomere attrition rates may be better linked with cardiovascular ageing than
baseline telomere length, a major advantage of the Asklepios Study is the fact
that all subjects were apparently healthy at inclusion. For the results from the
ﬁrst round of the study, as presented in chapter 2, this implies that interme-
diate endpoints at most can be used for cross-sectional analysis. However, as
the ageing process in the study population continues, harder endpoints will in-
evitably occur and will enable us to evaluate to what extent baseline telomere
length (and/or telomere attrition) is predictive of clinically relevant systolic,
diastolic and vascular (dys)function. This will already be the case for the sec-
ond round results, which is currently ongoing and will yield an overview of
the different cardiovascular parameters for analyses in the near future.
Our current results likely contain a mix of causal, associated and spurious
methylation changes and further experiments will be required to determine the
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nature of each. One approach to showing causality would be to wait for suc-
cessive rounds of the Asklepios Study. By observing more volunteers in sev-
eral rounds, it might be possible to determine which methylation changes oc-
cur before the alterations in phenotype. For this type of experiment however,
it would be more interesting to follow a much smaller cohort at more frequent
intervals. Unrelated methylation changes are expected to be more stochas-
tic in nature, whereas associated or causative epimutations would likely be
present more consistently from their initial occurrence onward.
For the atherosclerosis progression markers the strongest proof of causal-
ity is an experimental set-up where one can randomly assign near identical
subjects to a treatment and a control group. Although ethical considera-
tions would prohibit any experimental design that actively encourages athe-
rosclerosis development in humans, animal studies could be used as a surro-
gate. Analogously to the very successful CRISPR-Cas technique for genome
editing [15], several groups are working on techniques which allow targeted
(de)methylation to engineer the desired methylation status [16,17]. Obviously
one cannot assign a study group to a non-ageing category with regards to the
ageing associated markers but one could study the occurrence ”rejuvenating”
effects upon methylation pattern alteration.
Moreover, ongoing technological advances allow us to infer several fea-
tures of future studies on the topic. More speciﬁcally, lower cost of sequen-
cing should will enable population wide DNA methylation studies leading
to the epigenetic equivalent of genome-wide association studies [18]. Single
molecule real-time sequencing technology entails the promise of direct as-
sessment of not only the DNA sequence and its methylation status (thereby
avoiding the often tricky bisulphite conversion step) but also of other nucleic
acid based epigenetic features such as DNA hydroxymethylation [19]. Single
molecule sequencing technologies typically offer far longer reads (up to tens
of kbps), which could offer the possibility to assess the full length telomere
directly and also entails a far easier (computational) discrimination of cell
types. Indeed, given sufﬁcient read length, phasing of methylation status be-
tween different genomic position will be possible [19]. This phasing will
allow one to pinpoint epigenetic alterations associated with the phenotype of
interest to speciﬁc cell type sub-populations.
The data currently available to us, did not enable us to do this but the
Asklepios samples remain available for follow-up research. Although lesser
quantitative shifts in leukocyte subtypes are expected for atherosclerosis than
for ageing as such, it is still of major interest to identify the speciﬁc cell
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type(s) involved. A ﬁrst validation indicated that several DNA methylation
changes were indeed present, but the next step should be to identify the cell
type(s) driving the observed differences.
As CpG level information was provided by the validation study, this en-
ables the development of relatively inexpensive methylation-speciﬁc quantita-
tive PCR assays. The latter also require limited input material and can there-
fore be used on leukocyte sub-populations, generated by e.g. ﬂuorescence-
activated cell sorting, in a novel case-control study for atherosclerosis or lon-
gitudinal study of ageing. Using this extra knowledge, it can subsequently
be decided to perform a large scale validation study on solely the relevant
fraction, or − if the other leukocyte sub-populations have no major impact
− on whole blood leukocytes as a proxy for the speciﬁc fraction involved.
This will enable the identiﬁcation of the determinants of the relevant epige-
netic modiﬁcations but also to assess to what extent these biomarkers/risk
factors are relevant in the general population. Once the optimal methylation
markers have been established this methodology could also be translated to a
cost-efﬁcient diagnostic test.
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Summary − Samenvatting
Cardiovascular ageing is a complex phenomenon that is affected by a host
of internal and external factors. These factors are both pre-determined and
changeable throughout a person’s life span. Epigenetics is the information
layer superimposed on the genetic information encoded in DNA. By deﬁni-
tion it reﬂects phenotypic variation that is changeable over time, adaptive to
environmental circumstances and at least partially heritable independent of
the underlying DNA sequence. In this thesis we studied the role of epigenet-
ics in cardiovascular ageing.
The study samples were all drawn from the Asklepios longitudinal study
on (successful) cardiovascular ageing, which included over 2500 volunteers
aged approximately 35 to 55 years and apparently healthy when the study
started in 2002−2004. The ﬁrst follow-up round was initiated in 2012 and
is currently still ongoing. We made use of ﬁrst round and already available
second round samples as well as phenotypic information to focus both on
hemodynamic parameters and atherosclerosis, the gradual calciﬁcation and
restriction of arteries that is closely linked with cardiovascular disease.
The length dynamics of peripheral blood leukocyte telomeres, the pro-
tective ends of the chromosomes, have been intensely studied both in the
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Asklepios and other populations. We found that many parameters of cardio-
vascular function which had previously been described to be associated with
telomere length, were not so in this age range. We observed that telomere
length was related to sensitive and clinically relevant indicators of diastolic
function, thus suggesting that telomeres, which can also be regarded as epige-
netic traits, are involved early on in certain cardiovascular ageing processes.
Follow-up research is required to determine how telomere length has changed
in the Asklepios Study and what the implications are for the associations with
diastolic function.
We also applied second generation sequencing technology which allowed
us to proﬁle multiple samples in a genome-wide way with regards to cyto-
sine DNA methylation. Through a carefully considered study design and de-
spite some limitations, we identiﬁed distinct methylation patterns associated
with atherosclerosis progression and with ageing between study rounds. Sum-
marising these results to the level of biological pathways, we found support
for the hypothesis that ageing and atherosclerosis progression are functionally
similar from the perspective of leukocytes.
We also found methylation difference which preceded atherosclerosis pro-
gression in the following decade. For the time being it is too soon to extra-
polate these results to the general population. More advanced study designs,
possibly using the fast-approaching single-molecule sequencers, will need to
distinguish which leukocyte subtypes are characterised by the methylation
changes we observed.
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Cardiovasculaire veroudering is een complex fenomeen dat door een reeks
intrinsieke en extrinsieke factoren beı¨nvloed wordt. Sommige van deze zijn
bepaald bij de conceptie, andere varie¨ren gedurende het leven. Epigenetica,
een verzameling mechanismen die fenotypische informatie coderen bovenop
het DNA, is per deﬁnitie veranderlijk in de tijd, adaptief aan omstandighe-
den en ten minste gedeeltelijk erfelijk onafhankelijk van het onderliggende
DNA. Dit proefschrift handelt over de rol van epigenetica in cardiovasculaire
veroudering.
De stalen gebruikt in dit onderzoek zijn afkomstig van de longitudinale
Asklepios Studie over (succesvolle) cardiovasculaire veroudering. Meer dan
2500 vrijwilligers verkerende in ogenschijnlijk goede gezondheid en met een
leeftijd van ongeveer 35 a` 55 jaar, namen deel aan de initie¨le studieronde in
2002−2004. In 2012 begon de eerste opvolgronde en hoewel deze nog steeds
lopende is, werden waar mogelijk reeds tweede ronde stalen en informatie
gebruikt. Meer bepaald hebben we gefocust op hemodynamische parameters
en atherosclerose, de geleidelijke verkalking en vernauwing van slagaders die
een heel belangrijke rol speelt bij de meeste hart- en vaatziekten.
De gemiddelde lengte van telomeren, de beschermende uiteindes van de
chromosomen, werd reeds uitvoerig bestudeerd in de Asklepios populatie
maar ook in andere studies. Dit onderzoek heeft uitgewezen dat de meeste
parameters van cardiovasculaire functie die in het verleden geassocieerd wer-
den met telomeerlengte, niet signiﬁcant waren in onze relatief jonge popu-
latie. Wel werd geobserveerd dat telomeerlengte gecorreleerd was met gevoe-
lige, klinisch relevante parameters van diastolische functie. Dit suggereert dat
telomeerlengte, welke ook beschouwd kan worden als een epigenetisch me-
chanisme, reeds vroeg betrokken is bij bepaalde aspecten van cardiovasculaire
veroudering. Toekomstig onderzoek moet uitwijzen hoe telomeerlengte ver-
andert in de Asklepios studiepopulatie en wat dit betekent voor de associaties
met diastolische functie.
Verder werd tweede-generatie sequeneringstechnologie gebruikt om ver-
schillende stalen genoomwijd te proﬁleren op het vlak van DNA cytosinemethy-
latie. Door middel van een weloverwogen studieontwerp gebaseerd op de
gedetailleerd gezondheidsinformatie in de Asklepios Studie en ondanks een
aantal limitaties, waren we in staat om onafhankelijke wijzigingen in DNA
methylatie te detecteren die geassocieerd waren met veroudering tussen de
studierondes of de progressie van atherosclerose. Wanneer deze resultaten
echter geaggregeerd werden tot het niveau van biologische gennetwerken,
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vonden we aanwijzingen dat veroudering en atheroscleroseprogressie func-
tioneel gelijkaardig zijn vanuit het perspectief van leukocyten.
Bovendien werden in de eerste ronde methylatieverschillen waargenomen
die voorafgingen aan atheroscleroseprogressie. Op dit moment kunnen deze
resultaten echter nog niet extrapoleerd worden naar de algemene bevolking.
Meer geavanceerde studieontwerpen, die mogelijk gebruik maken van de komende
generatie technologiee¨n voor de sequentie¨ring van individuele DNAmoleculen,
zullen nodig zijn om te bepalen welke leukocytsubtypes bepalend zijn voor de
geobserveerde methylatieverschillen.
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A
R-Code
A.1 Chapter 2
### Load da ta s e t ###
load ( ” Dy a s t o l i cDy s f u n c t i o n BNP . RData ” )
### Sca l e t o S I u n i t s ###
DATA$TDE<−DATA$TDE∗−0.1
Females $TDE<−Females $TDE∗−0.1
Males$TDE<−Males$TDE∗−0.1
DATA$TDA<−DATA$TDA∗−0.1
Females $TDA<−Females $TDA∗−0.1
Males$TDA<−Males$TDA∗−0.1
DATA$TDSMAX<−DATA$TDSMAX∗ 0 . 1
Females $TDSMAX<−Females $TDSMAX∗ 0 . 1
Males$TDSMAX<−Males$TDSMAX∗ 0 . 1
### Summary measures ###
l eng th ( Males$ Pu l s e p r e s s u r e mmHg[ i s . na ( Males$ Pu l s e
↪→ p r e s s u r e mmHg) ==TRUE] )
mean ( Males$ Pu l s e p r e s s u r e mmHg, na . rm=TRUE)
A-2 APPENDIX A
var ( Males$ Pu l s e p r e s s u r e mmHg, na . rm=TRUE) ˆ 0 . 5
. . .
l eng th ( Males$ spher ic iNDBF2 [ i s . na ( Males$
↪→ spher ic iNDBF2 ) ==TRUE] )
mean ( Males$ sphericiNDBF2 , na . rm=TRUE)
var ( Males$ sphericiNDBF2 , na . rm=TRUE) ˆ 0 . 5
l eng th ( Females $ Pu l s e p r e s s u r e mmHg[ i s . na ( Females $
↪→ Pu l s e p r e s s u r e mmHg) ==TRUE] )
mean ( Females $ Pu l s e p r e s s u r e mmHg, na . rm=TRUE)
var ( Females $ Pu l s e p r e s s u r e mmHg, na . rm=TRUE) ˆ 0 . 5
. . .
l eng th ( Females $ spher ic iNDBF2 [ i s . na ( Females $
↪→ spher ic iNDBF2 ) ==TRUE] )
mean ( Females $ sphericiNDBF2 , na . rm=TRUE)
var ( Females $ sphericiNDBF2 , na . rm=TRUE) ˆ 0 . 5
l eng th (DATA$ Pu l s e p r e s s u r e mmHg[ i s . na (DATA$ Pu l s e
↪→ p r e s s u r e mmHg) ==TRUE] )
mean (DATA$ Pu l s e p r e s s u r e mmHg, na . rm=TRUE)
var (DATA$ Pu l s e p r e s s u r e mmHg, na . rm=TRUE) ˆ 0 . 5
. . .
l eng th (DATA$ spher ic iNDBF2 [ i s . na (DATA$ spher ic iNDBF2 )
↪→ ==TRUE] )
mean (DATA$ sphericiNDBF2 , na . rm=TRUE)
var (DATA$ sphericiNDBF2 , na . rm=TRUE) ˆ 0 . 5
### De f i n e h e l p e r f u n c t i o n f o r 2 group compar i son
↪→ ###
autoCompare2<−f unc t i on ( Group1 , Group2 ) {
requ i re ( c a r )
Group1<−as . numeric ( Group1 )
Group2<−as . numeric ( Group2 )
p a r am e t r i c =”TRUE”
eqVar=”TRUE”
mean1<−mean ( Group1 )
mean2<−mean ( Group2 )
va r1<−var ( Group1 )
va r2<−var ( Group2 )
R-CODE A-3
norm1<−s h a p i r o . t e s t ( Group1 ) $p . v a l u e
norm2<−s h a p i r o . t e s t ( Group2 ) $p . v a l u e
i f ( norm1 < 0 .05 | norm2 < 0 . 0 5 ) {
message ( ”At l e a s t one group does no t f i t t h e
↪→ normal d i s t r i b u t i o n . ” )
p a r am e t r i c =”FALSE”
TEMP<−matrix ( 0 , nrow=( l eng th ( Group1 ) + l eng th ( Group2
↪→ ) ) , nco l =2)
colnames (TEMP)<−c ( ” measurements ” , ” F a c t o r ” )
TEMP<−as . data . frame (TEMP)
TEMP[ 1 : l eng th ( Group1 ) , 1 ]<−as . double ( Group1 )
TEMP[ ( l eng th ( Group1 ) +1) : dim (TEMP) [ 1 ] , 1 ]<−as .
↪→ double ( Group2 )
TEMP[ 1 : l eng th ( Group1 ) , 2 ]<−rep ( ”A” , l eng th ( Group1 ) )
TEMP[ ( l eng th ( Group1 ) +1) : dim (TEMP) [ 1 ] , 2 ]<−rep ( ”B” ,
↪→ l eng th ( Group2 ) )
TEMP[ , 2 ]<−as . f a c t o r (TEMP[ , 2 ] )
i f ( l e v e n eT e s t ( measurements ˜ Fac to r , data=TEMP)
↪→ [ 1 , 3 ] <0 . 05 ) {
eqVar=”FALSE”
}
rm (TEMP)
i f ( l eng th ( Group1 )>=30 && leng th ( Group1 ) >=30){
p a r am e t r i c =”TRUE”
message ( ” S u f f i c i e n t o b s e r v a t i o n s f o r p a r am e t r i c
↪→ t e s t i n g . \ n” )
}
}
e l s e {
i f ( var . t e s t ( Group1 , Group2 , r a t i o = 1 , a l t e r n a t i v e =
↪→ c ( ” two . s i d e d ” ) , con f . l e v e l = 0 . 9 5 ) $p . va lue
↪→ <0.05) {
eqVar=”FALSE”
}
}
i f ( p a r am e t r i c ==”TRUE” & eqVar==”TRUE” ) {
message ( ” Per fo rmed two−s i d e d S t u d en t t− t e s t on
↪→ no rma l l y d i s t r i b u t e d , homosc eda s t i c d a t a . ” )
re turn ( t . t e s t ( Group1 , Group2 , a l t e r n a t i v e = ” two .
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↪→ s i d e d ” , mu = 0 , p a i r e d = FALSE , var . equal =
↪→ TRUE, con f . l e v e l = 0 . 9 5 ) )
}
i f ( p a r am e t r i c ==”TRUE” & eqVar==”FALSE” ) {
message ( ” Per fo rmed two−s i d e d Welch t− t e s t on
↪→ no rma l l y d i s t r i b u t e d , non−homosc eda s t i c
↪→ d a t a . ” )
message ( ca t ( ” E s t ima t e d v a r i a n c e r a t i o = ” , var .
↪→ t e s t ( Group1 , Group2 , r a t i o = 1 , a l t e r n a t i v e =c
↪→ ( ” two . s i d e d ” ) , con f . l e v e l = 0 . 9 5 ) $ e s t ima t e , ”
↪→ \n” , sep=” ” ) )
re turn ( t . t e s t ( Group1 , Group2 , a l t e r n a t i v e = ” two .
↪→ s i d e d ” , mu = 0 , p a i r e d = FALSE , var . equal =
↪→ FALSE , con f . l e v e l = 0 . 9 5 ) )
}
i f ( p a r am e t r i c ==”FALSE” ) {
message ( ” Per fo rmed two−s i d e d Wilcoxon rank sum
↪→ t e s t on non−no rma l l y d i s t r i b u t e d d a t a . ” )
re turn ( w i l cox . t e s t ( Group1 , Group2 , a l t e r n a t i v e = ”
↪→ two . s i d e d ” , mu = 0 , p a i r e d = FALSE , e x a c t =
↪→ NULL, c o r r e c t = TRUE, con f . i n t = FALSE ,
↪→ con f . l e v e l = 0 . 9 5 ) )
}
}
autoCompare2 ( Females $ Pu l s e p r e s s u r e mmHg, Males$
↪→ Pu l s e p r e s s u r e mmHg)
. . .
autoCompare2 ( Females $ sphericiNDBF2 , Males$
↪→ spher ic iNDBF2 )
##### Expor t model r e s u l t s as t a b l e ######
###### Model 1 ######
A<−rbind (
t ( summary ( glm (TMEAR ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDEAR ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TME ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
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t ( summary ( glm (TMA ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDE ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDA ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EoverEm ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TMDT ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( IVRT ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( l og ( NTproBNPpgml , 1 0 ) ˜ meanTRF , data
↪→ =DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( alloLVM ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (LVEDD2D ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EF ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDSMAX ˜ meanTRF , data=DATA) ) $
↪→ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] )
)
###### Model 2 ######
B<−rbind (
t ( summary ( glm (TMEAR ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDEAR ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TME ˜ meanTRF + Age y e a r s + Gender ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TMA ˜ meanTRF + Age y e a r s + Gender ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDE ˜ meanTRF + Age y e a r s + Gender ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDA ˜ meanTRF + Age y e a r s + Gender ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EoverEm ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TMDT ˜ meanTRF + Age y e a r s + Gender
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↪→ , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( IVRT ˜ meanTRF + Age y e a r s + Gender
↪→ , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( l og ( NTproBNPpgml , 1 0 ) ˜ meanTRF + Age
↪→ y e a r s + Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 ,
↪→ c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( alloLVM ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (LVEDD2D ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EF ˜ meanTRF + Age y e a r s + Gender ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDSMAX ˜ meanTRF + Age y e a r s +
↪→ Gender , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] )
)
###### Model 3 ######
C<−rbind (
t ( summary ( glm (TMEAR ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDEAR ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TME ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA)
↪→ ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TMA ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA)
↪→ ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDE ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA)
↪→ ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDA ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA)
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↪→ ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EoverEm ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TMDT ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass
↪→ Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=
↪→ DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( IVRT ˜ meanTRF + Age y e a r s + Gender
↪→ + D i a s t o l i c BP mmHg + TDHR + Body Mass
↪→ Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=
↪→ DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( l og ( NTproBNPpgml , 1 0 ) ˜ meanTRF + Age
↪→ y e a r s + Gender + D i a s t o l i c BP mmHg + TDHR +
↪→ Body Mass Index kgm2 + D r u g t r e a t e d
↪→ hyp e r t e n s i o n , data=DATA) ) $ c o e f f i c i e n t s [ 2 , c
↪→ ( 1 , 4 ) ] ) ,
t ( summary ( glm ( alloLVM ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (LVEDD2D ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm ( EF ˜ meanTRF + Age y e a r s + Gender +
↪→ D i a s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA) )
↪→ $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] ) ,
t ( summary ( glm (TDSMAX ˜ meanTRF + Age y e a r s +
↪→ Gender + D i a s t o l i c BP mmHg + TDHR + Body
↪→ Mass Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) ) $ c o e f f i c i e n t s [ 2 , c ( 1 , 4 ) ] )
)
AA<−cbind (A[ 1 , 1 ] ,A[ 1 , 2 ] )
f o r ( i i n 2 : dim (A) [ 1 ] ) {AA<−cbind (AA,A[ i , 1 ] ,A[ i , 2 ] ) }
BB<−cbind (B [ 1 , 1 ] ,B [ 1 , 2 ] )
f o r ( i i n 2 : dim (B) [ 1 ] ) {BB<−cbind (BB,B[ i , 1 ] ,B[ i , 2 ] ) }
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CC<−cbind (C[ 1 , 1 ] ,C [ 1 , 2 ] )
f o r ( i i n 2 : dim (C) [ 1 ] ) {CC<−cbind (CC,C[ i , 1 ] ,C[ i , 2 ] ) }
OUT<−rbind (AA,BB,CC)
rownames (OUT)<−c ( ”Model1 ” , ”Model2 ” , ”Model3 ” )
# colnames (OUT)<−c (”TMEAR” ,”TME” ,”TMA” ,”TDE” ,”TDA” ,”
↪→ TMDT” ,” IVRT” ,”NTproBNPpgml” ,” alloLVM” ,”
↪→ LVEDD2D” ,”EF” ,”S\ ’ ( TDSET ) ”)
OUT<−t (OUT)
op t i on s ( d i g i t s =22 , s c i p e n =22)
wr i t e . t a b l e (OUT, ” Impor tTab leMode l s . v4 . 0 SBPandDBP .
↪→ t x t ” , sep=”\ t ” , dec=” , ” , row . names=FALSE , c o l .
↪→ names=TRUE, quote=FALSE)
### P ropo r t i o n o f v a r i a n c e e x p l a i n e d ###
AB<−glm (TMEAR ˜ meanTRF + Age y e a r s + Gender +
↪→ S y s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA)
anova (AB)
summary (AB)
aov (AB)
(240 .76 −136 .70 ) / 240 .76
6 .364 / 240 .76
### Kuzne t sova 2010 & Vasan 2011 ###
summary ( glm ( alloLVM ˜ meanTRF + Age y e a r s + Gender
↪→ + S y s t o l i c BP mmHg + He igh t cm + Weight kg +
↪→ Drug t r e a t e d hyp e r t e n s i o n , data=DATA) )
summary ( glm (LV Mass 2D g ˜ meanTRF + Age y e a r s +
↪→ Gender + S y s t o l i c BP mmHg + He igh t cm +
↪→ Weight kg + D r u g t r e a t e d hyp e r t e n s i o n , data=
↪→ DATA) )
summary ( glm ( alloLVM ˜ meanTRF + Age y e a r s + Gender
↪→ + S y s t o l i c BP mmHg + TDHR + Body Mass Index
↪→ kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=DATA) )
summary ( glm (LV Mass 2D g ˜ meanTRF + Age y e a r s +
↪→ Gender + S y s t o l i c BP mmHg + TDHR + Body Mass
↪→ Index kgm2 + D r u g t r e a t e d hyp e r t e n s i o n , data=
↪→ DATA) )
summary ( glm ( alloLVM ˜ meanTRF + Age y e a r s + Gender
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↪→ + He igh t cm + Weight kg + a c t i v e smoking +
↪→ S y s t o l i c BP mmHg + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) )
summary ( glm (LV Mass 2D g ˜ meanTRF + Age y e a r s +
↪→ Gender + He igh t cm + Weight kg + a c t i v e
↪→ smoking + S y s t o l i c BP mmHg + D r u g t r e a t e d
↪→ hyp e r t e n s i o n , data=DATA) )
### TL as dependen t v a r i a b l e ###
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + IVRT , data=DATA) )
summary ( glm (meanTRF ˜ Age y e a r s + a g e f a t h e r b i r t h +
↪→ IVRT , data=Females ) )
summary ( glm (meanTRF ˜ Age y e a r s + a g e f a t h e r b i r t h +
↪→ IVRT , data=Males ) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + S y s t o l i c BP mmHg, data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + D r u g t r e a t e d hyp e r t e n s i o n ,
↪→ data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + alloLVM , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + LV Mass 2D g , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + LVEDD2D, data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + EF , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + TDSMAX, data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + PWVcar fem , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + Pu l s e p r e s s u r e mmHg, data=
↪→ DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + Ee , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + c rph igh , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
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↪→ a g e f a t h e r b i r t h + i l 6 a b ov e1 . 5 , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + Ur i c a c i d mgdl , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + IVRT + crph igh , data=DATA) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + IVRT + i l 6 a b ov e 1 . 5 , data=DATA
↪→ ) )
summary ( glm (meanTRF ˜ Gender + Age y e a r s +
↪→ a g e f a t h e r b i r t h + IVRT + Ur i c a c i d mgdl , data=
↪→ DATA) )
### P l o t f i g u r e s ###
l i b r a r y ( g gp l o t 2 )
p <− ggp l o t ( data = DATA, ae s (meanTRF , TMEAR, c o l o u r =
↪→ Gender ) )
p + geom po i n t ( a l p h a =1 / 2 ,na . rm=TRUE, s i z e =1 . 25 ) +
↪→ geom ab l i n e ( i n t e r c e p t =0 .70647805 , s l o p e
↪→ =0.06956889 , s i z e =0 . 5 ) + x l ab ( ” Telomere Length
↪→ ( kbp ) ” ) + y l ab ( ”E /A” ) + theme ( t e x t = e l emen t
↪→ t e x t ( s i z e =8) , ax i s . t i t l e . y = e l emen t t e x t (
↪→ s i z e = r e l ( 1 . 3 ) , a ng l e = 90) ) + theme ( ax i s .
↪→ t i c k s . margin = u n i t ( 1 , ”mm” ) ) + theme ( ax i s .
↪→ t i t l e . x = e l emen t t e x t ( s i z e = r e l ( 1 . 3 ) , a ng l e
↪→ = 0) ) + theme ( ax i s . t i t l e . x= e l emen t t e x t (
↪→ v j u s t =0 . 25 ) ) + theme ( ax i s . t i t l e . y= e l emen t
↪→ t e x t ( v j u s t =0 . 35 ) ) + theme ( p l o t . margin = u n i t (
↪→ c ( rep ( 1 , 4 ) ) , ”mm” ) )
ggsave ( ”LTLvsTMEAR 600 dp i co lourByGender . t i f f ” ,
↪→ wid th = 4 . 2677 , h e i g h t = 3 . 2677 , dp i =600 ,
↪→ compre s s i on=” lzw ” )
p <− ggp l o t ( data = DATA, ae s (meanTRF , IVRT ) )
p + geom po i n t ( a l p h a =1 / 3 , c o l o u r =” r ed ” ,na . rm=TRUE,
↪→ s i z e =1 . 25 ) + geom ab l i n e ( i n t e r c e p t
↪→ =107 .094972 , s l o p e =−2.695635 , s i z e =0 . 5 ) + x l ab (
↪→ ” Telomere Length ( kbp ) ” ) + y l ab ( ”IVRT (ms ) ” )
↪→ + theme ( t e x t = e l emen t t e x t ( s i z e =8) , ax i s .
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↪→ t i t l e . y = e l emen t t e x t ( s i z e = r e l ( 1 . 3 ) , a ng l e
↪→ = 90) ) + theme ( ax i s . t i c k s . margin = u n i t ( 1 , ”
↪→ mm” ) ) + theme ( ax i s . t i t l e . x = e l emen t t e x t (
↪→ s i z e = r e l ( 1 . 3 ) , a ng l e = 0) ) + theme ( ax i s .
↪→ t i t l e . x= e l emen t t e x t ( v j u s t =0 . 25 ) ) + theme (
↪→ ax i s . t i t l e . y= e l emen t t e x t ( v j u s t =0 . 35 ) ) +
↪→ theme ( p l o t . margin = u n i t ( c ( rep ( 1 , 4 ) ) , ”mm” ) )
ggsave ( ”PBL TL vs IVRT 600 dp i . t i f f ” , w id th =
↪→ 3 . 2677 , h e i g h t = 3 . 2677 , dp i =600 , compre s s i on=”
↪→ lzw ” )
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A.2 Chapter 3 & 4
A.2.1 MethylCap-seq Analyses
##### D i f f e r e n t i a l Me t h y l a t i o n A n a l y s i s A s k l e p i o s
↪→ MethylCap s t u d y p a r t 1 : t ime and h e a l t h
↪→ w i t h o u t s u b j e c t i d e n t i t y #####
### Read i n p u t da ta ###
MHMcounts<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ coun t s . t x t ” , quote=” ” , comment . char=” ” , s k i p
↪→ =2 , h e ade r =TRUE, sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ MappingProps . t x t ” , comment . char=” ” , h e ade r =TRUE
↪→ , row . names=1 , sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s [ 1 , ]<−as . numeric ( as . charac t er ( t o t c o u n t s
↪→ [ 1 , ] ) )
### Load a n a l y s i s t o o l ###
l i b r a r y ( edgeR )
### Re t a i n t e c h n i c a l r e p l i c a t e s w i t h h i g h e s t
↪→ cove rage ###
t o t c o u n t s [ c ( ”AS1 . 20 ” , ”AS1 . 21 ” , ”AS2 . 29 ” , ”AS2 . 47 ” ) ]
So r t e d<−MHMcounts [ dup l i c a t ed (MHMcounts$ r e g i o n ID ) ==
↪→ FALSE , c ( 1 3 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ]
rownames ( So r t e d )<−MHMcounts$ r e g i o n ID [ dup l i c a t ed (
↪→ MHMcounts$ r e g i o n ID ) ==FALSE]
L i b s i z e s<−as . data . frame ( t o t c o u n t s [ 1 , colnames ( So r t e d
↪→ ) ] )
dim (MHMcounts )
dim ( So r t e d )
### Normal i z e c oun t s ###
#NormFacts<−ca lcNormFac tor s ( Sor t ed , method=”TMM” ,
↪→ re fColumn = NULL , l o g r a t i o T r im = 0 . 3 , sumTrim
↪→ = 0 . 05 , doWe igh t ing = TRUE , A c u t o f f = −1e
↪→ +10)
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NormFacts<−c ( rep ( 1 , 4 0 ) )
names ( NormFacts )<−colnames ( So r t e d )
### edgeR GLM− l i k e approach ###
So r t e d<−So r t e d [ rowSums ( So r t e d ) >=10 ,]
dim (MHMcounts )
dim ( So r t e d )
P r o gS t a t u s <− f a c t o r ( c ( rep ( ” np ” , 10 ) , rep ( ”p” , 10 ) , rep
↪→ ( ” np ” , 10 ) , rep ( ”p” , 10 ) ) )
P r o gS t a t u s<−r e l e v e l ( P r ogS t a t u s , r e f =” np ” )
Round <− f a c t o r ( c ( rep ( ” t 1 ” , 10 ) , rep ( ” t 1 ” , 10 ) , rep ( ” t 2
↪→ ” , 10 ) , rep ( ” t 2 ” , 10 ) ) )
Round<−r e l e v e l ( Round , r e f =” t 1 ” )
roundProg=as . f a c t o r ( pas t e ( Round , P r ogS t a t u s , sep=” ” )
↪→ )
d e s i g n <− model . matrix ( ˜ −1+roundProg )
A<−Sys . t ime ( )
yNC <− DGEList ( c oun t s =Sor t ed , group=c ( rep ( 1 , 1 0 ) , rep
↪→ ( 2 , 1 0 ) , rep ( 3 , 1 0 ) , rep ( 4 , 1 0 ) ) , l i b . s i z e = u n l i s t (
↪→ L i b s i z e s ) , norm . f a c t o r s =NormFacts )
yNC <− estimateGLMCommonDisp (yNC , d e s i g n )
yNC <− es t imateGLMTrendedDisp (yNC , d e s i g n )
yNC <− est imateGLMTagwiseDisp (yNC , d e s i g n )
f i tNC <− g lmF i t (yNC , d e s i g n )
B<−Sys . t ime ( )
B−A
save . image ( ”MCapAthero t ime and h e a l t h MHM
↪→ Libs izeNorm Rea lLabe l s . RData ” )
# load (”MCapAthero t ime and h e a l t h MHM Libs i z eNorm
↪→ Rea lLabe l s . RData ”)
# l i b r a r y ( edgeR )
### d e f i n e c o n t r a s t s ###
c on t r a s t s=matrix ( 0 , nco l =6 ,nrow=4)
rownames ( c on t r a s t s ) =colnames ( d e s i g n )
colnames ( c on t r a s t s ) =c ( ” d i f f . p . np t 1 ” , ” d i f f . p . np t 2 ”
↪→ , ” a vgD i f f . p . np ” , ” d i f f . t 2 . t 1 np ” , ” d i f f . t 2 . t 1 p
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↪→ ” , ” avgD i f f . t 2 . t 1 ” )
c on t r a s t s [ 1 : 2 , 1 ] = c (−1 ,1)
c on t r a s t s [ 3 : 4 , 2 ] = c (−1 ,1)
c on t r a s t s [ 1 : 4 , 3 ] = c (−1 ,1 ,−1 ,1) / 2
c on t r a s t s [ c ( 1 , 3 ) , 4 ]= c (−1 ,1)
c on t r a s t s [ c ( 2 , 4 ) , 5 ]= c (−1 ,1)
c on t r a s t s [ 1 : 4 , 6 ] = c (−1 ,−1 ,1 ,1) / 2
C<−Sys . t ime ( )
l r t L i s t P r o g =apply ( c on t r a s t s [ , 1 : 3 ] , 2 , f unc t i on ( x )
↪→ glmLRT ( f i tNC , c o n t r a s t =x ) )
names ( l r t L i s t P r o g ) =colnames ( c on t r a s t s ) [ 1 : 3 ]
l r t L i s t P r o g $” progSam”=glmLRT ( f i tNC , c o n t r a s t =
↪→ c on t r a s t s [ , 1 : 2 ] )
l r t L i s t T im e =apply ( c on t r a s t s [ , 4 : 6 ] , 2 , f unc t i on ( x )
↪→ glmLRT ( f i tNC , c o n t r a s t =x ) )
names ( l r t L i s t P r o g ) =colnames ( c on t r a s t s ) [ 4 : 6 ]
l r t L i s t T im e $” timeSam”=glmLRT ( f i tNC , c o n t r a s t =
↪→ c on t r a s t s [ , 4 : 5 ] )
D<−Sys . t ime ( )
D−C
save . image ( ”MCapAthero t ime and h e a l t h MHM
↪→ Libs izeNorm Rea lLabe l s . RData ” )
s e s s i o n I n f o ( )
q ( save=”no ” )
load ( ”MCapAthero t ime and h e a l t h MHM Libs izeNorm
↪→ Rea lLabe l s . RData ” )
l i b r a r y ( ” edgeR ” )
names ( l r t L i s t P r o g )
topTags ( l r t L i s t P r o g [ [ 4 ] ] )
### P r i n t Group R e s u l t s ( bo th rounds ) ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 3 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 3 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
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↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) , ] )
op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR
↪→ <0.05) , ] , ” Ana l y s i s MHM g roupD i f f s Rea lLabe l s .
↪→ t x t ” , sep=”\ t ” , row . names=FALSE , c o l . names=TRUE,
↪→ na=” ” , quote=FALSE)
# w r i t e . t a b l e (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR
↪→ <0.10) , ] , ” A n a l y s i s MHM gr o u pD i f f s Rea lLabe l s
↪→ FDR0 . 1 0 . t x t ” , sep=”\ t ” , row . names=FALSE , c o l .
↪→ names=TRUE , na=””, quo t e=FALSE )
### P r i n t Time R e s u l t s ( bo th prog and non−prog
↪→ unpa i r ed ) ###
TEMP<−t opTags ( l r t L i s t T im e [ [ 3 ] ] , n=dim ( l r t L i s t T im e
↪→ [ [ 3 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) , ] )
op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR
↪→ <0.05) , ] , ” Ana l y s i s MHM t im eD i f f s Rea lLabe l s .
↪→ t x t ” , sep=”\ t ” , row . names=FALSE , c o l . names=TRUE,
↪→ na=” ” , quote=FALSE)
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### P r i n t R e s u l t s Round 1 d i f f e r e n c e s ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 1 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 1 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR<0.10) , ] )
op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR
↪→ <0.10) , ] , ” Ana l y s i s MHM Round1Dif f s Rea lLabe l s
↪→ FDR 0 . 1 0 . t x t ” , sep=”\ t ” , row . names=FALSE , c o l .
↪→ names=TRUE, na=” ” , quote=FALSE)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR
↪→ <0.10)& ! i s . na (TEMP$ En t r e z . Gene . Id ) , 4 ] , ”
↪→ I n p u t L i s t R1 FDR0 . 1 0 . t x t ” , sep=”\ t ” , row . names=
↪→ FALSE , c o l . names=TRUE, na=” ” , quote=FALSE)
### P r i n t R e s u l t s Round 2 d i f f e r e n c e s ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 2 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 2 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) , ] )
dim (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR<0.10) , ] )
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op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR
↪→ <0.10) , ] , ” Ana l y s i s MHM Round2Dif f s Rea lLabe l s
↪→ FDR 0 . 1 0 . t x t ” , sep=”\ t ” , row . names=FALSE , c o l .
↪→ names=TRUE, na=” ” , quote=FALSE)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR
↪→ <0.10)& ! i s . na (TEMP$ En t r e z . Gene . Id ) , 4 ] , ”
↪→ I n p u t L i s t R2 FDR0 . 1 0 . t x t ” , sep=”\ t ” , row . names=
↪→ FALSE , c o l . names=TRUE, na=” ” , quote=FALSE)
### P r i n t R e s u l t s Non−Prog r e s s o r s over t ime ###
TEMP<−t opTags ( l r t L i s t T im e [ [ 1 ] ] , n=dim ( l r t L i s t T im e
↪→ [ [ 1 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) , ] ) #
↪→ 11142
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) &
↪→ dup l i c a t ed (TEMP$ r e g i o n ID ) ==FALSE , ] ) # 10520
op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
wr i t e . t a b l e (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR
↪→ <0.05) , ] , ” Ana l y s i s MHM NonP r og r e s s o rD i f f s
↪→ Rea lLabe l s . t x t ” , sep=”\ t ” , row . names=FALSE , c o l .
↪→ names=TRUE, na=” ” , quote=FALSE)
### P r i n t R e s u l t s P r og r e s s o r s over t ime ###
TEMP<−t opTags ( l r t L i s t T im e [ [ 2 ] ] , n=dim ( l r t L i s t T im e
↪→ [ [ 2 ] ] ) [ 1 ] ) $ t ab l e
TEMP<−TEMP[ order ( as . numeric ( rownames (TEMP) ) ) , ]
TEMP<−cbind ( rownames (TEMP) ,TEMP)
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colnames (TEMP) [ 1 ]<−” r e g i o n ID”
TEMP<−merge (MHMcounts [ , c ( 1 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ] ,TEMP
↪→ , by=” r e g i o n ID” , a l l . x=TRUE)
TEMP<−cbind (TEMP[ , − ( 13 : 52 ) ] , round ( t ( t (TEMP[ , 1 3 : 5 2 ] )
↪→ / u n l i s t ( L i b s i z e s ) ) ∗ mean ( u n l i s t ( L i b s i z e s ) ) ) )
TEMP<−as . data . frame (TEMP)
TEMP<−TEMP[ order (TEMP$PValue ) , ]
dim (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR<0.05) , ] )
dim (TEMP[TEMP$FDR<0.10 & ! i s . na (TEMP$FDR<0.10) , ] )
op t i on s ( s c i p e n =28)
op t i on s ( d i g i t s =22)
# w r i t e . t a b l e (TEMP[TEMP$FDR<0.05 & ! i s . na (TEMP$FDR
↪→ <0.05) , ] , ” A n a l y s i s MHM Pr o g r e s s o rD i f f s
↪→ Rea lLabe l s . t x t ” , sep=”\ t ” , row . names=FALSE , c o l .
↪→ names=TRUE , na=””, quo t e=FALSE )
wr i t e . t a b l e (TEMP[ 1 : 2 0 0 , ] , ” Ana l y s i s MHM
↪→ P r o g r e s s o rD i f f s Rea lLabe l s . t x t ” , sep=”\ t ” , row .
↪→ names=FALSE , c o l . names=TRUE, na=” ” , quote=FALSE)
q ( save=”no ” )
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A.2.2 Permutation Progressor Status
##### D i f f e r e n t i a l Me t h y l a t i o n A n a l y s i s A s k l e p i o s
↪→ MethylCap s t u d y p a r t 1 . b : p r o g r e s s o r s t a t u s
↪→ p e rmu t a t i o n approach #####
### Read i n p u t da ta ###
MHMcounts<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ coun t s . t x t ” , quote=” ” , comment . char=” ” , s k i p
↪→ =2 , h e ade r =TRUE, sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ MappingProps . t x t ” , comment . char=” ” , h e ade r =TRUE
↪→ , row . names=1 , sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s [ 1 , ]<−as . numeric ( as . charac t er ( t o t c o u n t s
↪→ [ 1 , ] ) )
### Load a n a l y s i s t o o l ###
l i b r a r y ( edgeR )
### Re t a i n t e c h n i c a l r e p l i c a t e s w i t h h i g h e s t
↪→ cove rage ###
t o t c o u n t s [ c ( ”AS1 . 20 ” , ”AS1 . 21 ” , ”AS2 . 29 ” , ”AS2 . 47 ” ) ]
So r t e d<−MHMcounts [ dup l i c a t ed (MHMcounts$ r e g i o n ID ) ==
↪→ FALSE , c ( 1 3 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ]
rownames ( So r t e d )<−MHMcounts$ r e g i o n ID [ dup l i c a t ed (
↪→ MHMcounts$ r e g i o n ID ) ==FALSE]
L i b s i z e s<−as . data . frame ( t o t c o u n t s [ 1 , colnames ( So r t e d
↪→ ) ] )
dim (MHMcounts )
dim ( So r t e d )
### Normal i z e c oun t s ###
#NormFacts<−ca lcNormFac tor s ( Sor t ed , method=”TMM” ,
↪→ re fColumn = NULL , l o g r a t i o T r im = 0 . 3 , sumTrim
↪→ = 0 . 05 , doWe igh t ing = TRUE , A c u t o f f = −1e
↪→ +10)
NormFacts<−c ( rep ( 1 , 4 0 ) )
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names ( NormFacts )<−colnames ( So r t e d )
### edgeR GLM− l i k e approach ###
So r t e d<−So r t e d [ rowSums ( So r t e d ) >=10 ,]
dim (MHMcounts )
dim ( So r t e d )
P r o gS t a t u s <− f a c t o r ( c ( rep ( ” np ” , 10 ) , rep ( ”p” , 10 ) , rep
↪→ ( ” np ” , 10 ) , rep ( ”p” , 10 ) ) )
P r o gS t a t u s<−r e l e v e l ( P r ogS t a t u s , r e f =” np ” )
Round <− f a c t o r ( c ( rep ( ” t 1 ” , 10 ) , rep ( ” t 1 ” , 10 ) , rep ( ” t 2
↪→ ” , 10 ) , rep ( ” t 2 ” , 10 ) ) )
Round<−r e l e v e l ( Round , r e f =” t 1 ” )
roundProg=as . f a c t o r ( pas t e ( Round , P r ogS t a t u s , sep=” ” )
↪→ )
d e s i g n <− model . matrix ( ˜ −1+roundProg )
# c o n t r a s t e n van i n t e r e s s e
c on t r a s t s=matrix ( 0 , nco l =6 ,nrow=4)
rownames ( c on t r a s t s ) =colnames ( d e s i g n )
colnames ( c on t r a s t s ) =c ( ” d i f f . p . np t 1 ” , ” d i f f . p . np t 2 ”
↪→ , ” a vgD i f f . p . np ” , ” d i f f . t 2 . t 1 np ” , ” d i f f . t 2 . t 1 p
↪→ ” , ” avgD i f f . t 2 . t 1 ” )
c on t r a s t s [ 1 : 2 , 1 ] = c (−1 ,1)
c on t r a s t s [ 3 : 4 , 2 ] = c (−1 ,1)
c on t r a s t s [ 1 : 4 , 3 ] = c (−1 ,1 ,−1 ,1) / 2
c on t r a s t s [ c ( 1 , 3 ) , 4 ]= c (−1 ,1)
c on t r a s t s [ c ( 2 , 4 ) , 5 ]= c (−1 ,1)
c on t r a s t s [ 1 : 4 , 6 ] = c (−1 ,−1 ,1 ,1) / 2
## Par t 2 : Pe rmu ta t i on group membership once
↪→ k e ep i ng h a l f o f them c o n s t a n t f o r maximum
↪→ e n t r o p y ##
s e t . s eed (9481547)
C<−Sys . t ime ( )
permuteSamps=sample ( 1 : 1 0 , 5 )
permuteSamps
P rogS t a t u sPe rm<−P r o gS t a t u s
P rogS t a t u sPe rm [ permuteSamps ]<−”p”
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P rogS t a t u sPe rm [ permuteSamps +10]<−” np ”
P rogS t a t u sPe rm [ 2 1 : 4 0 ]<−ProgS t a t u sPe rm [ 1 : 2 0 ]
P rogS t a t u sPe rm
roundProgPerm=as . f a c t o r ( pas t e ( Round , P rogS ta tu sPe rm ,
↪→ sep=” ” ) )
des ignProgPerm=model . matrix ( ˜ −1+roundProgPerm )
yProgPerm <− DGEList ( c oun t s =Sor t ed , norm . f a c t o r s =
↪→ NormFacts )
yProgPerm <− estimateGLMCommonDisp ( yProgPerm ,
↪→ des ignProgPerm )
yProgPerm <− es t imateGLMTrendedDisp ( yProgPerm ,
↪→ des ignProgPerm )
yProgPerm <− est imateGLMTagwiseDisp ( yProgPerm ,
↪→ des ignProgPerm )
f i t P r o gPe rm <− g lmF i t ( yProgPerm , des ignProgPerm )
l r t L i s t P r o g =apply ( c on t r a s t s [ , 1 : 3 ] , 2 , f unc t i on ( x )
↪→ lmLRT ( f i t P rogPe rm , c o n t r a s t =x ) )
names ( l r t L i s t P r o g ) =colnames ( c on t r a s t s ) [ 1 : 3 ]
l r t L i s t P r o g $” progSam”=glmLRT ( f i t P rogPe rm , c o n t r a s t =
↪→ c on t r a s t s [ , 1 : 2 ] )
D<−Sys . t ime ( )
save . image ( ”MCapAthero t ime and h e a l t h MHM
↪→ Libs izeNorm GroupPermuteHal f . RData ” )
message ( pas t e ( ” Completed group ( h a l f ) p e rmu t a t i o n
↪→ i n ” ,D−C , ” hou r s ” , sep=” ” ) )
s e s s i o n I n f o ( )
q ( save=”no ” )
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A.2.3 Plot Density Permutation Progressors
l i b r a r y ( g gp l o t 2 )
l i b r a r y ( edgeR )
F<−Sys . t ime ( )
load ( ”MCapAthero t ime and h e a l t h MHM Libs izeNorm
↪→ Rea lLabe l s . RData ” )
Rea l np . vs . p . avg .TEMP<−t opTags ( l r t L i s t P r o g [ [ 3 ] ] , n=
↪→ dim ( l r t L i s t P r o g [ [ 3 ] ] ) [ 1 ] ) $ t ab l e
Real np . vs . p . t 1 .TEMP<−t opTags ( l r t L i s t P r o g [ [ 1 ] ] , n=
↪→ dim ( l r t L i s t P r o g [ [ 1 ] ] ) [ 1 ] ) $ t ab l e
Real np . vs . p . t 2 .TEMP<−t opTags ( l r t L i s t P r o g [ [ 2 ] ] , n=
↪→ dim ( l r t L i s t P r o g [ [ 2 ] ] ) [ 1 ] ) $ t ab l e
load ( ”MCapAthero t ime and h e a l t h MHM Libs izeNorm
↪→ GroupPermuteHal f . RData ” )
G<−Sys . t ime ( )
G−F
### Both Rounds ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 3 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 3 ] ] ) [ 1 ] ) $ t ab l e
dG<−ggp l o t (TEMP, ( a e s ( x=PValue ) ) ) + geom den s i t y ( )
↪→ + yl im ( 0 , 3 ) #+ s c a l e x log10 ( )
ggsave ( ” Den s i t y GroupDi f f s h a l f P e rmu t a t i o n . pdf ” ,
↪→ wid th =7 , h e i g h t =7)
dG<−ggp l o t ( Rea l np . vs . p . avg .TEMP, ( a e s ( x=PValue ) ) ) +
↪→ geom den s i t y ( ) + y l im ( 0 , 3 ) #+ s c a l e x log10
↪→ ( )
ggsave ( ” Den s i t y GroupDi f f s Rea lLabe l s . pdf ” , wid th =7 ,
↪→ h e i g h t =7)
rm ( dG)
### Round 1 ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 1 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 1 ] ] ) [ 1 ] ) $ t ab l e
dG<−ggp l o t (TEMP, ( a e s ( x=PValue ) ) ) + geom den s i t y ( ) +
↪→ yl im ( 0 , 3 ) #+ s c a l e x log10 ( )
ggsave ( ” Den s i t y Round1Dif f s Ha l f P e rmu t a t i o n . pdf ” ,
↪→ wid th =7 , h e i g h t =7)
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dG<−ggp l o t ( Rea l np . vs . p . t 1 .TEMP, ( a e s ( x=PValue ) ) ) +
↪→ geom den s i t y ( ) + y l im ( 0 , 3 ) #+ s c a l e x log10
↪→ ( )
ggsave ( ” Den s i t y Round1Dif f s Rea lLabe l s . pdf ” , wid th
↪→ =7 , h e i g h t =7)
rm ( dG)
### Round 2 ###
TEMP<−t opTags ( l r t L i s t P r o g [ [ 2 ] ] , n=dim ( l r t L i s t P r o g
↪→ [ [ 2 ] ] ) [ 1 ] ) $ t ab l e
dG<−ggp l o t (TEMP, ( a e s ( x=PValue ) ) ) + geom den s i t y ( ) +
↪→ yl im ( 0 , 3 ) #+ s c a l e x log10 ( )
ggsave ( ” Den s i t y Round2Dif f s Ha l f P e rmu t a t i o n . pdf ” ,
↪→ wid th =7 , h e i g h t =7)
dG<−ggp l o t ( Rea l np . vs . p . t 1 .TEMP, ( a e s ( x=PValue ) ) ) +
↪→ geom den s i t y ( ) + y l im ( 0 , 3 ) #+ s c a l e x log10
↪→ ( )
ggsave ( ” Den s i t y Round2Dif f s Rea lLabe l s . pdf ” , wid th
↪→ =7 , h e i g h t =7)
rm ( dG)
q ( save=”no ” )
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A.2.4 Paired Time Analysis
##### D i f f e r e n t i a l Me t h y l a t i o n A n a l y s i s A s k l e p i o s
↪→ MCap s t u d y pa r t 3 . a : t ime pa i r e d ( b a s i c model
↪→ ) #####
### Read i n p u t da ta ###
# Z i l l e r C o u n t s<−read . t a b l e ( ” . / Z i l l e r DMR/ MCapAthero
↪→ summarizedReads DMRs noDups PEco r r e c t i o n . t x t
↪→ ” , comment . char =”” , header=TRUE , sep=”\ t ” ,
↪→ s t r i n g s A s F a c t o r s=FALSE )
MHMcounts<−read . t a b l e ( ” . . /MCap Athero MHM coun t s .
↪→ t x t ” , quote=” ” , comment . char=” ” , s k i p =2 ,
↪→ heade r =TRUE, sep=”\ t ” , s t r i n g sA s F a c t o r s =FALSE
↪→ )
t o t c o u n t s<−read . t a b l e ( ” . . /MCap Athero MHM
↪→ MappingProps . t x t ” , comment . char=” ” , h e ade r =TRUE
↪→ , row . names=1 , sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
nonDupCounts<−read . t a b l e ( ” . . / . . /MCap Ask l e p i o s
↪→ nonDup MappingProps . t x t ” , comment . char=” ” ,
↪→ heade r =TRUE, sep=”\ t ” , s t r i n g sA s F a c t o r s =FALSE ,
↪→ c o l C l a s s e s =c ( ” c h a r a c t e r ” , ” i n t e g e r ” ) )
t o t c o u n t s [ 1 , ]<−as . numeric ( as . charac t er ( t o t c o u n t s
↪→ [ 1 , ] ) )
### Load a n a l y s i s t o o l ###
l i b r a r y ( edgeR )
### Re t a i n t e c h n i c a l r e p l i c a t e s w i t h h i g h e s t
↪→ cove rage ###
t o t c o u n t s [ c ( ”AS1 . 20 ” , ”AS1 . 21 ” , ”AS2 . 29 ” , ”AS2 . 47 ” ) ]
So r t e d<−MHMcounts [ dup l i c a t ed (MHMcounts$ r e g i o n ID ) ==
↪→ FALSE , c ( 1 3 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ]
rownames ( So r t e d )<−MHMcounts$ r e g i o n ID [ dup l i c a t ed (
↪→ MHMcounts$ r e g i o n ID ) ==FALSE]
L i b s i z e s<−as . data . frame ( t o t c o u n t s [ 1 , colnames ( So r t e d
↪→ ) ] )
dim (MHMcounts )
dim ( So r t e d )
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### Normal i z e c oun t s ###
#NormFacts<−ca lcNormFac tor s ( Sor t ed , method=”TMM” ,
↪→ re fColumn = NULL , l o g r a t i o T r im = 0 . 3 , sumTrim
↪→ = 0 . 05 , doWe igh t ing = TRUE , A c u t o f f = −1e
↪→ +10)
NormFacts<−c ( rep ( 1 , 4 0 ) )
names ( NormFacts )<−colnames ( So r t e d )
### edgeR GLM− l i k e approach ###
So r t e d<−So r t e d [ rowSums ( So r t e d ) >=10 ,]
dim (MHMcounts )
dim ( So r t e d )
F a c t I n d i v i d u a l <− f a c t o r ( c ( 1 : 2 0 , 1 : 2 0 ) )
FactRound<− f a c t o r ( c ( rep ( ” F i r s t ” , 20 ) , rep ( ” Second ”
↪→ , 2 0 ) ) )
FactRound<−r e l e v e l ( FactRound , r e f =” F i r s t ” )
d e s i g n <− model . matrix ( ˜ −1 + F a c t I n d i v i d u a l +
↪→ FactRound )
A<−Sys . t ime ( )
y <− DGEList ( c oun t s =Sor t ed , l i b . s i z e = u n l i s t (
↪→ L i b s i z e s ) , norm . f a c t o r s =NormFacts )
y <− estimateGLMCommonDisp ( y , d e s i g n )
y <− es t imateGLMTrendedDisp ( y , d e s i g n )
y <− est imateGLMTagwiseDisp ( y , d e s i g n )
f i t <− g lmF i t ( y , d e s i gn )
l r t <− glmLRT ( f i t )
B<−Sys . t ime ( )
B−A
save . image ( ”MCapAthero T imePa i r ed MHM Libs izeNorm .
↪→ RData ” )
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A.2.5 Paired Time Permutation Approach
### Read i n p u t da ta ###
MHMcounts<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ coun t s . t x t ” , quote=” ” , comment . char=” ” , s k i p
↪→ =2 , h e ade r =TRUE, sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s<−read . t a b l e ( ” . . /MHM/MCap Athero MHM
↪→ MappingProps . t x t ” , comment . char=” ” , h e ade r =TRUE
↪→ , row . names=1 , sep=”\ t ” , s t r i n g sA s F a c t o r s =
↪→ FALSE)
t o t c o u n t s [ 1 , ]<−as . numeric ( as . charac t er ( t o t c o u n t s
↪→ [ 1 , ] ) )
### Load a n a l y s i s t o o l ###
l i b r a r y ( edgeR )
### Re t a i n t e c h n i c a l r e p l i c a t e s w i t h h i g h e s t
↪→ cove rage ###
t o t c o u n t s [ c ( ”AS1 . 20 ” , ”AS1 . 21 ” , ”AS2 . 29 ” , ”AS2 . 47 ” ) ]
So r t e d<−MHMcounts [ dup l i c a t ed (MHMcounts$ r e g i o n ID ) ==
↪→ FALSE , c ( 1 3 : 3 2 , 3 4 : 4 0 , 5 4 , 4 2 : 5 3 ) ]
rownames ( So r t e d )<−MHMcounts$ r e g i o n ID [ dup l i c a t ed (
↪→ MHMcounts$ r e g i o n ID ) ==FALSE]
L i b s i z e s<−as . data . frame ( t o t c o u n t s [ 1 , colnames ( So r t e d
↪→ ) ] )
dim (MHMcounts )
dim ( So r t e d )
### Normal i z e c oun t s : TMM no t per fo rmed based on
↪→ per fo rmance i n t e c h n i c a l r e p l i c a t e s ###
#NormFacts<−ca lcNormFac tor s ( Sor t ed , method=”TMM” ,
↪→ re fColumn = NULL , l o g r a t i o T r im = 0 . 3 , sumTrim
↪→ = 0 . 05 , doWe igh t ing = TRUE , A c u t o f f = −1e
↪→ +10)
NormFacts<−c ( rep ( 1 , 4 0 ) )
names ( NormFacts )<−colnames ( So r t e d )
### edgeR GLM− l i k e approach ###
So r t e d<−So r t e d [ rowSums ( So r t e d ) >=10 ,]
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dim (MHMcounts )
dim ( So r t e d )
F a c t I n d i v i d u a l <− f a c t o r ( c ( 1 : 2 0 , 1 : 2 0 ) )
P r o gS t a t u s <− f a c t o r ( c ( rep ( ” np ” , 10 ) , rep ( ”p” , 10 ) , rep
↪→ ( ” np ” , 10 ) , rep ( ”p” , 10 ) ) )
P r o gS t a t u s<−r e l e v e l ( P r ogS t a t u s , r e f =” np ” )
Round <− f a c t o r ( c ( rep ( ” t 1 ” , 10 ) , rep ( ” t 1 ” , 10 ) , rep ( ” t 2
↪→ ” , 10 ) , rep ( ” t 2 ” , 10 ) ) )
Round<−r e l e v e l ( Round , r e f =” t 1 ” )
s e t . s e ed (1364 )
RoundPerm<−Round
Shuf f l eNonProg<−sample ( 1 : 1 0 , 5 )
Shuf f l eNonProg
Shu f f l e P r o g<−sample ( 1 1 : 2 0 , 5 )
S hu f f l e P r o g
RoundPerm [ c ( Shuf f l eNonProg , S h u f f l e P r o g ) ]<−” t 2 ”
RoundPerm [ c ( Shuf f l eNonProg , S h u f f l e P r o g ) +20]<−” t 1 ”
RoundPerm
Fac tRPShu f f l e d<− as . charac t er ( pas t e ( P r ogS t a t u s ,
↪→ RoundPerm , sep=” ” ) )
Fac tRPShu f f l e d [ Fac tRPShu f f l e d ==”np t 1 ” ]<−” t 1 ”
Fac tRPShu f f l e d [ Fac tRPShu f f l e d ==”p t 1 ” ]<−” t 1 ”
Fac tRPShu f f l e d<−f a c t o r ( Fac tRPShuf f l ed , l e v e l s =c ( ” t 1
↪→ ” , ” np t 2 ” , ”p t 2 ” ) )
Fac tRPShu f f l e d
d e s i g n <− model . matrix ( ˜ −1 + Fac tRPShu f f l e d +
↪→ F a c t I n d i v i d u a l )
A<−Sys . t ime ( )
y <− DGEList ( c oun t s =Sor t ed , l i b . s i z e = u n l i s t (
↪→ L i b s i z e s ) , norm . f a c t o r s =NormFacts )
y <− estimateGLMCommonDisp ( y , d e s i g n )
y <− es t imateGLMTrendedDisp ( y , d e s i g n )
y <− est imateGLMTagwiseDisp ( y , d e s i g n )
f i t <− g lmF i t ( y , d e s i gn )
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B<−Sys . t ime ( )
B−A
save . image ( ”MCapAthero T imePa i r ed MHM Libs izeNorm
↪→ Wi thP rogS t a t u s Pe rmu teHa l f . RData ” )
s e s s i o n I n f o ( )
q ( save=”no ” )
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A.2.6 BS-seq Analyses
### Ana l y s e v a l i d a t i o n e xp e r imen t ###
### Load l i b r a r i e s ###
l i b r a r y ( GenomicRanges )
l i b r a r y ( me t hy lK i t )
### Read da ta ###
Samples<−read . t a b l e ( ” SampleTable . t x t ” , sep=”\ t ” ,
↪→ comment . char=” ” , h e ade r =FALSE , c o l C l a s s e s =c ( rep
↪→ ( ” c h a r a c t e r ” , 3 ) ) )
Index<−read . t a b l e ( ” SampleDec r ip t i onKey . t x t ” , sep=”\ t
↪→ ” , comment . char=” ” , h e ade r =TRUE)
DATA<−read . t a b l e ( ”BS t a b l e H2G2 . t x t ” , sep=”\ t ” ,
↪→ comment . char=” ” , h e ade r =TRUE)
colnames ( Samples )<−c ( ” Sample ” , ”Read1 ” , ”Read2 ” )
Samples $SampleOrder<−subs t r ( Samples $Sample , 5 , 9 )
Samples<−Samples [−dim ( Samples ) [ 1 ] , ]
Samples<−Samples [ order ( as . numeric ( Samples $
↪→ SampleOrder ) ) , ]
colnames (DATA) [ 7 : 9 4 ]<−pas t e ( ”ABS ” , Samples $
↪→ SampleOrder , ” met ” , sep=” ” )
colnames (DATA) [ 9 5 : 1 8 2 ]<−pas t e ( ”ABS ” , Samples $
↪→ SampleOrder , ” cov ” , sep=” ” )
dim (DATA)
### d e f i n e r e g i o n s t a r g e t t e d by pr imer p a i r s ###
r e g i o n s <− GRanges ( seqnames=c ( ”3” , ”4” , ”6” , ”6” , ” 14 ” ,
↪→ ” 15 ” , ” 22 ” , ”2” , ”2” , ”3” , ” 11 ” , ”4” , ”4” , ”4” , ”6” , ”6
↪→ ” , ”8” , ” 12 ” , ” 15 ” , ”7” , ”8” , ”8” , ” 10 ” ) , r a n g e s =
↪→ IRanges ( s t a r t = c
↪→ (186262961 ,152443952 ,83420357 ,158699387 ,50687972 ,22
↪→ , end = c
↪→ (186263187 ,152444259 ,83420808 ,158699681 ,50688193 ,22
↪→ ) )
DATAreg<−GRanges ( seqnames=DATA$chromosome , r a ng e s =
↪→ IRanges ( s t a r t = DATA$ s t a r t , end=DATA$end ) )
DATA<−DATA[ ove r l apsAny (DATAreg , r e g i o n s ) , ]
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dim (DATA)
### Conver t t o Me t h y lK i t I n p u t ###
f o r ( i i n 1 : l eng th ( Samples $SampleOrder ) ) {
sample<−pas t e ( ”ABS ” , Samples $SampleOrder [ i ] , sep=” ”
↪→ )
tempo<−cbind (
ch rBase=pas t e ( ” ch r ” , as . charac t er (DATA$chromosome
↪→ ) , ” . ” ,DATA$ s t a r t , s ep=” ” ) ,
ch r =as . charac t er (DATA$chromosome ) ,
ba se=DATA$ s t a r t ,
s t r a n d =rep ( ”F” ,dim (DATA) [ 1 ] ) ,
c ove r age=DATA[ , pas t e ( sample , ” cov ” , sep=” ” ) ] ,
f r eqC=DATA[ , pas t e ( sample , ” met ” , sep=” ” ) ] ,
f r eqT=100−DATA[ , pas t e ( sample , ” met ” , sep=” ” ) ]
)
tempo [ i s . na ( tempo [ , 5 ] ) , 5 ]<−”0”
tempo [ as . numeric ( as . charac t er ( tempo [ , 5 ] ) ) <100 ,5:7]
↪→ <−rep (NA, 3 )
tempo<−tempo [ ! i s . na ( tempo [ , 5 ] ) , ]
wr i t e . t a b l e ( tempo , pas t e ( ” . / Methy lKi t noLowCov / ” ,
↪→ sample , ” me t h y lK i t I n p u t . t x t ” , sep=” ” ) , sep=”\
↪→ t ” , quote=FALSE , c o l . names=TRUE, row . names=
↪→ FALSE)
}
### Read Me t h y lK i t I n p u t ###
f i l e . l i s t =as . l i s t ( l i s t . f i l e s ( ” . / Methy lKi t noLowCov”
↪→ , f u l l . names=TRUE) )
f i l e . l i s t<− f i l e . l i s t [ order ( as . numeric ( sub ( ” . /
↪→ Methy lKi t noLowCov /ABS ([0−9IVMDKO]+ )
↪→ me t h y lK i t I n p u t . t x t ” , ” \\1 ” , f i l e . l i s t ) ) ) ]
f i l e . l i s t 2 = f i l e . l i s t [ 8 7 : 8 8 ]
##### Time d i f f e r e n c e , un−pa i r e d #####
myobj=read ( f i l e . l i s t [ 1 : 8 6 ] , sample . i d =as . l i s t (
↪→ pas t e ( ”ABS ” , Samples $SampleOrder [ 1 : 8 6 ] , sep=” ”
↪→ ) ) , a s sembly=” hg19 ” , t r e a tm e n t =c ( rep ( 0 , 4 6 ) , rep
↪→ ( 1 , 4 0 ) ) )
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#myobj=read ( f i l e . l i s t 2 , sample . i d= l i s t (”DKO” ,”IVM
↪→ ”) , a s semb ly=”hg19 ” , t r e a tm e n t=c ( 0 , 1 ) )
g e tM e t h y l a t i o n S t a t s ( myobj [ [ 1 ] ] , p l o t=FALSE , bo th .
↪→ s t r a n d s =FALSE , na . rm=TRUE)
g e tM e t h y l a t i o n S t a t s ( myobj [ [ 2 ] ] , p l o t=FALSE , bo th .
↪→ s t r a n d s =FALSE , na . rm=TRUE)
g e tM e t h y l a t i o n S t a t s ( myobj [ [ 1 ] ] , p l o t=TRUE, bo th .
↪→ s t r a n d s =FALSE)
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
↪→ group =10L) # min . per . group=2L
t a i l ( meth )
# g e t C o r r e l a t i o n ( meth , p l o t=TRUE)
myDiff t ime= c a l c u l a t eD i f fMe t h ( meth , weighted .mean=
↪→ FALSE , s l im=FALSE)
myDi f f s i gn t ime=ge t . me t hy lD i f f ( myDiff time ,
↪→ d i f f e r e n c e =1 , qva l u e =0 . 01 )
# gene . ob j=read . t r a n s c r i p t . f e a t u r e s (” r e f s e q . hg19 . bed
↪→ . t x t ”)
# gene . ob j=read . t r a n s c r i p t . f e a t u r e s (” ensembl . hg19 .
↪→ bed . t x t ”)
# anno t a t e . W i t hGen i cPar t s ( myDi f f s i gn , gene . ob j )
##### NonProg d i f f e r e n c e , un−pa i r e d #####
myobj=read ( f i l e . l i s t [ c ( 1 : 2 3 , 4 7 : 6 7 ) ] , sample . i d =as .
↪→ l i s t ( pas t e ( ”ABS ” , Samples $SampleOrder [ c
↪→ ( 1 : 2 3 , 4 7 : 6 7 ) ] , sep=” ” ) ) , a s sembly=” hg19 ” ,
↪→ t r e a tm e n t =c ( rep ( 0 , 2 3 ) , rep ( 1 , 2 1 ) ) )
#myobj=read ( f i l e . l i s t 2 , sample . i d= l i s t (”DKO” ,”IVM
↪→ ”) , a s semb ly=”hg19 ” , t r e a tm e n t=c ( 0 , 1 ) )
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
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↪→ group =10L) # min . per . group=2L
# t a i l ( meth )
# g e t C o r r e l a t i o n ( meth , p l o t=TRUE)
myDiff t imeNonProg= c a l c u l a t eD i f fMe t h ( meth , weighted .
↪→ mean=FALSE , s l im=FALSE)
myDi f f s i gn t imeNonProg=ge t . me t hy lD i f f ( myDiff
↪→ t imeNonProg , d i f f e r e n c e =1 , qva l u e =0 . 01 )
##### Prog d i f f e r e n c e , un−pa i r e d #####
myobj=read ( f i l e . l i s t [ c ( 2 4 : 4 6 , 6 8 : 8 6 ) ] , sample . i d =as
↪→ . l i s t ( pas t e ( ”ABS ” , Samples $SampleOrder [ c
↪→ ( 2 4 : 4 6 , 6 8 : 8 6 ) ] , sep=” ” ) ) , a ssembly=” hg19 ” ,
↪→ t r e a tm e n t =c ( rep ( 0 , 2 3 ) , rep ( 1 , 1 9 ) ) )
#myobj=read ( f i l e . l i s t 2 , sample . i d= l i s t (”DKO” ,”IVM
↪→ ”) , a s semb ly=”hg19 ” , t r e a tm e n t=c ( 0 , 1 ) )
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
↪→ group =10L) # min . per . group=2L
# t a i l ( meth )
# g e t C o r r e l a t i o n ( meth , p l o t=TRUE)
myDiff t imeProg= c a l c u l a t eD i f fMe t h ( meth , weighted .
↪→ mean=FALSE , s l im=FALSE)
myDi f f s i gn t imeProg=ge t . me t h y lD i f f ( myDiff t imeProg ,
↪→ d i f f e r e n c e =1 , qva l u e =0 . 01 )
##### Group d i f f e r e n c e Round 1 #####
myobj=read ( f i l e . l i s t [ 1 : 4 6 ] , sample . i d =as . l i s t (
↪→ pas t e ( ”ABS ” , Samples $SampleOrder [ 1 : 4 6 ] , sep=” ”
↪→ ) ) , a s sembly=” hg19 ” , t r e a tm e n t =c ( rep ( 0 , 2 3 ) , rep
↪→ ( 1 , 2 3 ) ) )
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
↪→ group =10L) # min . per . group=2L
t a i l ( meth )
myDiff R1= c a l c u l a t eD i f fMe t h ( meth , weighted .mean=
R-CODE A-33
↪→ FALSE , s l im=FALSE)
myDi f f s i gn R1=ge t . me t h y lD i f f ( myDiff R1 , d i f f e r e n c e
↪→ =1 , qva l u e =0 . 01 )
##### Group d i f f e r e n c e Round 2 #####
myobj=read ( f i l e . l i s t [ 4 7 : 8 6 ] , sample . i d =as . l i s t (
↪→ pas t e ( ”ABS ” , Samples $SampleOrder [ 4 7 : 8 6 ] , sep=”
↪→ ” ) ) , a s sembly=” hg19 ” , t r e a tm e n t =c ( rep ( 0 , 2 1 ) , rep
↪→ ( 1 , 1 9 ) ) )
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
↪→ group =10L) # min . per . group=2L
t a i l ( meth )
myDiff R2= c a l c u l a t eD i f fMe t h ( meth , weighted .mean=
↪→ FALSE , s l im=FALSE)
myDi f f s i gn R2=ge t . me t h y lD i f f ( myDiff R2 , d i f f e r e n c e
↪→ =1 , qva l u e =0 . 01 )
##### Group d i f f e r e n c e #####
myobj=read ( f i l e . l i s t [ 1 : 8 6 ] , sample . i d =as . l i s t (
↪→ pas t e ( ”ABS ” , Samples $SampleOrder [ 1 : 8 6 ] , sep=” ”
↪→ ) ) , a s sembly=” hg19 ” , t r e a tm e n t =c ( rep ( 0 , 2 3 ) , rep
↪→ ( 1 , 2 3 ) , rep ( 0 , 2 1 ) , rep ( 1 , 1 9 ) ) )
f i l t e r e d . myobj= f i l t e r B yCov e r a g e ( myobj , l o . count =100 ,
↪→ l o . p e r c =NULL, h i . count=NULL, h i . p e r c =NULL)
meth= u n i t e ( f i l t e r e d . myobj , d e s t r a n d =FALSE , min . p e r .
↪→ group =10L) # min . per . group=2L
t a i l ( meth )
myDiff Groups= c a l c u l a t eD i f fMe t h ( meth , weighted .mean=
↪→ FALSE , s l im=FALSE)
myDi f f s i gn Groups=ge t . me t h y lD i f f ( myDiff Groups ,
↪→ d i f f e r e n c e =1 , qva l u e =0 . 01 )
##### Sub s e t t a r g e t t e d r e g i o n s ( o p t i o n a l ) #####
TimeTarge t s<−as ( myDi f f s i gn time , ”GRanges ” )
R1Targe t s<−as ( myDi f f s i gn R1 , ”GRanges ” )
R2Targe t s<−as ( myDi f f s i gn R2 , ”GRanges ” )
A-34 APPENDIX A
GroupTa rge t s<−as ( myDi f f s i gn Groups , ”GRanges ” )
T imeTarge t s<−s ub s e tByOve r l a p s ( TimeTarge t s , r e g i o n s
↪→ [ 1 7 : 2 3 ] ) # r e g i o n s [17 : 23 ]
R1Targe t s<−s ub s e tByOve r l a p s ( R1Targe ts , r e g i o n s
↪→ [ 1 : 4 ] ) # r e g i o n s [ 1 : 4 ]
R2Targe t s<−s ub s e tByOve r l a p s ( R2Targe ts , r e g i o n s
↪→ [ 1 2 : 1 6 ] ) # r e g i o n s [12 : 16 ]
GroupTa rge t s<−s ub s e tByOve r l a p s ( GroupTarge t s ,
↪→ r e g i o n s [ 5 : 1 1 ] ) # r e g i o n s [ 5 : 11 ]
### Reg iona l Leve l , r e p e a t a n a l y s e s bu t f o r g l o b a l
↪→ me t h y l a t i o n o f each ampl i con ######
### Read Me t h y lK i t I n p u t ###
f i l e . l i s t =as . l i s t ( l i s t . f i l e s ( ” . / Methy lKi t noLowCov”
↪→ , f u l l . names=TRUE) )
f i l e . l i s t<− f i l e . l i s t [ order ( as . numeric ( sub ( ” . /
↪→ Methy lKi t noLowCov /ABS ([0−9IVMDKO]+ )
↪→ me t h y lK i t I n p u t . t x t ” , ” \\1 ” , f i l e . l i s t ) ) ) ]
f i l e . l i s t 2 = f i l e . l i s t [ 8 7 : 8 8 ]
##### Time d i f f e r e n c e , un−pa i r e d #####
myobj=read ( f i l e . l i s t [ 1 : 8 6 ] , sample . i d =as . l i s t (
↪→ pas t e ( ”ABS ” , Samples $SampleOrder [ 1 : 8 6 ] , sep=” ”
↪→ ) ) , a s sembly=” hg19 ” , t r e a tm e n t =c ( rep ( 0 , 4 6 ) , rep
↪→ ( 1 , 4 0 ) ) )
t a r g e t R e g i o n s = r eg i onCoun t s ( myobj , r e g i o n s )
. . .
####### P l o t f i g u r e s w i t h g g p l o t #######
### group d i f f e r e n c e s ###
l i b r a r y ( g gp l o t 2 )
d a t a 1<−data . frame ( Meth=c ( u n l i s t (DATA[DATA$CpG==”
↪→ 15:22347472 ” , c ( 8 : 3 0 , 5 4 : 7 4 ) ] ) , u n l i s t (DATA[DATA
↪→ $CpG==” 15:22347472 ” , c ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) , u n l i s t (
↪→ DATA[DATA$CpG==” 11:43095973 ” , c ( 8 : 3 0 , 5 4 : 7 4 ) ] ) ,
↪→ u n l i s t (DATA[DATA$CpG==” 11:43095973 ” , c
↪→ ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 3:162767494 ” , c ( 8 : 3 0 , 5 4 : 7 4 ) ] ) , u n l i s t (DATA[DATA
↪→ $CpG==” 3:162767494 ” , c ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) ) ,
R-CODE A-35
CpG=c ( rep ( ” 15:22347472 ” , l eng th ( u n l i s t (DATA[DATA$
↪→ CpG==” 15:22347472 ” , c ( 8 : 3 0 , 5 4 : 7 4 ) ] ) ) + l eng th (
↪→ u n l i s t (DATA[DATA$CpG==” 15:22347472 ” , c
↪→ ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) ) ) , rep ( ” 11:43095973 ” , l eng th (
↪→ u n l i s t (DATA[DATA$CpG==” 11:43095973 ” , c
↪→ ( 8 : 3 0 , 5 4 : 7 4 ) ] ) ) + l eng th ( u n l i s t (DATA[DATA$CpG
↪→ ==” 11:43095973 ” , c ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) ) ) , rep ( ”
↪→ 3:162767494 ” , l eng th ( u n l i s t (DATA[DATA$CpG==”
↪→ 3:162767494 ” , c ( 8 : 3 0 , 5 4 : 7 4 ) ] ) ) + l eng th ( u n l i s t
↪→ (DATA[DATA$CpG==” 3:162767494 ” , c
↪→ ( 3 1 : 5 3 , 7 5 : 9 3 ) ] ) ) ) ) ,
Group=rep ( c ( rep ( ”Non−P r o g r e s s o r ” ,23+21) , rep ( ”
↪→ P r o g r e s s o r ” ,23+19) ) , 3 )
)
d a t a 1 $CpG<− f a c t o r ( d a t a 1 $CpG , l e v e l s = c ( ”
↪→ 3:162767494 ” , ” 11:43095973 ” , ” 15:22347472 ” ) )
P1 <− ggp l o t ( da ta1 , a e s ( x= f a c t o r (CpG) , y=Meth , , f i l l
↪→ = Group ) ) + geom boxp lo t ( o u t l i e r . shape=NA) +
geom po i n t ( a l ph a =0 . 5 , p o s i t i o n = p o s i t i o n
↪→ j i t t e r d o d g e ( j i t t e r . w id th =0 . 2 ) ) + l a b s ( x =
↪→ ”CpG l o c a t i o n ” , y = ” Me t hy l a t i o n Degree (%) ”
↪→ )
P1
ggsave ( ” F i g u r e 1 Me t h y l a t i o nD i f f e r e n c e s Al lSamples .
↪→ pdf ” , P1 , wid th =7 , h e i g h t =5)
### t ime d i f f e r e n c e s ###
da t a 2<−data . frame ( Meth=c ( u n l i s t (DATA[DATA$CpG==”
↪→ 7:33828043 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 7:33828043 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG==
↪→ ” 8:2511694 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 8:2511694 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 8:2511817 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 8:2511817 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 8:26669622 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$CpG==”
↪→ 8:26669622 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG==
↪→ ” 8:26669687 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$CpG==
↪→ ” 8:26669687 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[DATA$CpG
↪→ ==” 10:98145961 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA[DATA$
↪→ CpG==” 10:98145961 ” , c ( 5 4 : 9 3 ) ] ) , u n l i s t (DATA[
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↪→ DATA$CpG==” 12:44148898 ” , c ( 8 : 5 3 ) ] ) , u n l i s t (DATA
↪→ [DATA$CpG==” 12:44148898 ” , c ( 5 4 : 9 3 ) ] ) ) ,
CpG=c ( rep ( ” 7 :33828043 ” ,46+40) , rep ( ” 8 :2511694 ”
↪→ , 46+40) , rep ( ” 8 :2511817 ” ,46+40) , rep ( ”
↪→ 8:26669622 ” ,46+40) , rep ( ” 8 :26669687 ” ,46+40) ,
↪→ rep ( ” 10:98145961 ” ,46+40) , rep ( ” 12:44148898 ”
↪→ , 46+40) ) ,
Round=rep ( c ( rep ( ” F i r s t ” , 46 ) , rep ( ” Second ” , 40 ) ) , 7 )
)
d a t a 2 $CpG<− f a c t o r ( d a t a 2 $CpG , l e v e l s = c ( ”
↪→ 7:33828043 ” , ” 8 :2511694 ” , ” 8 :2511817 ” , ”
↪→ 8:26669622 ” , ” 8 :26669687 ” , ” 10:98145961 ” , ”
↪→ 12:44148898 ” ) )
P1 <− ggp l o t ( da ta2 , a e s ( x= f a c t o r (CpG) , y=Meth , , f i l l
↪→ = Round ) ) + geom boxp lo t ( o u t l i e r . shape=NA) +
↪→ yl im (35 , 100 ) + theme ( ax i s . t e x t . x = e l emen t
↪→ t e x t ( a ng l e = 90 , h j u s t = 1 ) ) +
geom po i n t ( a l ph a =0 . 5 , p o s i t i o n = p o s i t i o n
↪→ j i t t e r d o d g e ( j i t t e r . w id th =0 . 2 ) ) + l a b s ( x =
↪→ ”CpG l o c a t i o n ” , y = ” Me t hy l a t i o n Degree (%) ”
↪→ )
P1
ggsave ( ” F i g u r e XXX Me t h y l a t i o nD i f f e r e n c e s Time . pdf ”
↪→ , P1 , wid th =8 , h e i g h t =8)
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Figure B.1: A CpG fragment plot showing that mapped fragments in each sample are
enriched in CpG content. The average enrichment curve (blue) shows a peak around 4
CpGs/fragment.
SUPPLEMENTARY FIGURES B-3
Figure B.2: Scatterplot of peak coverage in all methylation cores of the technical replicates.
The top row shows the raw count, the bottom row represents normalised counts. The left
panels depict the ﬁrst round replicates and the right panels contain the second round
replicates.
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Figure B.3: Unsupervised clustering based on the peak coverage of the 2000 most variable
methylation cores shows correct pairing of ﬁrst and second round samples with the
exception of AS1.07-AS2.28.
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Figure B.4: Density plots of the P-values for progressor versus non-progressor differential
methylation obtained from the real data (ﬁrst column) and the permuted data (second
column) without a subject speciﬁc term in the model. The ﬁrst row shows round 1 and round
2 samples combined, the second row only round 1 samples and the last row only round 2
samples.
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Figure B.5: Density plots of the P-values for inter-round differential methylation obtained
from the real data (ﬁrst column) and the permuted data (second column) with the inclusion
of a subject speciﬁc term progressor status in the model. The ﬁrst row shows round 1 vs.
round 2 combined, the second row only the non-progressors and the last row only the
progressors.
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Table C.3: Summary statistics for MethylCap-seq results.
Patient Number of sequenced reads Mapped Reads Mapping Percentage
AS1.01 26420862 16765738 63.5%
AS1.02 29335634 19443989 66.3%
AS1.03 56821828 28689322 50.5%
AS1.43 48131200 33229553 69.0%
AS1.05 38748299 24700461 63.8%
AS1.06 53831659 34332784 63.8%
AS1.07 49035192 33065763 67.4%
AS1.08 34578036 22878488 66.2%
AS1.09 27525918 18083808 65.7%
AS1.10 75169812 47901720 63.7%
AS1.45 30306313 18757175 61.9%
AS1.12 26632727 18970945 71.2%
AS1.13 31633415 21128998 66.8%
AS1.14 35419833 23821420 67.3%
AS1.15 24229197 15237524 62.9%
AS1.16 13428110 9210488 68.6%
AS1.17 33960434 21851992 64.4%
AS1.18 56375966 35777729 63.5%
AS1.19 53920080 31588567 58.6%
AS1.20 76920869 49577548 64.5%
AS1.21 44337119 29403469 66.3%
AS2.22 18994347 11585635 61.0%
AS2.23 45335229 28945794 63.9%
AS2.24 55119830 33519219 60.8%
AS2.44 57331447 35603739 62.1%
AS2.26 40902371 24895402 60.9%
AS2.27 41066697 25790668 62.8%
AS2.28 37931760 23209210 61.2%
AS2.29 39640041 25935663 65.4%
AS2.30 28162071 17394222 61.8%
AS2.31 26417516 16791956 63.6%
AS2.46 35662502 21197878 59.4%
AS2.33 34413172 22328669 64.9%
AS2.34 60115268 36346797 60.5%
AS2.35 32660158 20878919 63.9%
AS2.36 35140777 20893016 59.5%
AS2.37 40282893 22101179 54.9%
AS2.38 36065404 22166726 61.5%
AS2.39 24692348 15524679 62.9%
AS2.40 59533619 38031074 63.9%
AS2.41 65110198 43317960 66.5%
AS2.47 75340968 48231507 64.0%
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Table C.6: Validation results for differential methylation between the second and ﬁrst study
rounds at the individual CpG level.
PrimerPair ID CpG NonProg NonProg Prog Prog Average Average
FDR Meth. Diff. FDR Meth. Diff. FDR Meth. Diff.
INTERGEN5 1 7:33827925 0,31 -0,76% 0,00 1,19% 0,00 0,18%
INTERGEN5 1 7:33827953 0,48 -0,57% 0,69 -0,27% 0,91 -0,41%
INTERGEN5 1 7:33827968 0,04 -0,07% 0,00 0,13% 0,00 0,03%
INTERGEN5 1 7:33827974 0,00 -0,50% 0,34 -0,07% 0,20 -0,29%
INTERGEN5 1 7:33828043 0,16 -0,22% 0,07 -0,16% 0,01 -0,20%
INTERGEN5 1 7:33828111 0,21 -0,48% 0,00 0,27% 0,00 -0,11%
INTERGEN5 1 7:33828145 0,81 -0,24% 0,62 0,02% 0,52 -0,13%
INTERGEN5 1 7:33828169 0,83 -0,11% 0,02 -0,13% 0,08 -0,12%
INTERGEN6 2 8:2511598 NA NA NA NA NA NA
INTERGEN6 2 8:2511626 0,40 0,64% 0,00 0,63% 0,06 0,66%
INTERGEN6 2 8:2511640 0,00 0,96% 0,20 0,20% 0,00 0,61%
INTERGEN6 2 8:2511647 NA NA NA NA NA NA
INTERGEN6 2 8:2511665 0,12 -0,29% 0,12 -0,70% 0,01 -0,50%
INTERGEN6 2 8:2511694 0,00 1,54% 0,97 0,03% 0,00 0,79%
INTERGEN6 2 8:2511697 0,12 0,56% 0,38 -0,73% 0,03 0,01%
INTERGEN6 1 8:2511777 NA NA NA NA NA NA
INTERGEN6 1 8:2511817 0,02 -0,51% 0,00 -0,72% 0,00 -0,66%
INTERGEN6 1 8:2511824 0,00 -1,11% 0,14 -0,63% 0,00 -0,86%
INTERGEN6 1 8:2511894 0,79 -0,04% 0,84 -0,26% 0,63 -0,16%
INTERGEN6 1 8:2511933 0,00 -0,84% 0,08 0,18% 0,00 -0,34%
INTERGEN6 1 8:2511938 0,00 -0,80% 0,51 -0,21% 0,00 -0,54%
INTERGEN6 1 8:2511948 0,00 -0,62% 0,00 -0,42% 0,00 -0,45%
ADRA1A 1 8:26669622 0,00 -4,42% 0,45 1,97% 0,01 -1,23%
ADRA1A 1 8:26669687 0,24 0,25% 0,00 1,94% 0,00 1,05%
ADRA1A 1 8:26669722 0,31 -0,16% 0,69 -0,39% 0,27 -0,34%
TLL2 1 10:98145811 0,35 -0,06% 0,20 0,61% 0,91 0,26%
TLL2 1 10:98145855 0,00 -0,63% 0,45 0,07% 0,00 -0,31%
TLL2 1 10:98145865 0,00 -0,64% 0,13 -0,08% 0,00 -0,35%
TLL2 1 10:98145914 0,78 0,54% 0,00 0,72% 0,01 0,65%
TLL2 1 10:98145961 0,00 0,98% 0,00 0,33% 0,00 0,64%
TLL2 1 10:98145978 0,77 0,95% 0,01 0,14% 0,10 0,51%
PUS7L 1 12:44148715 0,84 -0,12% 0,69 -0,10% 0,91 -0,10%
PUS7L 1 12:44148898 0,00 -0,44% 0,00 -0,72% 0,00 -0,56%
PUS7L 1 12:44148988 0,61 -0,36% 0,04 -0,05% 0,31 -0,19%
GPR176 1 15:40152461 0,00 -0,57% 0,00 -0,35% 0,00 -0,45%
GPR176 1 15:40152523 0,00 0,12% 0,07 0,18% 0,00 0,14%
GPR176 1 15:40152613 NA NA NA NA NA NA
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Table C.7: Overlap of KEGG pathways identiﬁed based on differentially methylated genes
in atherosclerosis progression and inter-round ageing. The ”Fraction of Affected Genes” is
calculated as ”Overlap” divided by the size of the union of ”Athero” and ”Time”.
Pathway Time (n) Athero (n) Overlap Pathway
Size
Fraction of Af-
fected Genes
Pancreatic secretion 25 25 16 101 0,4706
Long-term depression 25 14 12 70 0,4444
Long-term potentiation 25 15 12 70 0,4286
Salivary secretion 30 21 15 89 0,4167
ErbB signaling pathway 29 22 15 87 0,4167
Gap junction 27 21 14 90 0,4118
Axon guidance 44 26 20 129 0,4000
Prostate cancer 24 16 11 89 0,3793
GnRH signaling pathway 31 24 15 101 0,3750
Type II diabetes mellitus 16 10 7 48 0,3684
Glioma 18 12 8 65 0,3636
Arrhythmogenic right ven-
tricular cardiomyopathy
(ARVC)
29 20 13 74 0,3611
Hypertrophic cardiomyopa-
thy (HCM)
25 17 11 83 0,3548
Phosphatidylinositol signa-
ling system
30 16 12 78 0,3529
Regulation of actin cy-
toskeleton
51 31 21 213 0,3443
Amoebiasis 34 17 13 106 0,3421
Melanogenesis 27 17 11 101 0,3333
Neurotrophin signaling
pathway
26 23 12 127 0,3243
Pathways in cancer 85 54 34 326 0,3238
Focal adhesion 66 38 25 200 0,3165
ECM-receptor interaction 30 16 11 85 0,3143
Calcium signaling pathway 58 31 21 177 0,3088
Wnt signaling pathway 35 25 14 150 0,3043
Dilated cardiomyopathy 30 22 12 90 0,3000
Chemokine signaling path-
way
38 27 15 189 0,3000
Gastric acid secretion 29 15 10 74 0,2941
Leukocyte transendothelial
migration
27 17 10 116 0,2941
MAPK signaling pathway 69 37 24 268 0,2927
Vascular smooth muscle
contraction
34 21 12 116 0,2791
Adherens junction 29 13 9 73 0,2727
Tight junction 40 25 13 132 0,2500
Neuroactive ligand-receptor
interaction
62 32 18 272 0,2368
Progesterone-mediated
oocyte maturation
18 15 5 86 0,1786
Metabolic pathways 224 116 49 1130 0,1684
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